

# Massimo Filippi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5021783/publications.pdf>

Version: 2024-02-01

1,413  
papers

98,756  
citations

333

137  
h-index

735

251  
g-index

1469  
all docs

1469  
docs citations

1469  
times ranked

42583  
citing authors

#	ARTICLE	IF	CITATIONS
1	Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria. <i>Annals of Neurology</i> , 2011, 69, 292-302.	2.8	8,001
2	Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. <i>Lancet Neurology</i> , The, 2018, 17, 162-173.	4.9	4,605
3	Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". <i>Annals of Neurology</i> , 2005, 58, 840-846.	2.8	4,495
4	Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. <i>Brain</i> , 1997, 120, 2059-2069.	3.7	1,077
5	Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. <i>Lancet</i> , The, 2001, 357, 1576-1582.	6.3	1,025
6	Multiple sclerosis. <i>Nature Reviews Disease Primers</i> , 2018, 4, 43.	18.1	767
7	European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. <i>Annals of Neurology</i> , 2001, 49, 290-297.	2.8	695
8	MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines. <i>Lancet Neurology</i> , The, 2016, 15, 292-303.	4.9	679
9	Differential diagnosis of suspected multiple sclerosis: a consensus approach. <i>Multiple Sclerosis Journal</i> , 2008, 14, 1157-1174.	1.4	560
10	Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. <i>Lancet</i> , The, 2009, 374, 1503-1511.	6.3	551
11	Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis. <i>Lancet Neurology</i> , The, 2005, 4, 281-288.	4.9	513
12	Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial. <i>Nature Medicine</i> , 2000, 6, 1176-1182.	15.2	506
13	Resting state fMRI in Alzheimer's disease: beyond the default mode network. <i>Neurobiology of Aging</i> , 2012, 33, 1564-1578.	1.5	497
14	Diffusion tensor magnetic resonance imaging in multiple sclerosis. <i>Neurology</i> , 2001, 56, 304-311.	1.5	491
15	White matter damage in Alzheimer's disease assessed in vivo using diffusion tensor magnetic resonance imaging. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2002, 72, 742-746.	0.9	486
16	Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. <i>Lancet</i> , The, 1999, 353, 964-969.	6.3	476
17	Cortical Lesions and Atrophy Associated With Cognitive Impairment in Relapsing-Remitting Multiple Sclerosis. <i>Archives of Neurology</i> , 2009, 66, 1144-50.	4.9	458
18	Evidence of early cortical atrophy in MS. <i>Neurology</i> , 2003, 60, 1157-1162.	1.5	446

#	ARTICLE	IF	CITATIONS
19	Clinical and imaging assessment of cognitive dysfunction in multiple sclerosis. <i>Lancet Neurology</i> , The, 2015, 14, 302-317.	4.9	437
20	MAGNIMS consensus guidelines on the use of MRI in multiple sclerosisâ€”establishing disease prognosis and monitoring patients. <i>Nature Reviews Neurology</i> , 2015, 11, 597-606.	4.9	422
21	Cognition in multiple sclerosis. <i>Neurology</i> , 2018, 90, 278-288.	1.5	384
22	250 ð¼g or 500 ð¼g interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. <i>Lancet Neurology</i> , The, 2009, 8, 889-897.	4.9	377
23	Diseaseâ€”Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis. <i>Annals of Neurology</i> , 2021, 89, 780-789.	2.8	370
24	Magnetization transfer changes in the normal appearing white matter precede the appearance of enhancing lesions in patients with multiple sclerosis. <i>Annals of Neurology</i> , 1998, 43, 809-814.	2.8	356
25	Diagnostic criteria for primary progressive multiple sclerosis: A position paper. <i>Annals of Neurology</i> , 2000, 47, 831-835.	2.8	356
26	Association between pathological and MRI findings in multiple sclerosis. <i>Lancet Neurology</i> , The, 2012, 11, 349-360.	4.9	356
27	MAGNIMS consensus guidelines on the use of MRI in multiple sclerosisâ€”clinical implementation in the diagnostic process. <i>Nature Reviews Neurology</i> , 2015, 11, 471-482.	4.9	354
28	A Magnetization Transfer Imaging Study of Normal-Appearing White Matter in Multiple Sclerosis. <i>Neurology</i> , 1995, 45, 478-482.	1.5	353
29	Automated classification of Alzheimer's disease and mild cognitive impairment using a single MRI and deep neural networks. <i>NeuroImage: Clinical</i> , 2019, 21, 101645.	1.4	352
30	Functional Magnetic Resonance Imaging Correlates of Fatigue in Multiple Sclerosis. <i>NeuroImage</i> , 2002, 15, 559-567.	2.1	349
31	Placebo-Controlled Trial of Oral Laquinimod for Multiple Sclerosis. <i>New England Journal of Medicine</i> , 2012, 366, 1000-1009.	13.9	329
32	Evidence for widespread axonal damage at the earliest clinical stage of multiple sclerosis. <i>Brain</i> , 2003, 126, 433-437.	3.7	324
33	Genomeâ€”wide metaâ€”analysis identifies novel multiple sclerosis susceptibility loci. <i>Annals of Neurology</i> , 2011, 70, 897-912.	2.8	314
34	Quantitative brain MRI lesion load predicts the course of clinically isolated syndromes suggestive of multiple sclerosis. <i>Neurology</i> , 1994, 44, 635-635.	1.5	313
35	Cladribine and progressive MS. <i>Neurology</i> , 2000, 54, 1145-1155.	1.5	310
36	Assessment of lesions on magnetic resonance imaging in multiple sclerosis: practical guidelines. <i>Brain</i> , 2019, 142, 1858-1875.	3.7	303

#	ARTICLE	IF	CITATIONS
37	2021 MAGNIMSâ€“CMSCâ€“NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis. <i>Lancet Neurology</i> , The, 2021, 20, 653-670.	4.9	302
38	MRI in multiple sclerosis: current status and future prospects. <i>Lancet Neurology</i> , The, 2008, 7, 615-625.	4.9	295
39	Deep gray matter volume loss drives disability worsening in multiple sclerosis. <i>Annals of Neurology</i> , 2018, 83, 210-222.	2.8	295
40	Correlations between changes in disability and T <sub>2</sub> -weighted brain MRI activity in multiple sclerosis. <i>Neurology</i> , 1995, 45, 255-260.	1.5	292
41	MRI criteria for multiple sclerosis in patients presenting with clinically isolated syndromes: a multicentre retrospective study. <i>Lancet Neurology</i> , The, 2007, 6, 677-686.	4.9	292
42	Default-mode network dysfunction and cognitive impairment in progressive MS. <i>Neurology</i> , 2010, 74, 1252-1259.	1.5	292
43	Brain Gray Matter Changes in Migraine Patients With T2-Visible Lesions. <i>Stroke</i> , 2006, 37, 1765-1770.	1.0	291
44	Typical and atypical pathology in primary progressive aphasia variants. <i>Annals of Neurology</i> , 2017, 81, 430-443.	2.8	288
45	Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes. <i>Neurology</i> , 2010, 74, 1868-1876.	1.5	284
46	White matter damage in primary progressive aphasias: a diffusion tensor tractography study. <i>Brain</i> , 2011, 134, 3011-3029.	3.7	280
47	Glatiramer acetate reduces the proportion of new MS lesions evolving into â€œblack holesâ€“. <i>Neurology</i> , 2001, 57, 731-733.	1.5	274
48	Progression of regional grey matter atrophy in multiple sclerosis. <i>Brain</i> , 2018, 141, 1665-1677.	3.7	269
49	Brain atrophy and lesion load predict long term disability in multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013, 84, 1082-1091.	0.9	267
50	Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. <i>Lancet</i> , The, 2008, 371, 2085-2092.	6.3	265
51	The contribution of magnetic resonance imaging to the diagnosis of multiple sclerosis. <i>Neurology</i> , 1999, 53, 448-448.	1.5	263
52	Magnetisation transfer ratio and mean diffusivity of normal appearing white and grey matter from patients with multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2001, 70, 311-317.	0.9	263
53	White Matter Damage in Alzheimer Disease and Its Relationship to Gray Matter Atrophy. <i>Radiology</i> , 2011, 258, 853-863.	3.6	263
54	Evidence of thalamic gray matter loss in pediatric multiple sclerosis. <i>Neurology</i> , 2008, 70, 1107-1112.	1.5	258

#	ARTICLE	IF	CITATIONS
55	The current state-of-the-art of spinal cord imaging: Methods. <i>NeuroImage</i> , 2014, 84, 1070-1081.	2.1	256
56	Relation between MR abnormalities and patterns of cognitive impairment in multiple sclerosis. <i>Neurology</i> , 1998, 50, 1601-1608.	1.5	253
57	Diffusion MRI in multiple sclerosis. <i>Neurology</i> , 2005, 65, 1526-1532.	1.5	252
58	Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis. <i>Neurology</i> , 2014, 82, 573-581.	1.5	249
59	Clinical characteristics, course and prognosis of relapsing Devic's Neuromyelitis Optica. <i>Journal of Neurology</i> , 2004, 251, 47-52.	1.8	246
60	Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2004, 364, 1489-1496.	6.3	246
61	Secondary progressive multiple sclerosis: current knowledge and future challenges. <i>Lancet Neurology, The</i> , 2006, 5, 343-354.	4.9	246
62	The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. <i>Brain</i> , 2000, 123, 2256-2263.	3.7	242
63	A randomised, double blind, placebo controlled trial with vitamin D <sub>3</sub> as an add on treatment to interferon β <sup>2</sup> -1b in patients with multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2012, 83, 565-571.	0.9	242
64	Comparison of MS clinical phenotypes using conventional and magnetization transfer MRI. <i>Neurology</i> , 1999, 52, 588-588.	1.5	241
65	MR Imaging of Multiple Sclerosis. <i>Radiology</i> , 2011, 259, 659-681.	3.6	238
66	Cortical adaptation in patients with MS: a cross-sectional functional MRI study of disease phenotypes. <i>Lancet Neurology, The</i> , 2005, 4, 618-626.	4.9	235
67	Rapid semi-automatic segmentation of the spinal cord from magnetic resonance images: Application in multiple sclerosis. <i>NeuroImage</i> , 2010, 50, 446-455.	2.1	234
68	MRI criteria for MS in patients with clinically isolated syndromes. <i>Neurology</i> , 2010, 74, 427-434.	1.5	231
69	Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis. <i>Neurology</i> , 2008, 71, 136-144.	1.5	227
70	Adaptive functional changes in the cerebral cortex of patients with nondisabling multiple sclerosis correlate with the extent of brain structural damage. <i>Annals of Neurology</i> , 2002, 51, 330-339.	2.8	224
71	European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. <i>Annals of Neurology</i> , 2001, 49, 290-7.	2.8	224
72	Cognitive function in primary progressive and transitional progressive multiple sclerosis: A controlled study with MRI correlates. <i>Brain</i> , 1999, 122, 1341-1348.	3.7	223

#	ARTICLE	IF	CITATIONS
73	Cortical lesions in multiple sclerosis. <i>Nature Reviews Neurology</i> , 2010, 6, 438-444.	4.9	221
74	Language networks in semantic dementia. <i>Brain</i> , 2010, 133, 286-299.	3.7	220
75	MRI and the diagnosis of multiple sclerosis: expanding the concept of "no better explanation". <i>Lancet Neurology</i> , The, 2006, 5, 841-852.	4.9	217
76	Magnetic resonance studies of abnormalities in the normal appearing white matter and grey matter in multiple sclerosis. <i>Journal of Neurology</i> , 2003, 250, 1407-1419.	1.8	216
77	Spinal-cord MRI in multiple sclerosis. <i>Lancet Neurology</i> , The, 2003, 2, 555-562.	4.9	213
78	Persistent 7-tesla phase rim predicts poor outcome in new multiple sclerosis patient lesions. <i>Journal of Clinical Investigation</i> , 2016, 126, 2597-2609.	3.9	212
79	Cognitive dysfunction in patients with mildly disabling relapsing/remitting multiple sclerosis: an exploratory study with diffusion tensor MR imaging. <i>Journal of the Neurological Sciences</i> , 2002, 195, 103-109.	0.3	208
80	A Quantitative Study of Water Diffusion in Multiple Sclerosis Lesions and Normal-Appearing White Matter Using Echo-Planar Imaging. <i>Archives of Neurology</i> , 2000, 57, 1017.	4.9	203
81	Neuroimaging in amyotrophic lateral sclerosis: insights into structural and functional changes. <i>Lancet Neurology</i> , The, 2014, 13, 1228-1240.	4.9	201
82	Autologous hematopoietic stem cell transplantation in multiple sclerosis. <i>Neurology</i> , 2015, 84, 981-988.	1.5	201
83	Pathologic damage in MS assessed by diffusion-weighted and magnetization transfer MRI. <i>Neurology</i> , 2000, 54, 1139-1144.	1.5	193
84	Follow-up of interhemispheric differences of motor evoked potentials from the 'affected' and 'unaffected' hemispheres in human stroke. <i>Brain Research</i> , 1998, 803, 1-8.	1.1	191
85	A voxel-based morphometry study of grey matter loss in MS patients with different clinical phenotypes. <i>NeuroImage</i> , 2008, 42, 315-322.	2.1	189
86	Brain MRI atrophy quantification in MS. <i>Neurology</i> , 2017, 88, 403-413.	1.5	188
87	Assessment of system dysfunction in the brain through MRI-based connectomics. <i>Lancet Neurology</i> , The, 2013, 12, 1189-1199.	4.9	184
88	A method for obtaining tract-specific diffusion tensor MRI measurements in the presence of disease: application to patients with clinically isolated syndromes suggestive of multiple sclerosis. <i>NeuroImage</i> , 2005, 26, 258-265.	2.1	182
89	MRI T2 lesion burden in multiple sclerosis: A plateauing relationship with clinical disability. <i>Neurology</i> , 2006, 66, 1384-1389.	1.5	182
90	Magnetic resonance imaging pattern in natalizumab-associated progressive multifocal leukoencephalopathy. <i>Annals of Neurology</i> , 2012, 72, 779-787.	2.8	182

#	ARTICLE	IF	CITATIONS
91	Functional network connectivity in the behavioral variant of frontotemporal dementia. <i>Cortex</i> , 2013, 49, 2389-2401.	1.1	182
92	Quantification of tissue damage in AD using diffusion tensor and magnetization transfer MRI. <i>Neurology</i> , 2001, 57, 1135-1137.	1.5	181
93	Assessment of Normal-Appearing White and Gray Matter in Patients With Primary Progressive Multiple Sclerosis. <i>Archives of Neurology</i> , 2002, 59, 1406-12.	4.9	180
94	The utility of MRI in suspected MS [RETIRED]. <i>Neurology</i> , 2003, 61, 602-611.	1.5	178
95	Quantitative assessment of MRI lesion load in monitoring the evolution of multiple sclerosis. <i>Brain</i> , 1995, 118, 1601-1612.	3.7	176
96	Multiple Sclerosis: Effects of Cognitive Rehabilitation on Structural and Functional MR Imaging Measures—An Explorative Study. <i>Radiology</i> , 2012, 262, 932-940.	3.6	176
97	Multicenter Case-Control Study on Restless Legs Syndrome in Multiple Sclerosis: the REMS Study. <i>Sleep</i> , 2008, 31, 944-952.	0.6	175
98	A magnetization transfer histogram study of normal-appearing brain tissue in MS. <i>Neurology</i> , 2000, 54, 186-186.	1.5	174
99	Gray matter damage predicts the accumulation of disability 13 years later in MS. <i>Neurology</i> , 2013, 81, 1759-1767.	1.5	174
100	Correlations between Structural CNS Damage and Functional MRI Changes in Primary Progressive MS. <i>NeuroImage</i> , 2002, 15, 537-546.	2.1	173
101	The contribution of voxel-based morphometry in staging patients with mild cognitive impairment. <i>Neurology</i> , 2006, 67, 453-460.	1.5	173
102	Subregional Basal Forebrain Atrophy in Alzheimer's Disease: A Multicenter Study. <i>Journal of Alzheimer's Disease</i> , 2014, 40, 687-700.	1.2	173
103	MRI and magnetization transfer imaging changes in the brain and cervical cord of patients with Devic's neuromyelitis optica. <i>Neurology</i> , 1999, 53, 1705-1705.	1.5	172
104	Primary and transitional progressive MS. <i>Neurology</i> , 1999, 52, 839-839.	1.5	171
105	Changes in the normal appearing brain tissue and cognitive impairment in multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2000, 68, 157-161.	0.9	171
106	The current state-of-the-art of spinal cord imaging: Applications. <i>NeuroImage</i> , 2014, 84, 1082-1093.	2.1	169
107	Brain MRI correlates of cognitive impairment in primary and secondary progressive multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 1995, 132, 222-227.	0.3	167
108	The contribution of MRI in assessing cognitive impairment in multiple sclerosis. <i>Neurology</i> , 2010, 75, 2121-2128.	1.5	166

#	ARTICLE	IF	CITATIONS
109	Quantitative assessment of MRI lesion load in multiple sclerosis: A comparison of conventional spin-echo with fast fluidattenuated inversion recovery. <i>Brain</i> , 1996, 119, 1349-1355.	3.7	164
110	Large-scale neuronal network dysfunction in relapsing-remitting multiple sclerosis. <i>Neurology</i> , 2012, 79, 1449-1457.	1.5	164
111	In vivo assessment of the brain and cervical cord pathology of patients with primary progressive multiple sclerosis. <i>Brain</i> , 2001, 124, 2540-2549.	3.7	163
112	Association between pathological and MRI findings in multiple sclerosis. <i>Lancet Neurology</i> , The, 2019, 18, 198-210.	4.9	163
113	Automatic segmentation of the spinal cord and intramedullary multiple sclerosis lesions with convolutional neural networks. <i>NeuroImage</i> , 2019, 184, 901-915.	2.1	163
114	Mean diffusivity and fractional anisotropy histograms of patients with multiple sclerosis. <i>American Journal of Neuroradiology</i> , 2001, 22, 952-8.	1.2	163
115	Central vein sign differentiates Multiple Sclerosis from central nervous system inflammatory vasculopathies. <i>Annals of Neurology</i> , 2018, 83, 283-294.	2.8	160
116	Intracortical lesions. <i>Neurology</i> , 2010, 75, 1988-1994.	1.5	159
117	Longitudinal Changes in Fiber Tract Integrity in Healthy Aging and Mild Cognitive Impairment: A DTI Follow-Up Study. <i>Journal of Alzheimer's Disease</i> , 2010, 22, 507-522.	1.2	157
118	The current role of MRI in differentiating multiple sclerosis from its imaging mimics. <i>Nature Reviews Neurology</i> , 2018, 14, 199-213.	4.9	157
119	Behavioral and Psychological Effects of Coronavirus Disease-19 Quarantine in Patients With Dementia. <i>Frontiers in Psychiatry</i> , 2020, 11, 578015.	1.3	157
120	Autologous hematopoietic stem cell transplantation suppresses Gd-enhanced MRI activity in MS. <i>Neurology</i> , 2001, 57, 62-68.	1.5	156
121	Towards a neuroimaging biomarker for amyotrophic lateral sclerosis. <i>Lancet Neurology</i> , The, 2011, 10, 400-403.	4.9	156
122	Brain reserve and cognitive reserve protect against cognitive decline over 4.5 years in MS. <i>Neurology</i> , 2014, 82, 1776-1783.	1.5	156
123	A selective review of structural connectivity abnormalities of schizophrenic patients at different stages of the disease. <i>Schizophrenia Research</i> , 2015, 161, 19-28.	1.1	155
124	Apolipoprotein E $\epsilon$ 4 is associated with disease-specific effects on brain atrophy in Alzheimer's disease and frontotemporal dementia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 2018-2022.	3.3	154
125	Brain structural and functional connectivity in Parkinson's disease with freezing of gait. <i>Human Brain Mapping</i> , 2015, 36, 5064-5078.	1.9	154
126	Nocturnal sleep study in multiple sclerosis: Correlations with clinical and brain magnetic resonance imaging findings. <i>Journal of the Neurological Sciences</i> , 1994, 125, 194-197.	0.3	153



#	ARTICLE	IF	CITATIONS
127	Intra-observer reproducibility in measuring new putative MR markers of demyelination and axonal loss in multiple sclerosis: a comparison with conventional T2-weighted images. <i>Journal of Neurology</i> , 1997, 244, 266-270.	1.8	153
128	A 3-year magnetic resonance imaging study of cortical lesions in relapse-onset multiple sclerosis. <i>Annals of Neurology</i> , 2010, 67, 376-383.	2.8	153
129	Guidelines for using quantitative measures of brain magnetic resonance imaging abnormalities in monitoring the treatment of multiple sclerosis. <i>Annals of Neurology</i> , 1998, 43, 499-506.	2.8	152
130	Voxel-based morphometry study of brain volumetry and diffusivity in amyotrophic lateral sclerosis patients with mild disability. <i>Human Brain Mapping</i> , 2007, 28, 1430-1438.	1.9	152
131	Correlations between monthly enhanced MRI Lesion rate and changes in T2 Lesion volume in multiple sclerosis. <i>Annals of Neurology</i> , 1998, 43, 332-339.	2.8	150
132	MAGNIMS consensus recommendations on the use of brain and spinal cord atrophy measures in clinical practice. <i>Nature Reviews Neurology</i> , 2020, 16, 171-182.	4.9	150
133	White Matter Damage in Frontotemporal Lobar Degeneration Spectrum. <i>Cerebral Cortex</i> , 2012, 22, 2705-2714.	1.6	149
134	Brain reserve and cognitive reserve in multiple sclerosis. <i>Neurology</i> , 2013, 80, 2186-2193.	1.5	149
135	Evidence for widespread movement-associated functional MRI changes in patients with PPMS. <i>Neurology</i> , 2002, 58, 866-872.	1.5	147
136	Autologous HSCT for severe progressive multiple sclerosis in a multicenter trial: impact on disease activity and quality of life. <i>Blood</i> , 2005, 105, 2601-2607.	0.6	147
137	Inflammation in multiple sclerosis: the good, the bad, and the complex. <i>Lancet Neurology</i> , The, 2002, 1, 499-509.	4.9	146
138	Magnetization transfer imaging to monitor the evolution of MS. <i>Neurology</i> , 2000, 55, 940-946.	1.5	145
139	MRI techniques to monitor MS evolution. <i>Neurology</i> , 2002, 58, 1147-1153.	1.5	145
140	Quantification of brain gray matter damage in different MS phenotypes by use of diffusion tensor MR imaging. <i>American Journal of Neuroradiology</i> , 2002, 23, 985-8.	1.2	145
141	The organization of intrinsic brain activity differs between genders: A resting-state fMRI study in a large cohort of young healthy subjects. <i>Human Brain Mapping</i> , 2013, 34, 1330-1343.	1.9	144
142	Short-term brain volume change in relapsing-remitting multiple sclerosis: Effect of glatiramer acetate and implications. <i>Brain</i> , 2001, 124, 1803-1812.	3.7	143
143	Magnetization transfer MRI metrics predict the accumulation of disability 8 years later in patients with multiple sclerosis. <i>Brain</i> , 2006, 129, 2620-2627.	3.7	143
144	Thalamic Damage and Long-term Progression of Disability in Multiple Sclerosis. <i>Radiology</i> , 2010, 257, 463-469.	3.6	143

#	ARTICLE	IF	CITATIONS
145	Regional patterns of brain tissue loss associated with depression in Parkinson disease. <i>Neurology</i> , 2010, 75, 857-863.	1.5	143
146	In vivo assessment of cervical cord damage in MS patients: a longitudinal diffusion tensor MRI study. <i>Brain</i> , 2007, 130, 2211-2219.	3.7	141
147	Cortical/subcortical disease burden and cognitive impairment in patients with multiple sclerosis. <i>American Journal of Neuroradiology</i> , 2000, 21, 402-8.	1.2	141
148	Brain network connectivity assessed using graph theory in frontotemporal dementia. <i>Neurology</i> , 2013, 81, 134-143.	1.5	139
149	Evidence for axonal pathology and adaptive cortical reorganization in patients at presentation with clinically isolated syndromes suggestive of multiple sclerosis. <i>NeuroImage</i> , 2003, 18, 847-855.	2.1	138
150	A large-scale multicentre cerebral diffusion tensor imaging study in amyotrophic lateral sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 570-579.	0.9	138
151	Glatiramer acetate reduces the proportion of new MS lesions evolving into "black holes". <i>Neurology</i> , 2002, 58, 1440-1442.	1.5	136
152	Seven-tesla phase imaging of acute multiple sclerosis lesions: A new window into the inflammatory process. <i>Annals of Neurology</i> , 2013, 74, 669-678.	2.8	135
153	Guillain-Barré syndrome and COVID-19: an observational multicentre study from two Italian hotspot regions. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 751-756.	0.9	135
154	Age-related Changes in Conventional, Magnetization Transfer, and Diffusion-Tensor MR Imaging Findings: Study with Whole-Brain Tissue Histogram Analysis. <i>Radiology</i> , 2003, 227, 731-738.	3.6	134
155	Chronic cerebrospinal venous insufficiency and multiple sclerosis. <i>Annals of Neurology</i> , 2010, 67, 286-290.	2.8	134
156	Mild cognitive impairment in Parkinson's disease is associated with a distributed pattern of brain white matter damage. <i>Human Brain Mapping</i> , 2014, 35, 1921-1929.	1.9	134
157	Divergent brain network connectivity in amyotrophic lateral sclerosis. <i>Neurobiology of Aging</i> , 2013, 34, 419-427.	1.5	133
158	Assessment of White Matter Tract Damage in Patients with Amyotrophic Lateral Sclerosis: A Diffusion Tensor MR Imaging Tractography Study: Fig 1.. <i>American Journal of Neuroradiology</i> , 2010, 31, 1457-1461.	1.2	131
159	A conventional and magnetization transfer MRI study of the cervical cord in patients with MS. <i>Neurology</i> , 2000, 54, 207-207.	1.5	130
160	Association of Vitamin D Levels With Multiple Sclerosis Activity and Progression in Patients Receiving Interferon Beta-1b. <i>JAMA Neurology</i> , 2015, 72, 1458.	4.5	130
161	Weekly diffusion-weighted imaging of normal-appearing white matter in MS. <i>Neurology</i> , 2000, 55, 882-884.	1.5	129
162	Clinically isolated syndromes suggestive of multiple sclerosis, part 2: non-conventional MRI, recovery processes, and management. <i>Lancet Neurology</i> , The, 2005, 4, 341-348.	4.9	129

#	ARTICLE	IF	CITATIONS
163	A multicenter assessment of cervical cord atrophy among MS clinical phenotypes. <i>Neurology</i> , 2011, 76, 2096-2102.	1.5	129
164	Functional Basis of Memory Impairment in Multiple Sclerosis: A [18F]FDG PET Study. <i>NeuroImage</i> , 1996, 4, 87-96.	2.1	127
165	Comparison of triple dose versus standard dose gadolinium-DTPA for detection of MRI enhancing lesions in patients with MS. <i>Neurology</i> , 1996, 46, 379-384.	1.5	124
166	Whole brain volume changes in patients with progressive MS treated with cladribine. <i>Neurology</i> , 2000, 55, 1714-1718.	1.5	124
167	Cortical lesions in primary progressive multiple sclerosis. <i>Neurology</i> , 2009, 72, 1330-1336.	1.5	124
168	The Present and the Future of Neuroimaging in Amyotrophic Lateral Sclerosis. <i>American Journal of Neuroradiology</i> , 2010, 31, 1769-1777.	1.2	124
169	A multi-centre longitudinal study comparing the sensitivity of monthly MRI after standard and triple dose gadolinium-DTPA for monitoring disease activity in multiple sclerosis. Implications for phase II clinical trials. <i>Brain</i> , 1998, 121, 2011-2020.	3.7	123
170	Mean diffusivity and fractional anisotropy histogram analysis of the cervical cord in MS patients. <i>NeuroImage</i> , 2005, 26, 822-828.	2.1	123
171	MRI and motor evoked potential findings in nondisabled multiple sclerosis patients with and without symptoms of fatigue. <i>Journal of Neurology</i> , 2000, 247, 506-509.	1.8	122
172	Conventional and magnetization transfer MRI predictors of clinical multiple sclerosis evolution: a medium-term follow-up study. <i>Brain</i> , 2003, 126, 2323-2332.	3.7	122
173	Grey matter damage predicts the evolution of primary progressive multiple sclerosis at 5 years. <i>Brain</i> , 2006, 129, 2628-2634.	3.7	122
174	Tract-specific white matter structural disruption in patients with bipolar disorder. <i>Bipolar Disorders</i> , 2011, 13, 414-424.	1.1	122
175	Impaired functional integration in multiple sclerosis: a graph theory study. <i>Brain Structure and Function</i> , 2016, 221, 115-131.	1.2	122
176	High prevalence of restless legs syndrome in multiple sclerosis. <i>European Journal of Neurology</i> , 2007, 14, 534-539.	1.7	121
177	Imaging biomarkers in multiple sclerosis. <i>Journal of Magnetic Resonance Imaging</i> , 2010, 31, 770-788.	1.9	121
178	Validation of diagnostic magnetic resonance imaging criteria for multiple sclerosis and response to interferon $\beta$ 1a. <i>Annals of Neurology</i> , 2003, 53, 718-724.	2.8	120
179	MRI evidence for multiple sclerosis as a diffuse disease of the central nervous system. <i>Journal of Neurology</i> , 2005, 252, v16-v24.	1.8	120
180	Magnetic Resonance Techniques in Multiple Sclerosis. <i>Archives of Neurology</i> , 2011, 68, 1514.	4.9	120

#	ARTICLE	IF	CITATIONS
181	Assessment of white matter tract damage in mild cognitive impairment and Alzheimer's disease. <i>Human Brain Mapping</i> , 2010, 31, 1862-1875.	1.9	119
182	Pattern of brain tissue loss associated with freezing of gait in Parkinson disease. <i>Neurology</i> , 2012, 78, 409-416.	1.5	119
183	Diagnostic criteria for primary progressive multiple sclerosis: a position paper. <i>Annals of Neurology</i> , 2000, 47, 831-5.	2.8	119
184	Magnetization transfer and diffusion tensor MRI show gray matter damage in neuromyelitis optica. <i>Neurology</i> , 2004, 62, 476-478.	1.5	118
185	Restless legs syndrome is a common finding in multiple sclerosis and correlates with cervical cord damage. <i>Multiple Sclerosis Journal</i> , 2008, 14, 86-93.	1.4	117
186	A longitudinal diffusion tensor MRI study of the cervical cord and brain in amyotrophic lateral sclerosis patients. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2009, 80, 53-55.	0.9	117
187	Structural and functional MRI correlates of Stroop control in benign MS. <i>Human Brain Mapping</i> , 2009, 30, 276-290.	1.9	117
188	Altered functional and structural connectivities in patients with MS. <i>Neurology</i> , 2007, 69, 2136-2145.	1.5	116
189	MRI measurements of brainstem structures in patients with Richardson's syndrome, progressive supranuclear palsy-parkinsonism, and Parkinson's disease. <i>Movement Disorders</i> , 2011, 26, 247-255.	2.2	116
190	A spinal cord MRI study of benign and secondary progressive multiple sclerosis. <i>Journal of Neurology</i> , 1996, 243, 502-505.	1.8	115
191	Huntington Disease: Volumetric, Diffusion-weighted, and Magnetization Transfer MR Imaging of Brain. <i>Radiology</i> , 2004, 232, 867-873.	3.6	115
192	Guidelines for using proton MR spectroscopy in multicenter clinical MS studies. <i>Neurology</i> , 2007, 69, 1942-1952.	1.5	114
193	A Single, Early Magnetic Resonance Imaging Study in the Diagnosis of Multiple Sclerosis. <i>Archives of Neurology</i> , 2009, 66, 587-92.	4.9	114
194	Measurement error of two different techniques for brain atrophy assessment in multiple sclerosis. <i>Neurology</i> , 2004, 62, 1432-1434.	1.5	113
195	Voxel-based analysis derived from fractional anisotropy images of white matter volume changes with aging. <i>NeuroImage</i> , 2008, 41, 657-667.	2.1	113
196	Regional brain atrophy evolves differently in patients with multiple sclerosis according to clinical phenotype. <i>American Journal of Neuroradiology</i> , 2005, 26, 341-6.	1.2	113
197	MRI criteria for dissemination in space in patients with clinically isolated syndromes: a multicentre follow-up study. <i>Lancet Neurology</i> , The, 2006, 5, 221-227.	4.9	112
198	<sc>EFNS</sc> task force: the use of neuroimaging in the diagnosis of dementia. <i>European Journal of Neurology</i> , 2012, 19, 1487-1501.	1.7	112

#	ARTICLE	IF	CITATIONS
199	Multi-branch convolutional neural network for multiple sclerosis lesion segmentation. <i>NeuroImage</i> , 2019, 196, 1-15.	2.1	111
200	Influence of aging on brain gray and white matter changes assessed by conventional, MT, and DT MRI. <i>Neurology</i> , 2006, 66, 535-539.	1.5	109
201	Diffusion tensor MRI tractography and cognitive impairment in multiple sclerosis. <i>Neurology</i> , 2012, 78, 969-975.	1.5	109
202	Nonconventional MRI and microstructural cerebral changes in multiple sclerosis. <i>Nature Reviews Neurology</i> , 2015, 11, 676-686.	4.9	109
203	Lentiviral haematopoietic stem-cell gene therapy for early-onset metachromatic leukodystrophy: long-term results from a non-randomised, open-label, phase 1/2 trial and expanded access. <i>Lancet</i> , The, 2022, 399, 372-383.	6.3	109
204	The Cortical Signature of Amyotrophic Lateral Sclerosis. <i>PLoS ONE</i> , 2012, 7, e42816.	1.1	108
205	Intra- and inter-observer agreement of brain MRI lesion volume measurements in multiple sclerosis. <i>Brain</i> , 1995, 118, 1593-1600.	3.7	107
206	Brain involvement in systemic immune mediated diseases: magnetic resonance and magnetisation transfer imaging study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2000, 68, 170-177.	0.9	107
207	One year follow up study of primary and transitional progressive multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2000, 68, 713-718.	0.9	106
208	Short-term accrual of gray matter pathology in patients with progressive multiple sclerosis: an in vivo study using diffusion tensor MRI. <i>NeuroImage</i> , 2005, 24, 1139-1146.	2.1	106
209	Characterizing the Mechanisms of Progression in Multiple Sclerosis. <i>Archives of Neurology</i> , 2005, 62, 1345.	4.9	105
210	Autosomal Dominant Frontotemporal Lobar Degeneration Due to the C9ORF72 Hexanucleotide Repeat Expansion: Late-Onset Psychotic Clinical Presentation. <i>Biological Psychiatry</i> , 2013, 74, 384-391.	0.7	105
211	Cortical Abnormalities in Patients with Migraine: A Surface-based Analysis. <i>Radiology</i> , 2013, 268, 170-180.	3.6	105
212	MRI monitoring of pathological changes in the spinal cord in patients with multiple sclerosis. <i>Lancet Neurology</i> , The, 2015, 14, 443-454.	4.9	105
213	Functional network connectivity abnormalities in multiple sclerosis: Correlations with disability and cognitive impairment. <i>Multiple Sclerosis Journal</i> , 2018, 24, 459-471.	1.4	105
214	Fatigue and magnetic resonance imaging activity in multiple sclerosis. <i>Journal of Neurology</i> , 1999, 246, 454-458.	1.8	104
215	The effect of white matter lesions on cognition in the elderly—small but detectable. <i>Nature Clinical Practice Neurology</i> , 2007, 3, 620-627.	2.7	104
216	Improving interobserver variation in reporting gadolinium-enhanced MRI lesions in multiple sclerosis. <i>Neurology</i> , 1997, 49, 1682-1688.	1.5	103

#	ARTICLE	IF	CITATIONS
217	Progressive Gray Matter Damage in Patients With Relapsing-Remitting Multiple Sclerosis. Archives of Neurology, 2005, 62, 578.	4.9	103
218	Sensorimotor Functional Connectivity Changes in Amyotrophic Lateral Sclerosis. Cerebral Cortex, 2011, 21, 2291-2298.	1.6	102
219	Quantitative MRI in CADASIL. Neurology, 1999, 52, 1361-1361.	1.5	102
220	Prognostic value of MR and magnetization transfer imaging findings in patients with clinically isolated syndromes suggestive of multiple sclerosis at presentation. American Journal of Neuroradiology, 2000, 21, 1034-8.	1.2	102
221	Electroencephalographic coherence analysis in multiple sclerosis: correlation with clinical, neuropsychological, and MRI findings. Journal of Neurology, Neurosurgery and Psychiatry, 2000, 69, 192-198.	0.9	101
222	Diffusion-Tensor Magnetic Resonance Imaging Detects Normal-Appearing White Matter Damage Unrelated to Short-term Disease Activity in Patients at the Earliest Clinical Stage of Multiple Sclerosis. Archives of Neurology, 2005, 62, 803.	4.9	101
223	Predicting progression in primary progressive multiple sclerosis: A 10-year multicenter study. Annals of Neurology, 2008, 63, 790-793.	2.8	101
224	Selective decreased grey matter volume of the pain-matrix network in cluster headache. Cephalalgia, 2012, 32, 109-115.	1.8	101
225	Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 851-858.	0.9	101
226	Brain plasticity in Parkinson's disease with freezing of gait induced by action observation training. Journal of Neurology, 2017, 264, 88-101.	1.8	101
227	Quantification of cervical cord pathology in primary progressive MS using diffusion tensor MRI. Neurology, 2005, 64, 631-635.	1.5	99
228	A longitudinal study of cognition in primary progressive multiple sclerosis. Brain, 2005, 128, 2891-2898.	3.7	99
229	Corpus callosum damage and cognitive dysfunction in benign MS. Human Brain Mapping, 2009, 30, 2656-2666.	1.9	99
230	Structural <scp>MRI</scp> correlates of cognitive impairment in patients with multiple sclerosis. Human Brain Mapping, 2016, 37, 1627-1644.	1.9	99
231	Multicenter stability of diffusion tensor imaging measures: A European clinical and physical phantom study. Psychiatry Research - Neuroimaging, 2011, 194, 363-371.	0.9	98
232	Assessing response to interferon- $\beta$ in a multicenter dataset of patients with MS. Neurology, 2016, 87, 134-140.	1.5	98
233	Prediction of a multiple sclerosis diagnosis in patients with clinically isolated syndrome using the 2016 MAGNIMS and 2010 McDonald criteria: a retrospective study. Lancet Neurology, The, 2018, 17, 133-142.	4.9	98
234	Influence of the topography of brain damage on depression and fatigue in patients with multiple sclerosis. Multiple Sclerosis Journal, 2014, 20, 192-201.	1.4	97

#	ARTICLE	IF	CITATIONS
235	Simple and complex movement-associated functional MRI changes in patients at presentation with clinically isolated syndromes suggestive of multiple sclerosis. <i>Human Brain Mapping</i> , 2004, 21, 108-117.	1.9	96
236	Recommendations to improve imaging and analysis of brain lesion load and atrophy in longitudinal studies of multiple sclerosis. <i>Journal of Neurology</i> , 2013, 260, 2458-2471.	1.8	96
237	Brain magnetic resonance imaging correlates of cognitive impairment in multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 1993, 115, S66-S73.	0.3	95
238	Functional MRI in Multiple Sclerosis. <i>Journal of Neuroimaging</i> , 2007, 17, 36S-41S.	1.0	95
239	Magnetic resonance imaging correlates of physical disability in relapse onset multiple sclerosis of long disease duration. <i>Multiple Sclerosis Journal</i> , 2014, 20, 72-80.	1.4	95
240	Vitamin D levels and risk of multiple sclerosis in patients with clinically isolated syndromes. <i>Multiple Sclerosis Journal</i> , 2014, 20, 147-155.	1.4	94
241	Neuropsychological impairment in multiple sclerosis patients: the role of (juxta)cortical lesion on FLAIR. <i>Multiple Sclerosis Journal</i> , 2000, 6, 280-285.	1.4	93
242	Sensorimotor network rewiring in mild cognitive impairment and Alzheimer's disease. <i>Human Brain Mapping</i> , 2010, 31, 515-525.	1.9	93
243	Indirect evidence for early widespread gray matter involvement in relapsing&#x2013;remitting multiple sclerosis. <i>NeuroImage</i> , 2004, 21, 1825-1829.	2.1	92
244	Cognitive impairment in multiple sclerosis is associated to different patterns of gray matter atrophy according to clinical phenotype. <i>Human Brain Mapping</i> , 2011, 32, 1535-1543.	1.9	92
245	Correlates of MS disability assessed in vivo using aggregates of MR quantities. <i>Neurology</i> , 2001, 56, 1331-1334.	1.5	91
246	Sample sizes for brain atrophy outcomes in trials for secondary progressive multiple sclerosis. <i>Neurology</i> , 2009, 72, 595-601.	1.5	91
247	Regional Distribution and Clinical Correlates of White Matter Structural Damage in Huntington Disease: A Tract-Based Spatial Statistics Study. <i>American Journal of Neuroradiology</i> , 2010, 31, 1675-1681.	1.2	91
248	MR Imaging in Multiple Sclerosis: Review and Recommendations for Current Practice. <i>American Journal of Neuroradiology</i> , 2010, 31, 983-989.	1.2	91
249	Meeting Review: The management of multiple sclerosis in children: a European view. <i>Multiple Sclerosis Journal</i> , 2010, 16, 1258-1267.	1.4	91
250	Magnetization transfer and diffusion tensor MR imaging of acute disseminated encephalomyelitis. <i>American Journal of Neuroradiology</i> , 2002, 23, 267-72.	1.2	91
251	Microstructural changes and atrophy in brain white matter tracts with aging. <i>Neurobiology of Aging</i> , 2012, 33, 488-498.e2.	1.5	90
252	Brain network connectivity differs in early-onset neurodegenerative dementia. <i>Neurology</i> , 2017, 89, 1764-1772.	1.5	90

#	ARTICLE	IF	CITATIONS
253	The hippocampus in multiple sclerosis. <i>Lancet Neurology</i> , The, 2018, 17, 918-926.	4.9	90
254	Spatial mapping of T2 and gadolinium-enhancing T1 lesion volumes in multiple sclerosis: evidence for distinct mechanisms of lesion genesis?. <i>Brain</i> , 1999, 122, 1261-1270.	3.7	89
255	Pearls & Oysters: The medial longitudinal fasciculus in ocular motor physiology. <i>Neurology</i> , 2008, 70, e57-67.	1.5	89
256	Paramagnetic Rim Lesions are Specific to Multiple Sclerosis: An International Multicenter 3T MRI Study. <i>Annals of Neurology</i> , 2020, 88, 1034-1042.	2.8	89
257	Robust Automated Detection of Microstructural White Matter Degeneration in Alzheimer's Disease Using Machine Learning Classification of Multicenter DTI Data. <i>PLoS ONE</i> , 2013, 8, e64925.	1.1	89
258	The use of quantitative magnetic-resonance-based techniques to monitor the evolution of multiple sclerosis. <i>Lancet Neurology</i> , The, 2003, 2, 337-346.	4.9	88
259	A functional magnetic resonance imaging study of patients with secondary progressive multiple sclerosis. <i>NeuroImage</i> , 2003, 19, 1770-1777.	2.1	88
260	Unraveling treatment response in multiple sclerosis. <i>Neurology</i> , 2019, 92, 180-192.	1.5	88
261	Safety and efficacy of natalizumab in children with multiple sclerosis. <i>Neurology</i> , 2010, 75, 912-917.	1.5	87
262	Cognitive Functions and White Matter Tract Damage in Amyotrophic Lateral Sclerosis: A Diffusion Tensor Tractography Study. <i>American Journal of Neuroradiology</i> , 2011, 32, 1866-1872.	1.2	87
263	Effects of early treatment with glatiramer acetate in patients with clinically isolated syndrome. <i>Multiple Sclerosis Journal</i> , 2013, 19, 1074-1083.	1.4	87
264	Regional but Not Global Brain Damage Contributes to Fatigue in Multiple Sclerosis. <i>Radiology</i> , 2014, 273, 511-520.	3.6	87
265	Anatomical MRI and DTI in the Diagnosis of Alzheimer's Disease: A European Multicenter Study. <i>Journal of Alzheimer's Disease</i> , 2012, 31, S33-S47.	1.2	86
266	Identifying the Distinct Cognitive Phenotypes in Multiple Sclerosis. <i>JAMA Neurology</i> , 2021, 78, 414.	4.5	86
267	DMTs and Covid-19 severity in MS: a pooled analysis from Italy and France. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 1738-1744.	1.7	86
268	T1 hypointense lesions in secondary progressive multiple sclerosis: effect of interferon beta-1b treatment. <i>Brain</i> , 2001, 124, 1396-1402.	3.7	85
269	Cognitive impairment and structural brain damage in benign multiple sclerosis. <i>Neurology</i> , 2008, 71, 1521-1526.	1.5	85
270	Leptomeningeal gadolinium enhancement across the spectrum of chronic neuroinflammatory diseases. <i>Neurology</i> , 2017, 88, 1439-1444.	1.5	85



#	ARTICLE	IF	CITATIONS
271	The Impact of COVID-19 Quarantine on Patients With Dementia and Family Caregivers: A Nation-Wide Survey. <i>Frontiers in Aging Neuroscience</i> , 2020, 12, 625781.	1.7	85
272	Primary angiitis of the central nervous system: serial MRI of brain and spinal cord. <i>Neuroradiology</i> , 2001, 43, 599-607.	1.1	84
273	The effect of interferon $\beta$ -1b on quantities derived from MT MRI in secondary progressive MS. <i>Neurology</i> , 2003, 60, 853-860.	1.5	84
274	MR Spectroscopy in Multiple Sclerosis. <i>Journal of Neuroimaging</i> , 2007, 17, 31S-35S.	1.0	84
275	A diffusion tensor MRI study of patients with MCI and AD with a 2-year clinical follow-up. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2010, 81, 798-805.	0.9	84
276	MRI assessment of iron deposition in multiple sclerosis. <i>Journal of Magnetic Resonance Imaging</i> , 2011, 34, 13-21.	1.9	84
277	Structural brain correlates of cognitive and behavioral impairment in <scp>MND</scp>. <i>Human Brain Mapping</i> , 2016, 37, 1614-1626.	1.9	84
278	fMRI changes in relapsing-remitting multiple sclerosis patients complaining of fatigue after IFN $\beta$ -1a injection. <i>Human Brain Mapping</i> , 2007, 28, 373-382.	1.9	83
279	Structural and Functional Network Connectivity Breakdown in Alzheimer's Disease Studied with Magnetic Resonance Imaging Techniques. <i>Journal of Alzheimer's Disease</i> , 2011, 24, 455-474.	1.2	82
280	Magnetization transfer ratios in multiple sclerosis lesions enhancing after different doses of gadolinium. <i>Neurology</i> , 1998, 50, 1289-1293.	1.5	81
281	Most Patients With Multiple Sclerosis or a Clinically Isolated Demyelinating Syndrome Should Be Treated at the Time of Diagnosis. <i>Archives of Neurology</i> , 2006, 63, 614.	4.9	81
282	Functional cortical changes of the sensorimotor network are associated with clinical recovery in multiple sclerosis. <i>Human Brain Mapping</i> , 2008, 29, 562-573.	1.9	81
283	Intercenter differences in diffusion tensor MRI acquisition. <i>Journal of Magnetic Resonance Imaging</i> , 2010, 31, 1458-1468.	1.9	81
284	Quantitative magnetic resonance imaging towards clinical application in multiple sclerosis. <i>Brain</i> , 2021, 144, 1296-1311.	3.7	81
285	Effect of training and different measurement strategies on the reproducibility of brain MRI lesion load measurements in multiple sclerosis. <i>Neurology</i> , 1998, 50, 238-244.	1.5	80
286	Diffusion anisotropy of the cervical cord is strictly associated with disability in amyotrophic lateral sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2006, 78, 480-484.	0.9	80
287	MRI characteristics of atypical idiopathic inflammatory demyelinating lesions of the brain. <i>Journal of Neurology</i> , 2008, 255, 1-10.	1.8	80
288	Will Rogers phenomenon in multiple sclerosis. <i>Annals of Neurology</i> , 2008, 64, 428-433.	2.8	80

#	ARTICLE	IF	CITATIONS
289	Mitoxantrone prior to interferon beta-1b in aggressive relapsing multiple sclerosis: a 3-year randomised trial. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2011, 82, 1344-1350.	0.9	80
290	Hippocampal and Deep Gray Matter Nuclei Atrophy Is Relevant for Explaining Cognitive Impairment in MS: A Multicenter Study. <i>American Journal of Neuroradiology</i> , 2017, 38, 18-24.	1.2	80
291	Resting State Dynamic Functional Connectivity in Neurodegenerative Conditions: A Review of Magnetic Resonance Imaging Findings. <i>Frontiers in Neuroscience</i> , 2019, 13, 657.	1.4	80
292	Magnetic resonance techniques to monitor disease evolution and treatment trial outcomes in multiple sclerosis. <i>Current Opinion in Neurology</i> , 1999, 12, 337-344.	1.8	80
293	Irreversible Disability and Tissue Loss in Multiple Sclerosis. <i>Archives of Neurology</i> , 2002, 59, 250.	4.9	79
294	MR correlates of cerebral atrophy in patients with multiple sclerosis. <i>Journal of Neurology</i> , 2002, 249, 1072-1077.	1.8	79
295	Effects of oral glatiramer acetate on clinical and MRI-monitored disease activity in patients with relapsing multiple sclerosis: a multicentre, double-blind, randomised, placebo-controlled study. <i>Lancet Neurology</i> , 2006, 5, 213-220.	4.9	79
296	Disruption of structural connectivity along the dorsal and ventral language pathways in patients with nonfluent and semantic variant primary progressive aphasia: A DT MRI study and a literature review. <i>Brain and Language</i> , 2013, 127, 157-166.	0.8	79
297	Predicting Prodromal Alzheimer's Disease in Subjects with Mild Cognitive Impairment Using Machine Learning Classification of Multimodal Multicenter Diffusionâ€Tensor and Magnetic Resonance Imaging Data. <i>Journal of Neuroimaging</i> , 2015, 25, 738-747.	1.0	79
298	Longitudinal Assessment of Multiple Sclerosis with the Brainâ€Age Paradigm. <i>Annals of Neurology</i> , 2020, 88, 93-105.	2.8	79
299	Relative contributions of brain and cervical cord pathology to multiple sclerosis disability: a study with magnetisation transfer ratio histogram analysis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2000, 69, 723-727.	0.9	78
300	Overview of diffusion-weighted magnetic resonance studies in multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2001, 186, S37-S43.	0.3	78
301	Serum MMP-9/TIMP-1 and MMP-2/TIMP-2 ratios in multiple sclerosis: relationships with different magnetic resonance imaging measures of disease activity during IFN-beta-1a treatment. <i>Multiple Sclerosis Journal</i> , 2005, 11, 441-446.	1.4	78
302	Magnetization transfer magnetic resonance imaging of the brain, spinal cord, and optic nerve. <i>Neurotherapeutics</i> , 2007, 4, 401-413.	2.1	78
303	Evidence for relative cortical sparing in benign multiple sclerosis: a longitudinal magnetic resonance imaging study. <i>Multiple Sclerosis Journal</i> , 2009, 15, 36-41.	1.4	78
304	Cardiovascular disease and brain health: Focus on white matter hyperintensities. <i>IJC Heart and Vasculature</i> , 2018, 19, 63-69.	0.6	78
305	Changes in functional and structural brain connectome along the Alzheimerâ€™s disease continuum. <i>Molecular Psychiatry</i> , 2020, 25, 230-239.	4.1	78
306	Glymphatic system impairment in multiple sclerosis: relation with brain damage and disability. <i>Brain</i> , 2022, 145, 2785-2795.	3.7	78

#	ARTICLE	IF	CITATIONS
307	Interscanner variation in brain MRI lesion load measurements in MS: Implications for clinical trials. <i>Neurology</i> , 1997, 49, 371-377.	1.5	77
308	Cortico-striatal-thalamic network functional connectivity in hemiparkinsonism. <i>Neurobiology of Aging</i> , 2014, 35, 2592-2602.	1.5	77
309	Action observation training to improve motor function recovery: a systematic review. <i>Archives of Physiotherapy</i> , 2015, 5, 14.	0.7	77
310	Structural Brain Connectome and Cognitive Impairment in Parkinson Disease. <i>Radiology</i> , 2017, 283, 515-525.	3.6	77
311	Radiologically isolated syndrome or subclinical multiple sclerosis: MAGNIMS consensus recommendations. <i>Multiple Sclerosis Journal</i> , 2018, 24, 214-221.	1.4	77
312	Voxelwise Assessment of the Regional Distribution of Damage in the Brains of Patients with Multiple Sclerosis and Fatigue. <i>American Journal of Neuroradiology</i> , 2011, 32, 874-879.	1.2	76
313	Cognitive Impairment in Myotonic Dystrophy Type 1 Is Associated with White Matter Damage. <i>PLoS ONE</i> , 2014, 9, e104697.	1.1	76
314	Structural brain MRI abnormalities in pediatric patients with migraine. <i>Journal of Neurology</i> , 2014, 261, 350-357.	1.8	76
315	Intrahemispheric and interhemispheric structural network abnormalities in PLS and ALS. <i>Human Brain Mapping</i> , 2014, 35, 1710-1722.	1.9	76
316	Guidelines for autologous blood and marrow stem cell transplantation in multiple sclerosis: a consensus report written on behalf of the European Group for Blood and Marrow Transplantation and the European Charcot Foundation. <i>Journal of Neurology</i> , 2000, 247, 376-382.	1.8	75
317	Inflammatory demyelination and neurodegeneration in early multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2007, 259, 7-15.	0.3	75
318	Relating functional changes during hand movement to clinical parameters in patients with multiple sclerosis in a multi-centre fMRI study. <i>European Journal of Neurology</i> , 2008, 15, 113-122.	1.7	75
319	EFNS guidelines on the use of neuroimaging in the management of motor neuron diseases. <i>European Journal of Neurology</i> , 2010, 17, 526.	1.7	75
320	Assessment of Disease Activity in Multiple Sclerosis Phenotypes with Combined Gadolinium- and Superparamagnetic Iron Oxide-enhanced MR Imaging. <i>Radiology</i> , 2012, 264, 225-233.	3.6	75
321	Spatial distribution of multiple sclerosis lesions in the cervical spinal cord. <i>Brain</i> , 2019, 142, 633-646.	3.7	75
322	Erenumab in the prevention of high-frequency episodic and chronic migraine: Erenumab in Real Life in Italy (EARLY), the first Italian multicenter, prospective real-life study. <i>Headache</i> , 2021, 61, 363-372.	1.8	75
323	The Brain Functional Networks Associated to Human and Animal Suffering Differ among Omnivores, Vegetarians and Vegans. <i>PLoS ONE</i> , 2010, 5, e10847.	1.1	75
324	A modified protocol to improve the detection of enhancing brain and spinal cord lesions in multiple sclerosis. <i>Journal of Neurology</i> , 2001, 248, 215-224.	1.8	74

#	ARTICLE	IF	CITATIONS
325	A short-term randomized MRI study of high-dose oral vs intravenous methylprednisolone in MS. <i>Neurology</i> , 2009, 73, 1842-1848.	1.5	74
326	Disrupted brain connectome in semantic variant of primary progressive aphasia. <i>Neurobiology of Aging</i> , 2014, 35, 2646-2655.	1.5	74
327	Deficits in memory and visuospatial learning correlate with regional hippocampal atrophy in MS. <i>Brain Structure and Function</i> , 2015, 220, 435-444.	1.2	74
328	Brain tissue loss occurs after suppression of enhancement in patients with multiple sclerosis treated with autologous haematopoietic stem cell transplantation. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2004, 75, 643-4.	0.9	74
329	Correlations between clinical and MRI involvement in multiple sclerosis: assessment using T1, T2 and MT histograms. <i>Journal of the Neurological Sciences</i> , 1999, 171, 121-129.	0.3	73
330	Magnetization Transfer Magnetic Resonance Imaging in the Assessment of Neurological Diseases. <i>Journal of Neuroimaging</i> , 2004, 14, 303-313.	1.0	73
331	Role of magnetic resonance imaging within diagnostic criteria for multiple sclerosis. <i>Annals of Neurology</i> , 2004, 56, 273-278.	2.8	73
332	Normal-appearing white and grey matter damage in MS. <i>Journal of Neurology</i> , 2007, 254, 513-518.	1.8	73
333	Diffusion Tensor MR Imaging. <i>Neuroimaging Clinics of North America</i> , 2009, 19, 37-43.	0.5	73
334	Functional correlates of cognitive dysfunction in multiple sclerosis: A multicenter fMRI Study. <i>Human Brain Mapping</i> , 2014, 35, 5799-5814.	1.9	73
335	Cognitive rehabilitation correlates with the functional connectivity of the anterior cingulate cortex in patients with multiple sclerosis. <i>Brain Imaging and Behavior</i> , 2014, 8, 387-393.	1.1	73
336	Effects of glatiramer acetate on relapse rate and accumulated disability in multiple sclerosis: meta-analysis of three double-blind, randomized, placebo-controlled clinical trials. <i>Multiple Sclerosis Journal</i> , 2003, 9, 349-355.	1.4	72
337	Evidence for progressive gray matter loss in patients with relapsing-remitting MS. <i>Neurology</i> , 2005, 65, 1126-1128.	1.5	72
338	Functional and Structural Connectivity of the Motor Network in Pediatric and Adult-Onset Relapsing-Remitting Multiple Sclerosis. <i>Radiology</i> , 2010, 254, 541-550.	3.6	72
339	Natalizumab in the pediatric MS population: results of the Italian registry. <i>BMC Neurology</i> , 2015, 15, 174.	0.8	72
340	Neuroimaging Endpoints in Amyotrophic Lateral Sclerosis. <i>Neurotherapeutics</i> , 2017, 14, 11-23.	2.1	72
341	The <i>in vivo</i> distribution of brain tissue loss in Richardson's syndrome and PSP-parkinsonism: a VBM-DARTEL study. <i>European Journal of Neuroscience</i> , 2010, 32, 640-647.	1.2	71
342	Fractional Anisotropy Changes in Alzheimer's Disease Depend on the Underlying Fiber Tract Architecture: A Multiparametric DTI Study using Joint Independent Component Analysis. <i>Journal of Alzheimer's Disease</i> , 2014, 41, 69-83.	1.2	71

#	ARTICLE	IF	CITATIONS
343	Mapping the Progression of Atrophy in Early- and Late-Onset Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2015, 46, 351-364.	1.2	71
344	Resolution-dependent estimates of lesion volumes in magnetic resonance imaging studies of the brain in multiple sclerosis. <i>Annals of Neurology</i> , 1995, 38, 749-754.	2.8	70
345	Strategies for optimizing MRI techniques aimed at monitoring disease activity in multiple sclerosis treatment trials. <i>Journal of Neurology</i> , 1997, 244, 76-84.	1.8	70
346	Characteristics of chronic MS lesions in the cerebrum, brainstem, spinal cord, and optic nerve on T1-weighted MRI. <i>Neurology</i> , 1998, 50, 548-550.	1.5	70
347	Brain imaging and networks in restless legs syndrome. <i>Sleep Medicine</i> , 2017, 31, 39-48.	0.8	70
348	Method for intracellular magnetic labeling of human mononuclear cells using approved iron contrast agents. <i>Magnetic Resonance Imaging</i> , 1999, 17, 1521-1523.	1.0	69
349	Selective Diffusion Changes of The Visual Pathways in Patients with Migraine: A 3-T Tractography Study. <i>Cephalalgia</i> , 2008, 28, 1061-1068.	1.8	69
350	The El Escorial criteria: Strengths and weaknesses. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2015, 16, 1-7.	1.1	69
351	Connectivity-based parcellation of the thalamus in multiple sclerosis and its implications for cognitive impairment: A multicenter study. <i>Human Brain Mapping</i> , 2015, 36, 2809-2825.	1.9	69
352	Inter-sequence and inter-imaging unit variability of diffusion tensor MR imaging histogram-derived metrics of the brain in healthy volunteers. <i>American Journal of Neuroradiology</i> , 2003, 24, 638-43.	1.2	69
353	Comparison of triple dose versus standard dose gadolinium-DTPA for detection of MRI enhancing lesions in patients with primary progressive multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1995, 59, 540-544.	0.9	68
354	Normal-appearing white matter changes in multiple sclerosis: the contribution of magnetic resonance techniques. <i>Multiple Sclerosis Journal</i> , 1999, 5, 273-282.	1.4	68
355	Modelling MRI enhancing lesion counts in multiple sclerosis using a negative binomial model: implications for clinical trials. <i>Journal of the Neurological Sciences</i> , 1999, 163, 74-80.	0.3	68
356	Magnetic resonance imaging, magnetisation transfer imaging, and diffusion weighted imaging correlates of optic nerve, brain, and cervical cord damage in Leber's hereditary optic neuropathy. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2001, 70, 444-449.	0.9	68
357	MRI markers of destructive pathology in multiple sclerosis-related cognitive dysfunction. <i>Journal of the Neurological Sciences</i> , 2006, 245, 111-116.	0.3	68
358	Magnetization Transfer MRI in Multiple Sclerosis. <i>Journal of Neuroimaging</i> , 2007, 17, 22S-26S.	1.0	68
359	Amyloid- $\beta$ deposition and regional grey matter atrophy rates in dementia with Lewy bodies. <i>Brain</i> , 2016, 139, 2740-2750.	3.7	68
360	Motor Learning in Healthy Humans Is Associated to Gray Matter Changes: A Tensor-Based Morphometry Study. <i>PLoS ONE</i> , 2010, 5, e10198.	1.1	68

#	ARTICLE	IF	CITATIONS
361	Long-term changes of magnetization transfer-derived measures from patients with relapsing-remitting and secondary progressive multiple sclerosis. <i>American Journal of Neuroradiology</i> , 1999, 20, 821-7.	1.2	68
362	Diffusion-weighted MR of the brain: methodology and clinical application. <i>Radiologia Medica</i> , 2005, 109, 155-97.	4.7	68
363	Cognitive, EEG, and MRI features of COVID-19 survivors: a 10-month study. <i>Journal of Neurology</i> , 2022, 269, 3400-3412.	1.8	68
364	Role of magnetic resonance imaging in the diagnosis and monitoring of multiple sclerosis: Consensus report of the White Matter Study Group. <i>Journal of Magnetic Resonance Imaging</i> , 2002, 15, 499-504.	1.9	67
365	Functional cortical changes in patients with multiple sclerosis and nonspecific findings on conventional magnetic resonance imaging scans of the brain. <i>NeuroImage</i> , 2003, 19, 826-836.	2.1	67
366	Assessment of MRI abnormalities of the brainstem from patients with migraine and multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2006, 244, 137-141.	0.3	67
367	MRI monitoring of immunomodulation in relapse-onset multiple sclerosis trials. <i>Nature Reviews Neurology</i> , 2012, 8, 13-21.	4.9	67
368	Recent advances in amyotrophic lateral sclerosis. <i>Journal of Neurology</i> , 2016, 263, 1241-1254.	1.8	67
369	Identifying Progression in Multiple Sclerosis: New Perspectives. <i>Annals of Neurology</i> , 2020, 88, 438-452.	2.8	67
370	Sensitivity-encoded diffusion tensor MR imaging of the cervical cord. <i>American Journal of Neuroradiology</i> , 2003, 24, 1254-6.	1.2	67
371	Guidelines for using quantitative magnetization transfer magnetic resonance imaging for monitoring treatment of multiple sclerosis. <i>Journal of Magnetic Resonance Imaging</i> , 2003, 17, 389-397.	1.9	66
372	A whole brain MR spectroscopy study from patients with Alzheimer's disease and mild cognitive impairment. <i>NeuroImage</i> , 2005, 26, 1159-1163.	2.1	66
373	Blockade of chemokine signaling in patients with multiple sclerosis. <i>Neurology</i> , 2006, 67, 1880-1883.	1.5	66
374	Ventral and dorsal visual streams in posterior cortical atrophy: A DT MRI study. <i>Neurobiology of Aging</i> , 2012, 33, 2572-2584.	1.5	66
375	Changes of brain resting state functional connectivity predict the persistence of cognitive rehabilitation effects in patients with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2014, 20, 686-694.	1.4	66
376	Brain structural abnormalities in patients with major depression with or without generalized anxiety disorder comorbidity. <i>Journal of Neurology</i> , 2015, 262, 1255-1265.	1.8	66
377	Brain and cord imaging features in neuromyelitis optica spectrum disorders. <i>Annals of Neurology</i> , 2019, 85, 371-384.	2.8	66
378	Paraclinical tests in acute-onset optic neuritis: basal data and results of a short follow-up. <i>Acta Neurologica Scandinavica</i> , 1991, 84, 231-236.	1.0	65

#	ARTICLE	IF	CITATIONS
379	The effect of IFN $\beta$ -1b on the evolution of enhancing lesions in secondary progressive MS. <i>Neurology</i> , 2001, 57, 2185-2190.	1.5	65
380	A three-year, multi-parametric MRI study in patients at presentation with CIS. <i>Journal of Neurology</i> , 2008, 255, 683-691.	1.8	65
381	Longitudinal assessment of grey matter contraction in amyotrophic lateral sclerosis: A tensor based morphometry study. <i>Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders</i> , 2009, 10, 168-174.	2.3	65
382	Assessment of Brain White Matter Fiber Bundle Atrophy in Patients with Friedreich Ataxia. <i>Radiology</i> , 2010, 255, 882-889.	3.6	65
383	Phase III dose-comparison study of glatiramer acetate for multiple sclerosis. <i>Annals of Neurology</i> , 2011, 69, 75-82.	2.8	65
384	Intrinsic Damage to the Major White Matter Tracts in Patients with Different Clinical Phenotypes of Multiple Sclerosis: A Voxelwise Diffusion-Tensor MR Study. <i>Radiology</i> , 2011, 260, 541-550.	3.6	65
385	Mind the gap: The mismatch between clinical and imaging metrics in ALS. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2015, 16, 524-529.	1.1	65
386	Antenatal diagnosis of vein of Galen aneurysmal malformation: MR study of fetal brain and postnatal follow-up. <i>Neuroradiology</i> , 1996, 38, 87-90.	1.1	64
387	The effect of cladribine on T1 "black hole" changes in progressive MS. <i>Journal of the Neurological Sciences</i> , 2000, 176, 42-44.	0.3	64
388	A Magnetic Resonance Imaging Voxel-Based Morphometry Study of Regional Gray Matter Atrophy in Patients With Benign Multiple Sclerosis. <i>Archives of Neurology</i> , 2008, 65, 1223-30.	4.9	64
389	Is a preserved functional reserve a mechanism limiting clinical impairment in pediatric MS patients?. <i>Human Brain Mapping</i> , 2009, 30, 2844-2851.	1.9	64
390	Thalamic Damage Predicts the Evolution of Primary-Progressive Multiple Sclerosis at 5 Years. <i>American Journal of Neuroradiology</i> , 2011, 32, 1016-1020.	1.2	64
391	Progression of grey and white matter brain damage in Parkinson's disease: a critical review of structural MRI literature. <i>Journal of Neurology</i> , 2021, 268, 3144-3179.	1.8	63
392	Blood neurofilament light chain and total tau levels at admission predict death in COVID-19 patients. <i>Journal of Neurology</i> , 2021, 268, 4436-4442.	1.8	63
393	White matter lesions in the elderly: Pathophysiological hypothesis on the effect on brain plasticity and reserve. <i>Journal of the Neurological Sciences</i> , 2008, 273, 3-9.	0.3	62
394	Automatic Segmentation and Classification of Multiple Sclerosis in Multichannel MRI. <i>IEEE Transactions on Biomedical Engineering</i> , 2009, 56, 2461-2469.	2.5	62
395	Imaging resting state brain function in multiple sclerosis. <i>Journal of Neurology</i> , 2013, 260, 1709-1713.	1.8	62
396	Long-term (48 weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high-frequency episodic and chronic migraine in a real world: Results of the EARLY 2 study. <i>Headache</i> , 2021, 61, 1351-1363.	1.8	62

#	ARTICLE	IF	CITATIONS
397	Comparison of three MR sequences for the detection of cervical cord lesions in patients with multiple sclerosis. <i>American Journal of Neuroradiology</i> , 1999, 20, 1710-6.	1.2	62
398	Brain magnetic resonance imaging and multimodal evoked potentials in benign and secondary progressive multiple sclerosis.. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1995, 58, 31-37.	0.9	61
399	Peripheral levels of caspase-1 mRNA correlate with disease activity in patients with multiple sclerosis; a preliminary study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1999, 67, 785-788.	0.9	61
400	EFNS guidelines on the use of neuroimaging in the management of multiple sclerosis. <i>European Journal of Neurology</i> , 2006, 13, 313-325.	1.7	61
401	Early and late onset Alzheimer's disease patients have distinct patterns of white matter damage. <i>Neurobiology of Aging</i> , 2012, 33, 1023-1033.	1.5	61
402	Brain networks in posterior cortical atrophy: A single case tractography study and literature review. <i>Cortex</i> , 2012, 48, 1298-1309.	1.1	61
403	The topography of brain damage at different stages of Parkinson's disease. <i>Human Brain Mapping</i> , 2013, 34, 2798-2807.	1.9	61
404	In vivo signatures of nonfluent/agrammatic primary progressive aphasia caused by FTLD pathology. <i>Neurology</i> , 2014, 82, 239-247.	1.5	61
405	Correlation of multiple sclerosis measures derived from T2-weighted, T1-weighted, magnetization transfer, and diffusion tensor MR imaging. <i>American Journal of Neuroradiology</i> , 2001, 22, 1462-7.	1.2	61
406	Characteristic MR lesion pattern and correlation of T1 and T2 lesion volume with neurologic and neuropsychological findings in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL). <i>American Journal of Neuroradiology</i> , 1999, 20, 91-100.	1.2	61
407	Visual analysis of serial T2-weighted MRI in multiple sclerosis: intra- and interobserver reproducibility. <i>Neuroradiology</i> , 1999, 41, 882-888.	1.1	60
408	Cerebral grey matter pathology and fatigue in patients with multiple sclerosis: a preliminary study. <i>Journal of the Neurological Sciences</i> , 2002, 194, 71-74.	0.3	60
409	European Study on Intravenous Immunoglobulin in Multiple Sclerosis. <i>Archives of Neurology</i> , 2004, 61, 1409.	4.9	60
410	Conventional MRI in Multiple Sclerosis. <i>Journal of Neuroimaging</i> , 2007, 17, 3S-9S.	1.0	60
411	Quantitative volumetric analysis of brain magnetic resonance imaging from patients with multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 1998, 158, 148-153.	0.3	59
412	Cortical reorganisation in patients with MS. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2004, 75, 1087-1089.	0.9	59
413	A functional MRI study of movement-associated cortical changes in patients with Devic's neuromyelitis optica. <i>NeuroImage</i> , 2004, 21, 1061-1068.	2.1	59
414	A functional MRI study of cortical activations associated with object manipulation in patients with MS. <i>NeuroImage</i> , 2004, 21, 1147-1154.	2.1	59



#	ARTICLE	IF	CITATIONS
415	Long-term clinical outcome of primary progressive MS: Predictive value of clinical and MRI data. <i>Neurology</i> , 2005, 65, 633-635.	1.5	59
416	Diffusion Tensor MRI in Multiple Sclerosis. <i>Journal of Neuroimaging</i> , 2007, 17, 27S-30S.	1.0	59
417	Cognitive learning is associated with gray matter changes in healthy human individuals: A tensor-based morphometry study. <i>NeuroImage</i> , 2009, 48, 585-589.	2.1	59
418	Abnormalities of Resting State Functional Connectivity Are Related to Sustained Attention Deficits in MS. <i>PLoS ONE</i> , 2012, 7, e42862.	1.1	59
419	Forceps minor damage and co-occurrence of depression and fatigue in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2014, 20, 1633-1640.	1.4	59
420	Patterns of Brain Structural Changes in First-Contact, Antipsychotic Drug-Naïve Patients with Schizophrenia. <i>American Journal of Neuroradiology</i> , 2014, 35, 30-37.	1.2	59
421	Magnetization transfer imaging of patients with definite MS and negative conventional MRI. <i>Neurology</i> , 1999, 52, 845-845.	1.5	59
422	Acute transverse myelopathy: spinal and cranial MR study with clinical follow-up. <i>American Journal of Neuroradiology</i> , 1995, 16, 115-23.	1.2	59
423	MRI quantification of gray and white matter damage in patients with early-onset multiple sclerosis. <i>Journal of Neurology</i> , 2006, 253, 903-907.	1.8	58
424	Large-scale, multicentre, quantitative MRI study of brain and cord damage in primary progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2008, 14, 455-464.	1.4	58
425	Neuroanatomical correlates of depression and apathy in Parkinson's disease: Magnetic resonance imaging studies. <i>Journal of the Neurological Sciences</i> , 2011, 310, 61-63.	0.3	58
426	Magnetic resonance outcome measures in multiple sclerosis trials. <i>Current Opinion in Neurology</i> , 2014, 27, 290-299.	1.8	58
427	Hippocampalâ€‹<sc>DMN</sc> disconnectivity in <sc>MS</sc> is related to <sc>WM</sc> lesions and depression. <i>Human Brain Mapping</i> , 2015, 36, 5051-5063.	1.9	58
428	MRI in Leber's hereditary optic neuropathy: the relationship to multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015, 86, 537-542.	0.9	58
429	Carotid atherosclerosis, silent ischemic brain damage and brain atrophy: A systematic review and meta-analysis. <i>International Journal of Cardiology</i> , 2016, 223, 681-687.	0.8	58
430	Advanced magnetic resonance imaging of neurodegenerative diseases. <i>Neurological Sciences</i> , 2017, 38, 41-51.	0.9	58
431	The Role of T1-Weighted Derived Measures of Neurodegeneration for Assessing Disability Progression in Multiple Sclerosis. <i>Frontiers in Neurology</i> , 2017, 8, 433.	1.1	58
432	Assessment and correction of B1-induced errors in magnetization transfer ratio measurements. <i>Magnetic Resonance in Medicine</i> , 2005, 53, 134-140.	1.9	57

#	ARTICLE	IF	CITATIONS
433	Deep gray matter T2 hypointensity is present in patients with clinically isolated syndromes suggestive of multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2010, 16, 39-44.	1.4	57
434	Pathophysiological Bases of Comorbidity in Migraine. <i>Frontiers in Human Neuroscience</i> , 2021, 15, 640574.	1.0	57
435	COVID-19 Severity in Multiple Sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2022, 9, .	3.1	57
436	Cerebral involvement in celiac disease: A serial MRI study in a patient with brainstem and cerebellar symptoms. <i>Neurology</i> , 1997, 49, 1447-1450.	1.5	56
437	Correlations Between Clinical Findings and Magnetization Transfer Imaging Metrics of Tissue Damage in Individuals With Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy. <i>Stroke</i> , 2001, 32, 643-648.	1.0	56
438	Clinicalâ€“MRI correlations in a European trial of interferon beta-1b in secondary progressive MS. <i>Neurology</i> , 2001, 57, 2191-2197.	1.5	56
439	MRI metrics as surrogate markers for clinical relapse rate in relapsing-remitting MS patients. <i>Neurology</i> , 2002, 58, 417-421.	1.5	56
440	A preliminary study of magnetization transfer and diffusion tensor MRI of multiple sclerosis patients with fatigue. <i>Journal of Neurology</i> , 2002, 249, 535-537.	1.8	56
441	Occult tissue damage in patients with primary progressive multiple sclerosis is independent of T2-visible lesions. <i>Journal of Neurology</i> , 2003, 250, 456-460.	1.8	56
442	Natalizumab in pediatric multiple sclerosis: results of a cohort of 55 cases. <i>Multiple Sclerosis Journal</i> , 2013, 19, 1106-1112.	1.4	56
443	Posterior brain damage and cognitive impairment in pediatric multiple sclerosis. <i>Neurology</i> , 2014, 82, 1314-1321.	1.5	56
444	Basal Forebrain and Hippocampus as Predictors of Conversion to Alzheimerâ€™s Disease in Patients with Mild Cognitive Impairment â€“ A Multicenter DTI and Volumetry Study. <i>Journal of Alzheimer's Disease</i> , 2015, 48, 197-204.	1.2	56
445	COVID-19 in teriflunomide-treated patients with multiple sclerosis. <i>Journal of Neurology</i> , 2020, 267, 2790-2796.	1.8	56
446	Multicenter case-control study on restless legs syndrome in multiple sclerosis: the REMS study. <i>Sleep</i> , 2008, 31, 944-52.	0.6	56
447	Morphology and evolution of cortical lesions in multiple sclerosis. A longitudinal MRI study. <i>NeuroImage</i> , 2008, 42, 1324-1328.	2.1	55
448	T2 hypointensity in the deep gray matter of patients with benign multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2009, 15, 678-686.	1.4	55
449	Central nervous system dysregulation extends beyond the pain-matrix network in cluster headache. <i>Cephalalgia</i> , 2010, 30, 1383-1391.	1.8	55
450	Wallerian and trans-synaptic degeneration contribute to optic radiation damage in multiple sclerosis: a diffusion tensor MRI study. <i>Multiple Sclerosis Journal</i> , 2013, 19, 1610-1617.	1.4	55

#	ARTICLE	IF	CITATIONS
451	Postmortem Magnetic Resonance Imaging to Guide the Pathologic Cut. Journal of Neuropathology and Experimental Neurology, 2014, 73, 780-788.	0.9	55
452	White Matter Degeneration in Atypical Alzheimer Disease. Radiology, 2015, 277, 162-172.	3.6	55
453	Abnormal adaptation over time of motor network recruitment in multiple sclerosis patients with fatigue. Multiple Sclerosis Journal, 2016, 22, 1144-1153.	1.4	55
454	Multimodal structural MRI in the diagnosis of motor neuron diseases. NeuroImage: Clinical, 2017, 16, 240-247.	1.4	55
455	Single-cell analysis of cytokine production shows different immune profiles in multiple sclerosis patients with active or quiescent disease. Journal of Neuroimmunology, 2001, 121, 88-101.	1.1	54
456	Clinical trials of multiple sclerosis monitored with enhanced MRI: new sample size calculations based on large data sets. Journal of Neurology, Neurosurgery and Psychiatry, 2001, 70, 494-499.	0.9	54
457	Copaxone™s effect on MRI-monitored disease in relapsing MS is reproducible and sustained. Neurology, 2002, 59, 1284-1286.	1.5	54
458	Pyramidal tract lesions and movement-associated cortical recruitment in patients with MS. NeuroImage, 2004, 23, 141-147.	2.1	54
459	The Topography of Brain Microstructural Damage in Amyotrophic Lateral Sclerosis Assessed Using Diffusion Tensor MR Imaging. American Journal of Neuroradiology, 2011, 32, 1307-1314.	1.2	54
460	Patients with migraine do not have MRI-visible cortical lesions. Journal of Neurology, 2012, 259, 2695-2698.	1.8	54
461	Structural and functional brain signatures of C9orf72 in motor neuron disease. Neurobiology of Aging, 2017, 57, 206-219.	1.5	54
462	Brain structural and functional signatures of impulsive/compulsive behaviours in Parkinson™s disease. Molecular Psychiatry, 2018, 23, 459-466.	4.1	54
463	Abnormal functional connectivity of thalamic sub-regions contributes to fatigue in multiple sclerosis. Multiple Sclerosis Journal, 2018, 24, 1183-1195.	1.4	54
464	Reduced dynamics of functional connectivity and cognitive impairment in multiple sclerosis. Multiple Sclerosis Journal, 2020, 26, 476-488.	1.4	54
465	A magnetization transfer imaging study of the brain in patients with migraine. Neurology, 2000, 54, 507-507.	1.5	53
466	Intra-voxel and inter-voxel coherence in patients with multiple sclerosis assessed using diffusion tensor MRI. Journal of Neurology, 2002, 249, 875-883.	1.8	53
467	Evidence for Cortical Functional Changes in Patients With Migraine and White Matter Abnormalities on Conventional and Diffusion Tensor Magnetic Resonance Imaging. Stroke, 2003, 34, 665-670.	1.0	53
468	The long-term effect of AHSCT on MRI measures of MS evolution: a five-year follow-up study. Multiple Sclerosis Journal, 2007, 13, 1068-1070.	1.4	53

#	ARTICLE	IF	CITATIONS
469	Associations Between Cervical Cord Gray Matter Damage and Disability in Patients With Multiple Sclerosis. <i>Archives of Neurology</i> , 2007, 64, 1302.	4.9	53
470	Long-term follow-up of patients treated with glatiramer acetate: a multicentre, multinational extension of the European/Canadian double-blind, placebo-controlled, MRI-monitored trial. <i>Multiple Sclerosis Journal</i> , 2007, 13, 502-508.	1.4	53
471	Tactile-associated recruitment of the cervical cord is altered in patients with multiple sclerosis. <i>NeuroImage</i> , 2008, 39, 1542-1548.	2.1	53
472	Evidence for retrochiasmatic tissue loss in Leber's hereditary optic neuropathy. <i>Human Brain Mapping</i> , 2010, 31, 1900-1906.	1.9	53
473	MRI predictors of long-term evolution in amyotrophic lateral sclerosis. <i>European Journal of Neuroscience</i> , 2010, 32, 1490-1496.	1.2	53
474	Oral laquinimod in patients with relapsing-remitting multiple sclerosis: 36-week double-blind active extension of the multi-centre, randomized, double-blind, parallel-group placebo-controlled study. <i>Multiple Sclerosis Journal</i> , 2010, 16, 1360-1366.	1.4	53
475	T2 lesion location really matters: a 10 year follow-up study in primary progressive multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2011, 82, 72-77.	0.9	53
476	Location of brain lesions predicts conversion of clinically isolated syndromes to multiple sclerosis. <i>Neurology</i> , 2013, 80, 234-241.	1.5	53
477	Cerebellar contribution to motor and cognitive performance in multiple sclerosis: An MRI sub-regional volumetric analysis. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1194-1203.	1.4	53
478	Sensitivities and predictive values of paraclinical tests for diagnosing multiple sclerosis. <i>Journal of Neurology</i> , 1993, 241, 132-137.	1.8	52
479	A Preliminary Diffusion Tensor and Magnetization Transfer Magnetic Resonance Imaging Study of Early-Onset Multiple Sclerosis. <i>Archives of Neurology</i> , 2004, 61, 366.	4.9	52
480	Impairment of movement-associated brain deactivation in multiple sclerosis: further evidence for a functional pathology of interhemispheric neuronal inhibition. <i>Experimental Brain Research</i> , 2008, 187, 25-31.	0.7	52
481	MR Imaging of Gray Matter Involvement in Multiple Sclerosis: Implications for Understanding Disease Pathophysiology and Monitoring Treatment Efficacy. <i>American Journal of Neuroradiology</i> , 2010, 31, 1171-1177.	1.2	52
482	Mapping regional grey and white matter atrophy in relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2012, 18, 1027-1037.	1.4	52
483	Neuroimaging findings in frontotemporal lobar degeneration spectrum of disorders. <i>Cortex</i> , 2012, 48, 389-413.	1.1	52
484	White matter changes in paediatric multiple sclerosis and monophasic demyelinating disorders. <i>Brain</i> , 2017, 140, 1300-1315.	3.7	52
485	Neuroimaging in amyotrophic lateral sclerosis: current and emerging uses. <i>Expert Review of Neurotherapeutics</i> , 2018, 18, 395-406.	1.4	52
486	Resting-state Functional MRI in Parkinsonian Syndromes. <i>Movement Disorders Clinical Practice</i> , 2019, 6, 104-117.	0.8	52

#	ARTICLE	IF	CITATIONS
487	Sensitivity and reproducibility of volume change measurements of different brain portions on magnetic resonance imaging in patients with multiple sclerosis. <i>Journal of Neurology</i> , 2000, 247, 960-965.	1.8	51
488	A diffusion tensor magnetic resonance imaging study of brain tissue from patients with migraine. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2003, 74, 501-503.	0.9	51
489	Evidence for cervical cord tissue disorganisation with aging by diffusion tensor MRI. <i>NeuroImage</i> , 2007, 36, 728-735.	2.1	51
490	Abnormal connectivity of the sensorimotor network in patients with MS: A multicenter fMRI study. <i>Human Brain Mapping</i> , 2009, 30, 2412-2425.	1.9	51
491	Evidence for acute neurotoxicity after chemotherapy. <i>Annals of Neurology</i> , 2010, 68, 806-815.	2.8	51
492	Preserved brain adaptive properties in patients with benign multiple sclerosis. <i>Neurology</i> , 2010, 74, 142-149.	1.5	51
493	Weighing brain activity with the balance: Angelo Mosso's original manuscripts come to light. <i>Brain</i> , 2014, 137, 621-633.	3.7	51
494	Long-term disability progression in primary progressive multiple sclerosis: a 15-year study. <i>Brain</i> , 2017, 140, 2814-2819.	3.7	51
495	Functional MRI in Idiopathic Parkinson's Disease. <i>International Review of Neurobiology</i> , 2018, 141, 439-467.	0.9	51
496	Brain mapping in multiple sclerosis: Lessons learned about the human brain. <i>NeuroImage</i> , 2019, 190, 32-45.	2.1	51
497	<scp>Mega-analysis</scp> methods in <scp>ENIGMA</scp>: The experience of the generalized anxiety disorder working group. <i>Human Brain Mapping</i> , 2022, 43, 255-277.	1.9	51
498	Enhancement frequency decreases with increasing age in relapsing-remitting multiple sclerosis. <i>Neurology</i> , 2001, 56, 422-423.	1.5	51
499	Benign versus secondary-progressive multiple sclerosis: the potential role of proton MR spectroscopy in defining the nature of disability. <i>American Journal of Neuroradiology</i> , 1998, 19, 223-9.	1.2	51
500	Magnetization transfer ratios of multiple sclerosis lesions with variable durations of enhancement. <i>Journal of the Neurological Sciences</i> , 1998, 159, 162-165.	0.3	50
501	MRI metrics as surrogate endpoints for EDSS progression in SPMS patients treated with IFN $\beta$ -1b. <i>Neurology</i> , 2003, 60, 1462-1466.	1.5	50
502	Evidence for enhanced functional activity of cervical cord in relapsing multiple sclerosis. <i>Magnetic Resonance in Medicine</i> , 2008, 59, 1035-1042.	1.9	50
503	Clinical, cognitive, and behavioural correlates of white matter damage in progressive supranuclear palsy. <i>Journal of Neurology</i> , 2014, 261, 913-924.	1.8	50
504	Tumor necrosis factor $\alpha$ and its receptors in relapsing-remitting multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 1997, 152, 51-61.	0.3	49

#	ARTICLE	IF	CITATIONS
505	Grading cervical cord damage in neuromyelitis optica and MS by diffusion tensor MRI. <i>Neurology</i> , 2006, 67, 161-163.	1.5	49
506	The topographical distribution of tissue injury in benign MS: A 3T multiparametric MRI study. <i>NeuroImage</i> , 2008, 39, 1499-1509.	2.1	49
507	Reproducibility of fMRI in the clinical setting: Implications for trial designs. <i>NeuroImage</i> , 2008, 42, 603-610.	2.1	49
508	MRI measures of neurodegeneration in multiple sclerosis: implications for disability, disease monitoring, and treatment. <i>Journal of Neurology</i> , 2015, 262, 1-6.	1.8	49
509	Multiparametric MRI to distinguish early onset Alzheimer's disease and behavioural variant of frontotemporal dementia. <i>NeuroImage: Clinical</i> , 2017, 15, 428-438.	1.4	49
510	Gray matter volume modifications in migraine. <i>Neurology</i> , 2018, 91, e280-e292.	1.5	49
511	The emotional impact of the COVID-19 pandemic on individuals with progressive multiple sclerosis. <i>Journal of Neurology</i> , 2021, 268, 1598-1607.	1.8	49
512	Benign and secondary progressive multiple sclerosis: a preliminary quantitative MRI study. <i>Journal of Neurology</i> , 1994, 241, 246-251.	1.8	48
513	Magnetisation transfer ratios of contrast-enhancing and nonenhancing lesions in multiple sclerosis. <i>Neuroradiology</i> , 1996, 38, 115-119.	1.1	48
514	A multiparametric MRI study of frontal lobe dementia in multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 1999, 171, 135-144.	0.3	48
515	Image registration and subtraction to detect active T2 lesions in MS: an interobserver study. <i>Journal of Neurology</i> , 2002, 249, 767-773.	1.8	48
516	Axonal injury in early multiple sclerosis is irreversible and independent of the short-term disease evolution. <i>Neurology</i> , 2005, 65, 1626-1630.	1.5	48
517	MRI features of benign multiple sclerosis. <i>Neurology</i> , 2009, 72, 1693-1701.	1.5	48
518	Functional MR Imaging in Multiple Sclerosis. <i>Neuroimaging Clinics of North America</i> , 2009, 19, 59-70.	0.5	48
519	Diffusion tensor MRI contributes to differentiate Richardson's syndrome from PSP-parkinsonism. <i>Neurobiology of Aging</i> , 2012, 33, 2817-2826.	1.5	48
520	Fatigue in multiple sclerosis: The contribution of occult white matter damage. <i>Multiple Sclerosis Journal</i> , 2016, 22, 1676-1684.	1.4	48
521	Gray matter trophism, cognitive impairment, and depression in patients with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1864-1874.	1.4	48
522	The role of the cerebellum in multiple sclerosisâ€”150 years after Charcot. <i>Neuroscience and Biobehavioral Reviews</i> , 2018, 89, 85-98.	2.9	48

#	ARTICLE	IF	CITATIONS
523	Long-term disability trajectories in relapsing multiple sclerosis patients treated with early intensive or escalation treatment strategies. <i>Therapeutic Advances in Neurological Disorders</i> , 2021, 14, 175628642110195.	1.5	48
524	Whole-brain atrophy in multiple sclerosis measured by two segmentation processes from various MRI sequences. <i>Journal of the Neurological Sciences</i> , 2003, 216, 169-177.	0.3	47
525	Predicting gadolinium enhancement status in MS patients eligible for randomized clinical trials. <i>Neurology</i> , 2005, 65, 1447-1454.	1.5	47
526	MRI results from the European Study on Intravenous Immunoglobulin in Secondary Progressive Multiple Sclerosis (ESIMS). <i>Multiple Sclerosis Journal</i> , 2005, 11, 433-440.	1.4	47
527	Determinants of Disability in Multiple Sclerosis at Various Disease Stages. <i>Archives of Neurology</i> , 2007, 64, 1163.	4.9	47
528	Cortical lesions in children with multiple sclerosis. <i>Neurology</i> , 2011, 76, 910-913.	1.5	47
529	Determinants of iron accumulation in deep grey matter of multiple sclerosis patients. <i>Multiple Sclerosis Journal</i> , 2014, 20, 1692-1698.	1.4	47
530	Ultra-high-field MR imaging in multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014, 85, 60-66.	0.9	47
531	Relationship between Damage to the Cerebellar Peduncles and Clinical Disability in Multiple Sclerosis. <i>Radiology</i> , 2014, 271, 822-830.	3.6	47
532	The effect of action observation/execution on mirror neuron system recruitment: an fMRI study in healthy individuals. <i>Brain Imaging and Behavior</i> , 2017, 11, 565-576.	1.1	47
533	Measurement of Whole-Brain and Gray Matter Atrophy in Multiple Sclerosis: Assessment with MR Imaging. <i>Radiology</i> , 2018, 288, 554-564.	3.6	47
534	Urgent challenges in quantification and interpretation of brain grey matter atrophy in individual MS patients using MRI. <i>NeuroImage: Clinical</i> , 2018, 19, 466-475.	1.4	47
535	COVID-19 pandemic and mental distress in multiple sclerosis: implications for clinical management. <i>European Journal of Neurology</i> , 2020, 28, 3375-3383.	1.7	47
536	Disease-modifying therapies and SARS-CoV-2 vaccination in multiple sclerosis: an expert consensus. <i>Journal of Neurology</i> , 2021, 268, 3961-3968.	1.8	47
537	Role of White Matter Lesions in Cognitive Impairment of Vascular Origin. <i>Alzheimer Disease and Associated Disorders</i> , 1999, 13, S49-54.	0.6	47
538	Guidelines from The Italian Neurological and Neuroradiological Societies for the use of magnetic resonance imaging in daily life clinical practice of multiple sclerosis patients. <i>Neurological Sciences</i> , 2013, 34, 2085-2093.	0.9	46
539	Cognitive and neuropsychiatric disease manifestations in MS. <i>Multiple Sclerosis and Related Disorders</i> , 2013, 2, 4-12.	0.9	46
540	Anti-CD20 therapies for multiple sclerosis: current status and future perspectives. <i>Journal of Neurology</i> , 2022, 269, 1316-1334.	1.8	46

#	ARTICLE	IF	CITATIONS
541	Influence of Clinical Variables on Neuropsychological Performance in Multiple Sclerosis. <i>European Neurology</i> , 1994, 34, 324-328.	0.6	45
542	A high-resolution three-dimensional T1-weighted gradient echo sequence improves the detection of disease activity in multiple sclerosis. <i>Annals of Neurology</i> , 1996, 40, 901-907.	2.8	45
543	Magnetization transfer and diffusion tensor MR imaging of basal ganglia from patients with multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2001, 183, 69-72.	0.3	45
544	Linking structural, metabolic and functional changes in multiple sclerosis. <i>European Journal of Neurology</i> , 2001, 8, 291-297.	1.7	45
545	In-vivo tissue characterization of multiple sclerosis and other white matter diseases using magnetic resonance based techniques. <i>Journal of Neurology</i> , 2001, 248, 1019-1029.	1.8	45
546	Randomized, double-blind, dose-comparison study of glatiramer acetate in relapsingâ€“remitting MS. <i>Neurology</i> , 2007, 68, 939-944.	1.5	45
547	Intercenter agreement of brain atrophy measurement in multiple sclerosis patients using manuallyâ€“edited SIENA and SIENAX. <i>Journal of Magnetic Resonance Imaging</i> , 2007, 26, 881-885.	1.9	45
548	MRI and cognition in multiple sclerosis. <i>Neurological Sciences</i> , 2010, 31, 231-234.	0.9	45
549	Functional magnetic resonance imaging correlates of cognitive performance in patients with a clinically isolated syndrome suggestive of multiple sclerosis at presentation: an activation and connectivity study. <i>Multiple Sclerosis Journal</i> , 2012, 18, 153-163.	1.4	45
550	Proinflammatory cytokines regulate antigen-independent T-cell Activation by two separate calcium-signaling pathways in multiple sclerosis patients. <i>Annals of Neurology</i> , 1998, 43, 340-349.	2.8	44
551	Disturbed function and plasticity in multiple sclerosis as gleaned from functional magnetic resonance imaging. <i>Current Opinion in Neurology</i> , 2003, 16, 275-282.	1.8	44
552	Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsingâ€“remitting multiple sclerosis: an 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study). <i>Journal of Neurology</i> , 2017, 264, 2436-2449.	1.8	44
553	Recent advances in headache neuroimaging. <i>Current Opinion in Neurology</i> , 2018, 31, 379-385.	1.8	44
554	The â€œcentral vein signâ€“in patients with diagnostic â€œred flagsâ€“for multiple sclerosis: A prospective multicenter 3T study. <i>Multiple Sclerosis Journal</i> , 2020, 26, 421-432.	1.4	44
555	Post-infectious Guillainâ€“BarrÃ© syndrome related to SARS-CoV-2 infection: a case report. <i>Journal of Neurology</i> , 2020, 267, 2492-2494.	1.8	44
556	The effect of imprecise repositioning on lesion volume measurements in patients with multiple sclerosis. <i>Neurology</i> , 1997, 49, 274-276.	1.5	43
557	Two-year follow-up study of primary and transitional progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2002, 8, 108-114.	1.4	43
558	Magnetic resonance techniques for the in vivo assessment of multiple sclerosis pathology: Consensus report of the white matter study group. <i>Journal of Magnetic Resonance Imaging</i> , 2005, 21, 669-675.	1.9	43



#	ARTICLE	IF	CITATIONS
559	A multiparametric evaluation of regional brain damage in patients with primary progressive multiple sclerosis. <i>Human Brain Mapping</i> , 2009, 30, 3009-3019.	1.9	43
560	Structural and metabolic changes in the brain of patients with upper motor neuron disorders: A multiparametric MRI study. <i>Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders</i> , 2009, 10, 269-279.	2.3	43
561	Neuropsychological rehabilitation in adult multiple sclerosis. <i>Neurological Sciences</i> , 2010, 31, 271-274.	0.9	43
562	Interferon $\beta$ -1b and glatiramer acetate effects on permanent black hole evolution. <i>Neurology</i> , 2011, 76, 1222-1228.	1.5	43
563	Following the Spreading of Brain Structural Changes in Alzheimer's Disease: A Longitudinal, Multimodal MRI Study. <i>Journal of Alzheimer's Disease</i> , 2015, 47, 995-1007.	1.2	43
564	Diffusion MR imaging in multiple sclerosis: technical aspects and challenges. <i>American Journal of Neuroradiology</i> , 2007, 28, 411-20.	1.2	43
565	Comparison of MR pulse sequences in the detection of multiple sclerosis lesions. <i>American Journal of Neuroradiology</i> , 1997, 18, 959-63.	1.2	43
566	Amyloid-Related Imaging Abnormalities and $\beta$ -Amyloid Targeting Antibodies. <i>JAMA Neurology</i> , 2022, 79, 291.	4.5	43
567	Triple dose of gadolinium-DTPA and delayed MRI in patients with benign multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1996, 60, 526-530.	0.9	42
568	Cord damage elicits brain functional reorganization after a single episode of myelitis. <i>Neurology</i> , 2003, 61, 1078-1085.	1.5	42
569	An MT MRI study of the cervical cord in clinically isolated syndromes suggestive of MS. <i>Neurology</i> , 2004, 63, 584-585.	1.5	42
570	Voxel-wise mapping of cervical cord damage in multiple sclerosis patients with different clinical phenotypes. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013, 84, 35-41.	0.9	42
571	Regional Cervical Cord Atrophy and Disability in Multiple Sclerosis: A Voxel-based Analysis. <i>Radiology</i> , 2013, 266, 853-861.	3.6	42
572	White matter microstructure abnormalities in pediatric migraine patients. <i>Cephalalgia</i> , 2015, 35, 1278-1286.	1.8	42
573	Incidence and course of depression in multiple sclerosis in the multinational BEYOND trial. <i>Journal of Neurology</i> , 2016, 263, 1418-1426.	1.8	42
574	Insights into White Matter Damage in Alzheimer's Disease: From Postmortem to in vivo Diffusion Tensor MRI Studies. <i>Neurodegenerative Diseases</i> , 2016, 16, 26-33.	0.8	42
575	MRI in the evaluation of pediatric multiple sclerosis. <i>Neurology</i> , 2016, 87, S88-96.	1.5	42
576	Structural brain abnormalities in patients with vestibular migraine. <i>Journal of Neurology</i> , 2017, 264, 295-303.	1.8	42

#	ARTICLE	IF	CITATIONS
577	SVM recursive feature elimination analyses of structural brain MRI predicts near-term relapses in patients with clinically isolated syndromes suggestive of multiple sclerosis. <i>NeuroImage: Clinical</i> , 2019, 24, 102011.	1.4	42
578	MR imaging of Devic's neuromyelitis optica. <i>Neurological Sciences</i> , 2004, 25, s371-s373.	0.9	41
579	Magnetic resonance imaging metrics and their correlation with clinical outcomes in multiple sclerosis: a review of the literature and future perspectives. <i>Multiple Sclerosis Journal</i> , 2008, 14, 719-727.	1.4	41
580	MRI ASANOUTCOMEIN MULTIPLE SCLEROSIS CLINICAL TRIALS. <i>Neurology</i> , 2009, 73, 1932-1933.	1.5	41
581	Rituximab as a first-line preventive treatment in pediatric NMOSDs. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2014, 1, e46.	3.1	41
582	Resting state functional connectivity alterations in primary lateral sclerosis. <i>Neurobiology of Aging</i> , 2014, 35, 916-925.	1.5	41
583	Recurrent disease-activity rebound in a patient with multiple sclerosis after natalizumab discontinuations for pregnancy planning. <i>Multiple Sclerosis Journal</i> , 2016, 22, 1506-1508.	1.4	41
584	Hyperconnectivity of the dorsolateral prefrontal cortex following mental effort in multiple sclerosis patients with cognitive fatigue. <i>Multiple Sclerosis Journal</i> , 2016, 22, 1665-1675.	1.4	41
585	An investigation of cerebrovascular lesions in dementia with Lewy bodies compared to Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2017, 13, 257-266.	0.4	41
586	<i>MYD88</i> L265P mutation and interleukin-10 detection in cerebrospinal fluid are highly specific discriminating markers in patients with primary central nervous system lymphoma: results from a prospective study. <i>British Journal of Haematology</i> , 2021, 193, 497-505.	1.2	41
587	Slowly Expanding Lesions Predict 9-Year Multiple Sclerosis Disease Progression. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2022, 9, .	3.1	41
588	Correlation between multimodal evoked potentials and magnetic resonance imaging in multiple sclerosis. <i>Journal of Neurology</i> , 1989, 236, 4-8.	1.8	40
589	Diffusion tensor magnetic resonance imaging at 3.0 tesla shows subtle cerebral grey matter abnormalities in patients with migraine. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2006, 77, 686-689.	0.9	40
590	Lesional magnetization transfer ratio: a feasible outcome for remyelinating treatment trials in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2010, 16, 660-669.	1.4	40
591	White matter microstructural damage in Alzheimer's disease at different ages of onset. <i>Neurobiology of Aging</i> , 2013, 34, 2331-2340.	1.5	40
592	Present and future of fMRI in multiple sclerosis. <i>Expert Review of Neurotherapeutics</i> , 2013, 13, 27-31.	1.4	40
593	Intranetwork and internetwork functional connectivity abnormalities in pediatric multiple sclerosis. <i>Human Brain Mapping</i> , 2014, 35, 4180-4192.	1.9	40
594	Regional cortical thinning in multiple sclerosis and its relation with cognitive impairment: A multicenter study. <i>Multiple Sclerosis Journal</i> , 2016, 22, 901-909.	1.4	40

#	ARTICLE	IF	CITATIONS
595	Structural connectivityâ€defined thalamic subregions have different functional connectivity abnormalities in multiple sclerosis patients: Implications for clinical correlations. <i>Human Brain Mapping</i> , 2017, 38, 6005-6018.	1.9	40
596	Cervical Cord T1-weighted Hypointense Lesions at MR Imaging in Multiple Sclerosis: Relationship to Cord Atrophy and Disability. <i>Radiology</i> , 2018, 288, 234-244.	3.6	40
597	Lifespan normative data on rates of brain volume changes. <i>Neurobiology of Aging</i> , 2019, 81, 30-37.	1.5	40
598	Cognitive reserve, cognition, and regional brain damage in MS: A 2â€™-year longitudinal study. <i>Multiple Sclerosis Journal</i> , 2019, 25, 372-381.	1.4	40
599	Magnetic resonance imaging in the differential diagnosis and monitoring of the treatment of multiple sclerosis. <i>Current Opinion in Neurology</i> , 1996, 9, 178-186.	1.8	39
600	MRI signatures of the frontotemporal lobar degeneration continuum. <i>Human Brain Mapping</i> , 2015, 36, 2602-2614.	1.9	39
601	Tracking Cortical Changes Throughout Cognitive Decline in Parkinson's Disease. <i>Movement Disorders</i> , 2020, 35, 1987-1998.	2.2	39
602	Longitudinal brain connectivity changes and clinical evolution in Parkinsonâ€™s disease. <i>Molecular Psychiatry</i> , 2021, 26, 5429-5440.	4.1	39
603	Being the Family Caregiver of a Patient With Dementia During the Coronavirus Disease 2019 Lockdown. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 653533.	1.7	39
604	Early and unrestricted access to high-efficacy disease-modifying therapies: a consensus to optimize benefits for people living with multiple sclerosis. <i>Journal of Neurology</i> , 2022, 269, 1670-1677.	1.8	39
605	MR imaging assessment of brain and cervical cord damage in patients with neuroborreliosis. <i>American Journal of Neuroradiology</i> , 2006, 27, 892-4.	1.2	39
606	Serial contrast-enhanced MR in patients with multiple sclerosis and varying levels of disability. <i>American Journal of Neuroradiology</i> , 1997, 18, 1549-56.	1.2	39
607	Discontinuing monoclonal antibodies targeting CGRP pathway after one-year treatment: an observational longitudinal cohort study. <i>Journal of Headache and Pain</i> , 2021, 22, 154.	2.5	39
608	Enhanced magnetic resonance imaging in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2000, 6, 320-326.	1.4	38
609	Immunological patterns identifying disease course and evolution in multiple sclerosis patients. <i>Journal of Neuroimmunology</i> , 2005, 165, 192-200.	1.1	38
610	Short-term adaptation to a simple motor task: A physiological process preserved in multiple sclerosis. <i>NeuroImage</i> , 2009, 45, 500-511.	2.1	38
611	Structural and functional magnetic resonance imaging correlates of motor network dysfunction in primary progressive multiple sclerosis. <i>European Journal of Neuroscience</i> , 2010, 31, 1273-1280.	1.2	38
612	A diffusion tensor MRI study of cervical cord damage in benign and secondary progressive multiple sclerosis patients. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2010, 81, 26-30.	0.9	38

#	ARTICLE	IF	CITATIONS
613	Microstructural magnetic resonance imaging of cortical lesions in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2013, 19, 418-426.	1.4	38
614	Propagation of Pathology through Brain Networks in Neurodegenerative Diseases: From Molecules to Clinical Phenotypes. <i>CNS Neuroscience and Therapeutics</i> , 2015, 21, 754-767.	1.9	38
615	Progress towards a neuroimaging biomarker for amyotrophic lateral sclerosis. <i>Lancet Neurology</i> , 2015, 14, 786-788.	4.9	38
616	Clinically Isolated Syndrome Suggestive of Multiple Sclerosis: Dynamic Patterns of Gray and White Matter Changes—A 2-year MR Imaging Study. <i>Radiology</i> , 2016, 278, 841-853.	3.6	38
617	Axonal degeneration as substrate of fractional anisotropy abnormalities in multiple sclerosis cortex. <i>Brain</i> , 2019, 142, 1921-1937.	3.7	38
618	Magnetization-transfer histogram analysis of the cervical cord in patients with multiple sclerosis. <i>American Journal of Neuroradiology</i> , 1999, 20, 1803-8.	1.2	38
619	Progression is independent of relapse activity in early multiple sclerosis: a real-life cohort study. <i>Brain</i> , 2022, 145, 2796-2805.	3.7	38
620	A Longitudinal Magnetic Resonance Imaging Study of the Cervical Cord in Multiple Sclerosis. <i>Journal of Neuroimaging</i> , 1997, 7, 78-80.	1.0	37
621	Disease activity in multiple sclerosis studied by weekly triple-dose magnetic resonance imaging. <i>Journal of Neurology</i> , 1999, 246, 689-692.	1.8	37
622	An fMRI study of the motor system in patients with neuropsychiatric systemic lupus erythematosus. <i>NeuroImage</i> , 2006, 30, 478-484.	2.1	37
623	Spatial Normalization and Regional Assessment of Cord Atrophy: Voxel-Based Analysis of Cervical Cord 3D T1-Weighted Images. <i>American Journal of Neuroradiology</i> , 2012, 33, 2195-2200.	1.2	37
624	Interleukin 17F Level and Interferon Beta Response in Patients With Multiple Sclerosis. <i>JAMA Neurology</i> , 2013, 70, 1017.	4.5	37
625	Resting-state fMRI functional connectivity: a new perspective to evaluate pain modulation in migraine?. <i>Neurological Sciences</i> , 2015, 36, 41-45.	0.9	37
626	Longitudinal fMRI studies: Exploring brain plasticity and repair in MS. <i>Multiple Sclerosis Journal</i> , 2016, 22, 269-278.	1.4	37
627	Progression of regional atrophy in the left hemisphere contributes to clinical and cognitive deterioration in multiple sclerosis: A 5-year study. <i>Human Brain Mapping</i> , 2017, 38, 5648-5665.	1.9	37
628	Clinically relevant cranio-caudal patterns of cervical cord atrophy evolution in MS. <i>Neurology</i> , 2019, 93, e1852-e1866.	1.5	37
629	The Italian multicenter experience with edaravone in amyotrophic lateral sclerosis. <i>Journal of Neurology</i> , 2020, 267, 3258-3267.	1.8	37
630	Magnetization transfer magnetic resonance imaging in the assessment of neurological diseases. , 2004, 14, 303-13.		37

#	ARTICLE	IF	CITATIONS
631	T Cell Vaccination Benefits Relapsing Progressive Multiple Sclerosis Patients: A Randomized, Double-Blind Clinical Trial. PLoS ONE, 2012, 7, e50478.	1.1	37
632	Coefficient D(av) is more sensitive than fractional anisotropy in monitoring progression of irreversible tissue damage in focal nonactive multiple sclerosis lesions. American Journal of Neuroradiology, 2003, 24, 663-70.	1.2	37
633	Axonal Injury and Overall Tissue Loss Are Not Related in Primary Progressive Multiple Sclerosis. Archives of Neurology, 2005, 62, 898-902.	4.9	36
634	Therapeutic Considerations for Disease Progression in Multiple Sclerosis. Archives of Neurology, 2005, 62, 1519-30.	4.9	36
635	Magnetic Resonance Imaging Monitoring of Multiple Sclerosis Lesion Evolution. Journal of Neuroimaging, 2005, 15, 225-295.	1.0	36
636	A 3-year diffusion tensor MRI study of grey matter damage progression during the earliest clinical stage of MS. Journal of Neurology, 2008, 255, 1209-1214.	1.8	36
637	Disease reactivation after fingolimod discontinuation in two multiple sclerosis patients. Journal of Neurology, 2013, 260, 327-329.	1.8	36
638	Power estimation for non-standardized multisite studies. NeuroImage, 2016, 134, 281-294.	2.1	36
639	Nerve Compression Injuries After Prolonged Prone Position Ventilation in Patients With SARS-CoV-2: A Case Series. Archives of Physical Medicine and Rehabilitation, 2021, 102, 359-362.	0.5	36
640	Brain and spinal cord MR in benign multiple sclerosis: a follow-up study. Journal of the Neurological Sciences, 1996, 143, 143-149.	0.3	35
641	Frequency and patterns of subclinical cognitive impairment in patients with ANCA-associated small vessel vasculitides. Journal of the Neurological Sciences, 2002, 195, 161-166.	0.3	35
642	MRI to Monitor Treatment Efficacy in Multiple Sclerosis. Journal of Neuroimaging, 2007, 17, 50S-55S.	1.0	35
643	Aging. Neurological Sciences, 2008, 29, 296-300.	0.9	35
644	Primary progressive multiple sclerosis diagnostic criteria: a reappraisal. Multiple Sclerosis Journal, 2009, 15, 1459-1465.	1.4	35
645	Cervical cord functional MRI changes in relapse-onset MS patients. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, 405-408.	0.9	35
646	Fast progressive lower motor neuron disease is an ALS variant: A two-centre tract of interest-based MRI data analysis. NeuroImage: Clinical, 2018, 17, 145-152.	1.4	35
647	Multifocal laminar cortical brain lesions: a consistent MRI finding in neuro-COVID-19 patients. Journal of Neurology, 2020, 267, 2806-2809.	1.8	35
648	Correlation between brain MRI lesion volume and disability in patients with multiple sclerosis. Acta Neurologica Scandinavica, 1996, 94, 93-96.	1.0	34

#	ARTICLE	IF	CITATIONS
649	An MR study of tissue damage in the cervical cord of patients with migraine. <i>Journal of the Neurological Sciences</i> , 2001, 183, 43-46.	0.3	34
650	Imaging the optic nerve in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2005, 11, 537-541.	1.4	34
651	Combining Functional and Structural Brain Magnetic Resonance Imaging in Huntington Disease. <i>Journal of Computer Assisted Tomography</i> , 2007, 31, 574-580.	0.5	34
652	MRI of Spinal Cord in Multiple Sclerosis. <i>Journal of Neuroimaging</i> , 2007, 17, 46S-49S.	1.0	34
653	A reassessment of the plateauing relationship between T2 lesion load and disability in MS. <i>Neurology</i> , 2009, 73, 1538-1542.	1.5	34
654	Functional MR Imaging Correlates of Neuropsychological Impairment in Primary-Progressive Multiple Sclerosis. <i>American Journal of Neuroradiology</i> , 2010, 31, 1240-1246.	1.2	34
655	White matter abnormalities in Parkinson's disease patients with glucocerebrosidase gene mutations. <i>Movement Disorders</i> , 2013, 28, 772-778.	2.2	34
656	Differentiation between Subtypes of Primary Progressive Aphasia by Using Cortical Thickness and Diffusion-Tensor MR Imaging Measures. <i>Radiology</i> , 2015, 276, 219-227.	3.6	34
657	Structural and functional brain connectome in motor neuron diseases. <i>Neurology</i> , 2020, 95, e2552-e2564.	1.5	34
658	Multiple sclerosis lesions in motor tracts from brain to cervical cord: spatial distribution and correlation with disability. <i>Brain</i> , 2020, 143, 2089-2105.	3.7	34
659	Action Observation and Motor Imagery Improve <sc>Dual Task</sc> in Parkinson's Disease: A Clinical/<sc>fMRI</sc> Study. <i>Movement Disorders</i> , 2021, 36, 2569-2582.	2.2	34
660	Imaging primary progressive multiple sclerosis: the contribution of structural, metabolic, and functional MRI techniques. <i>Multiple Sclerosis Journal</i> , 2004, 10, S36-S45.	1.4	33
661	Magnetization Transfer Magnetic Resonance Imaging and Clinical Changes in Patients With Relapsing-Remitting Multiple Sclerosis. <i>Archives of Neurology</i> , 2006, 63, 736.	4.9	33
662	Functional MRI to study brain plasticity in clinical neurology. <i>Neurological Sciences</i> , 2006, 27, s24-s26.	0.9	33
663	A Three-Year Study of Brain Atrophy after Autologous Hematopoietic Stem Cell Transplantation in Rapidly Evolving Secondary Progressive Multiple Sclerosis. <i>American Journal of Neuroradiology</i> , 2007, 28, 1659-1661.	1.2	33
664	A composite score to predict short-term disease activity in patients with relapsing-remitting MS. <i>Neurology</i> , 2007, 69, 1230-1235.	1.5	33
665	Cerebral atrophy as outcome measure in short-term phase 2 clinical trials in multiple sclerosis. <i>Neuroradiology</i> , 2010, 52, 875-881.	1.1	33
666	Neutralizing antibodies to interferon beta-1b multiple sclerosis: a clinico-radiographic paradox in the BEYOND trial. <i>Multiple Sclerosis Journal</i> , 2012, 18, 181-195.	1.4	33

#	ARTICLE	IF	CITATIONS
667	Abnormal cervical cord function contributes to fatigue in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2012, 18, 1552-1559.	1.4	33
668	Extramotor Damage Is Associated with Cognition in Primary Lateral Sclerosis Patients. <i>PLoS ONE</i> , 2013, 8, e82017.	1.1	33
669	Searching for the neural basis of reserve against memory decline: intellectual enrichment linked to larger hippocampal volume in multiple sclerosis. <i>European Journal of Neurology</i> , 2016, 23, 39-44.	1.7	33
670	The European DTI Study on Dementia – A multicenter DTI and MRI study on Alzheimer's disease and Mild Cognitive Impairment. <i>NeuroImage</i> , 2017, 144, 305-308.	2.1	33
671	Imaging patterns of gray and white matter abnormalities associated with PASAT and SDMT performance in relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2019, 25, 204-216.	1.4	33
672	Progressive brain atrophy and clinical evolution in Parkinson's disease. <i>NeuroImage: Clinical</i> , 2020, 28, 102374.	1.4	33
673	Leukocyte Counts and Ratios Are Predictive of Stroke Outcome and Hemorrhagic Complications Independently of Infections. <i>Frontiers in Neurology</i> , 2020, 11, 201.	1.1	33
674	Brain Structural Changes in Focal Dystonia – What About Task Specificity? A Multimodal MRI Study. <i>Movement Disorders</i> , 2021, 36, 196-205.	2.2	33
675	Relevance of hypointense lesions on fast fluid-attenuated inversion recovery MR images as a marker of disease severity in cases of multiple sclerosis. <i>American Journal of Neuroradiology</i> , 1999, 20, 813-20.	1.2	33
676	Spinal cord MRI in multiple sclerosis with multicoil arrays: a comparison between fast spin echo and fast FLAIR. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1996, 61, 632-635.	0.9	32
677	Effects of seasons on magnetic resonance imaging-measured disease activity in patients with multiple sclerosis. <i>Annals of Neurology</i> , 2001, 49, 415-416.	2.8	32
678	Disturbed function and plasticity in multiple sclerosis as gleaned from functional magnetic resonance imaging. <i>Current Opinion in Neurology</i> , 2003, 16, 275-282.	1.8	32
679	The "mirror-neuron system" in MS. <i>Neurology</i> , 2008, 70, 255-262.	1.5	32
680	Hereditary Spastic Paraplegia: Beyond Clinical Phenotypes toward a Unified Pattern of Central Nervous System Damage. <i>Radiology</i> , 2015, 276, 207-218.	3.6	32
681	Parallel Atrophy of Cortex and Basal Forebrain Cholinergic System in Mild Cognitive Impairment. <i>Cerebral Cortex</i> , 2017, 27, bhw019.	1.6	32
682	Brain MR Imaging in Patients with Lower Motor Neuron – Predominant Disease. <i>Radiology</i> , 2016, 280, 545-556.	3.6	32
683	MR Imaging of Brachial Plexus and Limb-Girdle Muscles in Patients with Amyotrophic Lateral Sclerosis. <i>Radiology</i> , 2016, 279, 553-561.	3.6	32
684	Role of habenula and amygdala dysfunction in Parkinson disease patients with punding. <i>Neurology</i> , 2017, 88, 2207-2215.	1.5	32

#	ARTICLE	IF	CITATIONS
685	Microstructural MR Imaging Techniques in Multiple Sclerosis. <i>Neuroimaging Clinics of North America</i> , 2017, 27, 313-333.	0.5	32
686	Longitudinal spinal cord atrophy in multiple sclerosis using the generalized boundary shift integral. <i>Annals of Neurology</i> , 2019, 86, 704-713.	2.8	32
687	Sensitivity-Specificity of Tau and Amyloid $\beta^2$ Positron Emission Tomography in Frontotemporal Lobar Degeneration. <i>Annals of Neurology</i> , 2020, 88, 1009-1022.	2.8	32
688	Intraobserver and interobserver variability in schemes for estimating volume of brain lesions on MR images in multiple sclerosis. <i>American Journal of Neuroradiology</i> , 1998, 19, 239-44.	1.2	32
689	Early use of high-efficacy disease-modifying therapies makes the difference in people with multiple sclerosis: an expert opinion. <i>Journal of Neurology</i> , 2022, 269, 5382-5394.	1.8	32
690	Basic concepts of advanced MRI techniques. <i>Neurological Sciences</i> , 2008, 29, 290-295.	0.9	31
691	MRI—the perfect surrogate marker for multiple sclerosis?. <i>Nature Reviews Neurology</i> , 2009, 5, 182-183.	4.9	31
692	Diffusion tensor magnetic resonance imaging tractography in progressive supranuclear palsy. <i>Movement Disorders</i> , 2011, 26, 1751-1755.	2.2	31
693	Differential Cerebellar Functional Interactions during an Interference Task across Multiple Sclerosis Phenotypes. <i>Radiology</i> , 2012, 265, 864-873.	3.6	31
694	Multimodal Voxel-Based Meta-Analysis of White Matter Abnormalities in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2015, 47, 495-507.	1.2	31
695	Brain reserve against physical disability progression over 5 years in multiple sclerosis. <i>Neurology</i> , 2016, 86, 2006-2009.	1.5	31
696	Brain activity during lower limb movements in Parkinson's disease patients with and without freezing of gait. <i>Journal of Neurology</i> , 2020, 267, 1116-1126.	1.8	31
697	<sc>ENIGMA anxiety</sc> working group: Rationale for and organization of <sc>large-scale</sc> neuroimaging studies of anxiety disorders. <i>Human Brain Mapping</i> , 2022, 43, 83-112.	1.9	31
698	The Chronic Migraine Brain: What Have We Learned From Neuroimaging?. <i>Frontiers in Neurology</i> , 2019, 10, 1356.	1.1	31
699	Performance of the 2017 and 2010 Revised McDonald Criteria in Predicting MS Diagnosis After a Clinically Isolated Syndrome. <i>Neurology</i> , 2022, 98, .	1.5	31
700	A widespread pattern of cortical activations in patients at presentation with clinically isolated symptoms is associated with evolution to definite multiple sclerosis. <i>American Journal of Neuroradiology</i> , 2005, 26, 1136-9.	1.2	31
701	Risk of Getting COVID-19 in People With Multiple Sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2022, 9, .	3.1	31
702	A magnetic resonance imaging study of the cervical cord of patients with CADASIL. <i>Neurology</i> , 2001, 56, 1392-1394.	1.5	30



#	ARTICLE	IF	CITATIONS
703	Evidence of Subtle Gray-Matter Pathologic Changes in Healthy Elderly Individuals With Nonspecific White-Matter Hyperintensities. <i>Archives of Neurology</i> , 2003, 60, 1109.	4.9	30
704	Semi-automated thresholding technique for measuring lesion volumes in multiple sclerosis: effects of the change of the threshold on the computed lesion loads. <i>Acta Neurologica Scandinavica</i> , 1996, 93, 30-34.	1.0	30
705	Influence of task complexity during coordinated hand and foot movements in MS patients with and without fatigue. <i>Journal of Neurology</i> , 2009, 256, 470-482.	1.8	30
706	Exploring the relationship between motor impairment, vascular burden and cognition in Parkinsonâ€™s disease. <i>Journal of Neurology</i> , 2018, 265, 1320-1327.	1.8	30
707	Characterizing Rapid Fluctuations of Resting State Functional Connectivity in Demyelinating, Neurodegenerative, and Psychiatric Conditions: From Static to Time-Varying Analysis. <i>Frontiers in Neuroscience</i> , 2019, 13, 618.	1.4	30
708	Facing privacy in neuroimaging: removing facial features degrades performance of image analysis methods. <i>European Radiology</i> , 2020, 30, 1062-1074.	2.3	30
709	Fatigue in multiple sclerosis patients with different clinical phenotypes: a clinical and magnetic resonance imaging study. <i>European Journal of Neurology</i> , 2020, 27, 2549-2560.	1.7	30
710	Speech production differences in English and Italian speakers with nonfluent variant PPA. <i>Neurology</i> , 2020, 94, e1062-e1072.	1.5	30
711	Diagnosis of Progressive Multiple Sclerosis From the Imaging Perspective. <i>JAMA Neurology</i> , 2021, 78, 351.	4.5	30
712	Study protocol: improving cognition in people with progressive multiple sclerosis: a multi-arm, randomized, blinded, sham-controlled trial of cognitive rehabilitation and aerobic exercise (COGEx). <i>BMC Neurology</i> , 2020, 20, 204.	0.8	30
713	Multiple sclerosis: a white matter disease with associated gray matter damage. <i>Journal of the Neurological Sciences</i> , 2001, 185, 3-4.	0.3	29
714	The relation between MRI measures of inflammation and neurodegeneration in multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2005, 233, 15-19.	0.3	29
715	Clinical and conventional MRI predictors of disability and brain atrophy accumulation in RRMS. <i>Journal of Neurology</i> , 2008, 255, 1378-1383.	1.8	29
716	Primary Progressive Multiple Sclerosis: Tactile-associated Functional MR Activity in the Cervical Spinal Cord. <i>Radiology</i> , 2009, 253, 209-215.	3.6	29
717	Abnormalities of the executive control network in multiple sclerosis phenotypes: An fMRI effective connectivity study. <i>Human Brain Mapping</i> , 2016, 37, 2293-2304.	1.9	29
718	Correlates of Executive Functions in Multiple Sclerosis Based on Structural and Functional MR Imaging: Insights from a Multicenter Study. <i>Radiology</i> , 2016, 280, 869-879.	3.6	29
719	Unraveling ALS due to <i>SOD1</i> mutation through the combination of brain and cervical cord MRI. <i>Neurology</i> , 2018, 90, e707-e716.	1.5	29
720	Short-term evolution of individual enhancing MS lesions studied with magnetization transfer imaging. <i>Magnetic Resonance Imaging</i> , 1999, 17, 979-984.	1.0	28

#	ARTICLE	IF	CITATIONS
721	Brain MRI correlates of magnetization transfer imaging metrics in patients with multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 1999, 166, 58-63.	0.3	28
722	Modelling new enhancing MRI lesion counts in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2001, 7, 298-304.	1.4	28
723	Subcortical Damage and Cortical Functional Changes in Men and Women with Fabry Disease: A Multifaceted MR Study. <i>Radiology</i> , 2006, 241, 492-500.	3.6	28
724	Advances in monitoring and treatment of multiple sclerosis. <i>Nature Reviews Neurology</i> , 2011, 7, 74-75.	4.9	28
725	Direct MRI detection of impending plaque development in multiple sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2015, 2, e145.	3.1	28
726	Diffusion tensor imaging and functional MRI. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2016, 136, 1065-1087.	1.0	28
727	Regional hippocampal involvement and cognitive impairment in pediatric multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2016, 22, 628-640.	1.4	28
728	MRI in multiple sclerosis: what is changing?. <i>Current Opinion in Neurology</i> , 2018, 31, 386-395.	1.8	28
729	Structural connectivity in multiple sclerosis and modeling of disconnection. <i>Multiple Sclerosis Journal</i> , 2020, 26, 220-232.	1.4	28
730	Effects of Natalizumab and Fingolimod on Clinical, Cognitive, and Magnetic Resonance Imaging Measures in Multiple Sclerosis. <i>Neurotherapeutics</i> , 2020, 17, 208-217.	2.1	28
731	Diagnosing autoimmune encephalitis in a real-world single-centre setting. <i>Journal of Neurology</i> , 2020, 267, 449-460.	1.8	28
732	Association of Gray Matter Atrophy Patterns With Clinical Phenotype and Progression in Multiple Sclerosis. <i>Neurology</i> , 2021, 96, e1561-e1573.	1.5	28
733	Reproducibility of magnetization transfer ratio histogram-derived measures of the brain in healthy volunteers. <i>American Journal of Neuroradiology</i> , 2000, 21, 133-6.	1.2	28
734	Brain Stem Magnetic Resonance Imaging and Evoked Potential Studies of Symptomatic Multiple Sclerosis Patients. <i>European Neurology</i> , 1993, 33, 232-237.	0.6	27
735	Intra-observer, inter-observer and inter-scanner variations in brain MRI volume measurements in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2001, 7, 27-31.	1.4	27
736	An MRI study of Chlamydia pneumoniae infection in Italian multiple sclerosis patients. <i>Multiple Sclerosis Journal</i> , 2003, 9, 467-471.	1.4	27
737	A double blind, placebo-controlled, phase II, add-on study of cyclophosphamide (CTX) for 24 months in patients affected by multiple sclerosis on a background therapy with interferon-beta study denomination: CYCLIN. <i>Journal of the Neurological Sciences</i> , 2004, 223, 69-71.	0.3	27
738	Assessing atrophy of the major white matter fiber bundles of the brain from diffusion tensor MRI data. <i>Magnetic Resonance in Medicine</i> , 2007, 58, 527-534.	1.9	27

#	ARTICLE	IF	CITATIONS
739	Magnetic resonance techniques to quantify tissue damage, tissue repair, and functional cortical reorganization in multiple sclerosis. <i>Progress in Brain Research</i> , 2009, 175, 465-482.	0.9	27
740	Patterns of white matter diffusivity abnormalities in Leber's hereditary optic neuropathy: a tract-based spatial statistics study. <i>Journal of Neurology</i> , 2012, 259, 1801-1807.	1.8	27
741	Cervical cord FMRI abnormalities differ between the progressive forms of multiple sclerosis. <i>Human Brain Mapping</i> , 2012, 33, 2072-2080.	1.9	27
742	The role of advanced magnetic resonance imaging techniques in primary progressive MS. <i>Journal of Neurology</i> , 2012, 259, 611-621.	1.8	27
743	Imaging Cortical Damage and Dysfunction in Multiple Sclerosis. <i>JAMA Neurology</i> , 2013, 70, 556.	4.5	27
744	Frequency and topography of cerebral microbleeds in dementia with Lewy bodies compared to Alzheimer's disease. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 1101-1104.	1.1	27
745	Functional MRI in investigating cognitive impairment in multiple sclerosis. <i>Acta Neurologica Scandinavica</i> , 2016, 134, 39-46.	1.0	27
746	A review of recent literature on functional MRI and personal experience in two cases of definite vestibular migraine. <i>Neurological Sciences</i> , 2016, 37, 1399-1402.	0.9	27
747	Performance of five research-domain automated WM lesion segmentation methods in a multi-center MS study. <i>NeuroImage</i> , 2017, 163, 106-114.	2.1	27
748	Dynamic gray matter volume changes in pediatric multiple sclerosis. <i>Neurology</i> , 2019, 92, e1709-e1723.	1.5	27
749	Sensory trick phenomenon in cervical dystonia: a functional MRI study. <i>Journal of Neurology</i> , 2020, 267, 1103-1115.	1.8	27
750	Functional Connectomics and Disease Progression in Drug-Naïve Parkinson's Disease Patients. <i>Movement Disorders</i> , 2021, 36, 1603-1616.	2.2	27
751	Neutrophils predominate the immune signature of cerebral thrombi in COVID-19 stroke patients. <i>Acta Neuropathologica Communications</i> , 2022, 10, 14.	2.4	27
752	Acute myelopathy of unknown aetiology: a clinical, neurophysiological and MRI study of short-and long-term prognostic factors. <i>Journal of Neurology</i> , 1995, 242, 497-503.	1.8	26
753	Sensitivity of delayed gadolinium-enhanced MRI in multiple sclerosis. <i>Acta Neurologica Scandinavica</i> , 1997, 95, 331-334.	1.0	26
754	Effect of glatiramer acetate on MS lesions enhancing at different gadolinium doses. <i>Neurology</i> , 2002, 59, 1429-1432.	1.5	26
755	Magnetic Resonance Imaging of Multiple Sclerosis. <i>Journal of Neuroimaging</i> , 2002, 12, 289-301.	1.0	26
756	FMRI correlates of execution and observation of foot movements in left-handers. <i>Journal of the Neurological Sciences</i> , 2010, 288, 34-41.	0.3	26

#	ARTICLE	IF	CITATIONS
757	Working memory network dysfunction in relapse-onset multiple sclerosis phenotypes: A clinical-imaging evaluation. <i>Multiple Sclerosis Journal</i> , 2017, 23, 577-587.	1.4	26
758	Functional and structural plasticity following action observation training in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2019, 25, 1472-1487.	1.4	26
759	CSF p-tau/A $\beta$ 42 ratio and brain FDG-PET may reliably detect MCI "imminent" converters to AD. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 3152-3164.	3.3	26
760	Serum phosphorylated neurofilament heavy-chain levels reflect phenotypic heterogeneity and are an independent predictor of survival in motor neuron disease. <i>Journal of Neurology</i> , 2020, 267, 2272-2280.	1.8	26
761	Regional changes in thalamic shape and volume are related to cognitive performance in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021, 27, 134-138.	1.4	26
762	Risk of Persistent Disability in Patients With Pediatric-Onset Multiple Sclerosis. <i>JAMA Neurology</i> , 2021, 78, 726.	4.5	26
763	MTR discloses subtle changes in the normal-appearing tissue from relatives of patients with MS. <i>Neurology</i> , 2002, 58, 317-320.	1.5	26
764	A brain MRI study of different types of chronic-progressive multiple sclerosis. <i>Acta Neurologica Scandinavica</i> , 1995, 91, 231-233.	1.0	25
765	A one year study of new lesions in multiple sclerosis using monthly gadolinium enhanced MRI: Correlations with changes of T2 and magnetization transfer lesion loads. <i>Journal of the Neurological Sciences</i> , 1998, 158, 203-208.	0.3	25
766	Vanishing Balo-like lesions in multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2000, 69, 399-400.	0.9	25
767	Cervical cord magnetic resonance imaging findings in systemic immune-mediated diseases. <i>Journal of the Neurological Sciences</i> , 2000, 176, 128-130.	0.3	25
768	A multicentre study of motor functional connectivity changes in patients with multiple sclerosis. <i>European Journal of Neuroscience</i> , 2011, 33, 1256-1263.	1.2	25
769	Future MRI tools in multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2013, 331, 14-18.	0.3	25
770	Diagnostic value of brain chronic black holes on T1-weighted MR images in clinically isolated syndromes. <i>Multiple Sclerosis Journal</i> , 2014, 20, 1471-1477.	1.4	25
771	Late onset absolute neutropenia associated with ocrelizumab treatment in multiple sclerosis: A case report and review of the literature. <i>Journal of the Neurological Sciences</i> , 2020, 409, 116603.	0.3	25
772	Clinical Relevance of Multiparametric MRI Assessment of Cervical Cord Damage in Multiple Sclerosis. <i>Radiology</i> , 2020, 296, 605-615.	3.6	25
773	Integrated evaluation of a panel of neurochemical biomarkers to optimize diagnosis and prognosis in amyotrophic lateral sclerosis. <i>European Journal of Neurology</i> , 2022, 29, 1930-1939.	1.7	25
774	An Oblique Cylinder Contrast-Adjusted (OCCA) phantom to measure the accuracy of MRI brain lesion volume estimation schemes in multiple sclerosis. <i>Magnetic Resonance Imaging</i> , 1997, 15, 183-192.	1.0	24

#	ARTICLE	IF	CITATIONS
775	The contribution of fast-FLAIR MRI for lesion detection in the brain of patients with systemic autoimmune diseases. <i>Journal of Neurology</i> , 2000, 247, 29-33.	1.8	24
776	Multiparametric MRI in a patient with adult-onset leukoencephalopathy with vanishing white matter. <i>Neurology</i> , 2004, 62, 323-326.	1.5	24
777	A one-year prospective, randomized, placebo-controlled, quadruple-blinded, phase II safety pilot trial of combination therapy with interferon beta-1a and mycophenolate mofetil in early relapsing-remitting multiple sclerosis (TIME MS). <i>Therapeutic Advances in Neurological Disorders</i> , 2010, 3, 3-13.	1.5	24
778	Extra-Visual Functional and Structural Connection Abnormalities in Leber's Hereditary Optic Neuropathy. <i>PLoS ONE</i> , 2011, 6, e17081.	1.1	24
779	Deep grey matter T2 hypo-intensity in patients with paediatric multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2011, 17, 702-707.	1.4	24
780	In vivo evidence of hippocampal dentate gyrus expansion in multiple sclerosis. <i>Human Brain Mapping</i> , 2015, 36, 4702-4713.	1.9	24
781	A multimodal neuroimaging study of a case of crossed nonfluent/agrammatic primary progressive aphasia. <i>Journal of Neurology</i> , 2015, 262, 2336-2345.	1.8	24
782	Brain structural changes in spasmodic dysphonia: A multimodal magnetic resonance imaging study. <i>Parkinsonism and Related Disorders</i> , 2016, 25, 78-84.	1.1	24
783	Two-year dynamic functional network connectivity in clinically isolated syndrome. <i>Multiple Sclerosis Journal</i> , 2020, 26, 645-658.	1.4	24
784	Cognitive impairment and structural brain damage in multiple system atrophy-parkinsonian variant. <i>Journal of Neurology</i> , 2020, 267, 87-94.	1.8	24
785	Interferon Î²-1a (IFNÎ²-1a) in COVID-19 patients (INTERCOP): study protocol for a randomized controlled trial. <i>Trials</i> , 2020, 21, 939.	0.7	24
786	Cerebral involvement in COVID-19 is associated with metabolic and coagulation derangements: an EEG study. <i>Journal of Neurology</i> , 2020, 267, 3130-3134.	1.8	24
787	Neurite density explains cortical T1-weighted/T2-weighted ratio in multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 790-792.	0.9	24
788	Longitudinal clinical, cognitive, and neuroanatomical changes over 5 years in GBA-positive Parkinson's disease patients. <i>Journal of Neurology</i> , 2022, 269, 1485-1500.	1.8	24
789	Cortical and subcortical brain structure in generalized anxiety disorder: findings from 28 research sites in the ENIGMA-Anxiety Working Group. <i>Translational Psychiatry</i> , 2021, 11, 502.	2.4	24
790	Short-term correlations between clinical and MR imaging findings in relapsing-remitting multiple sclerosis. <i>American Journal of Neuroradiology</i> , 2003, 24, 75-81.	1.2	24
791	Magnetization transfer and diffusion-weighted imaging in nocturnal frontal lobe epilepsy. <i>Neurology</i> , 2000, 54, 2331-2333.	1.5	23
792	The value of new magnetic resonance techniques in multiple sclerosis. <i>Current Opinion in Neurology</i> , 2000, 13, 249-254.	1.8	23

#	ARTICLE	IF	CITATIONS
793	The distribution of magnetic resonance imaging response to interferon-1b in multiple sclerosis. <i>Journal of Neurology</i> , 2005, 252, 1455-1458.	1.8	23
794	The level of spinal cord involvement influences the pattern of movement-associated cortical recruitment in patients with isolated myelitis. <i>NeuroImage</i> , 2006, 30, 879-884.	2.1	23
795	Tactile-associated fMRI recruitment of the cervical cord in healthy subjects. <i>Human Brain Mapping</i> , 2009, 30, 340-345.	1.9	23
796	Brain macro- and microscopic damage in patients with paediatric MS. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2010, 81, 1357-1362.	0.9	23
797	MRI Predicts Efficacy of Constraint-Induced Movement Therapy in Children With Brain Injury. <i>Neurotherapeutics</i> , 2013, 10, 511-519.	2.1	23
798	Functional and structural brain networks in posterior cortical atrophy: A two-centre multiparametric MRI study. <i>NeuroImage: Clinical</i> , 2018, 19, 901-910.	1.4	23
799	Survival prediction models in motor neuron disease. <i>European Journal of Neurology</i> , 2019, 26, 1143-1152.	1.7	23
800	Role of artificial intelligence in MS clinical practice. <i>NeuroImage: Clinical</i> , 2022, 35, 103065.	1.4	23
801	Cardiac autonomic function during sleep and wakefulness in multiple sclerosis. <i>Journal of Neurology</i> , 1995, 242, 639-643.	1.8	22
802	Statistical power of MRI monitored trials in multiple sclerosis: new data and comparison with previous results. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1999, 66, 465-469.	0.9	22
803	Interferon beta treatment for multiple sclerosis has a graduated effect on MRI enhancing lesions according to their size and pathology. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1999, 67, 386-389.	0.9	22
804	Longitudinal evaluation of leukoaraiosis with whole brain ADC histograms. <i>Neurology</i> , 2002, 59, 938-940.	1.5	22
805	Magnetization transfer MRI in multiple sclerosis and other central nervous system disorders. <i>European Journal of Neurology</i> , 2003, 10, 3-10.	1.7	22
806	Movement preparation is affected by tissue damage in multiple sclerosis: Evidence from EEG event-related desynchronization. <i>Clinical Neurophysiology</i> , 2005, 116, 1515-1519.	0.7	22
807	An Integrated Segmentation and Classification Approach Applied to Multiple Sclerosis Analysis. , 0, , .		22
808	In-vivo evidence for stable neuroaxonal damage in the brain of patients with benign multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2009, 15, 789-794.	1.4	22
809	Multiple sclerosis imaging: recent advances. <i>Journal of Neurology</i> , 2013, 260, 929-935.	1.8	22
810	Elevated body temperature is linked to fatigue in an Italian sample of relapsing-remitting multiple sclerosis patients. <i>Journal of Neurology</i> , 2015, 262, 2440-2442.	1.8	22

#	ARTICLE	IF	CITATIONS
811	Reading, writing, and reserve: Literacy activities are linked to hippocampal volume and memory in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2016, 22, 1621-1625.	1.4	22
812	White matter tract alterations in Parkinson's disease patients with punding. <i>Parkinsonism and Related Disorders</i> , 2017, 43, 85-91.	1.1	22
813	Brain motor functional changes after somatosensory discrimination training. <i>Brain Imaging and Behavior</i> , 2018, 12, 1011-1021.	1.1	22
814	Are there two different forms of functional dystonia? A multimodal brain structural MRI study. <i>Molecular Psychiatry</i> , 2020, 25, 3350-3359.	4.1	22
815	Phosphorylated TDP-43 aggregates in peripheral motor nerves of patients with amyotrophic lateral sclerosis. <i>Brain</i> , 2022, 145, 276-284.	3.7	22
816	Contrast enhancement and the acute lesion in multiple sclerosis. <i>Neuroimaging Clinics of North America</i> , 2000, 10, 705-16 ,viii-ix.	0.5	22
817	Quantitative brain volumetric analysis from patients with multiple sclerosis: a follow-up study. <i>Journal of the Neurological Sciences</i> , 1999, 171, 8-10.	0.3	21
818	A comparison of the sensitivity of MRI after double- and triple-dose Gd-DTPA for detecting enhancing lesions in multiple sclerosis. <i>Magnetic Resonance Imaging</i> , 2000, 18, 761-763.	1.0	21
819	Assessment of the damage of the cerebral hemispheres in MS using neuroimaging techniques. <i>Journal of the Neurological Sciences</i> , 2000, 172, S63-S66.	0.3	21
820	Segmenting brain white matter, gray matter and cerebro-spinal fluid using diffusion tensor-MRI derived indices. <i>Magnetic Resonance Imaging</i> , 2001, 19, 1167-1172.	1.0	21
821	Programmed cell death of myelin basic protein-specific T lymphocytes is reduced in patients with acute multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2005, 166, 173-179.	1.1	21
822	The distribution of the magnetic resonance imaging response to glatiramer acetate in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2005, 11, 447-449.	1.4	21
823	Spinal fMRI during proprioceptive and tactile tasks in healthy subjects: activity detected using cross-correlation, general linear model and independent component analysis. <i>Neuroradiology</i> , 2008, 50, 895-902.	1.1	21
824	Sample size requirements for treatment effects using gray matter, white matter and whole brain volume in relapsing-remitting multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2009, 80, 1218-1224.	0.9	21
825	The results of two multicenter, open-label studies assessing efficacy, tolerability and safety of protiramer, a high molecular weight synthetic copolymeric mixture, in patients with relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2009, 15, 238-243.	1.4	21
826	Transitional progressive multiple sclerosis: MRI and MTI findings. <i>Acta Neurologica Scandinavica</i> , 1995, 92, 178-182.	1.0	21
827	Cognitive impairment in paediatric multiple sclerosis patients is not related to cortical lesions. <i>Multiple Sclerosis Journal</i> , 2015, 21, 956-959.	1.4	21
828	Relation between characteristics of carotid atherosclerotic plaques and brain white matter hyperintensities in asymptomatic patients. <i>Scientific Reports</i> , 2017, 7, 10559.	1.6	21

#	ARTICLE	IF	CITATIONS
829	Reproducibility of the whole-brain N-acetylaspartate level across institutions, MR scanners, and field strengths. <i>American Journal of Neuroradiology</i> , 2007, 28, 72-5.	1.2	21
830	Interscanner variation in brain MR lesion load measurements in multiple sclerosis using conventional spin-echo, rapid relaxation-enhanced, and fast-FLAIR sequences. <i>American Journal of Neuroradiology</i> , 1999, 20, 133-7.	1.2	21
831	Sensitivity and Reproducibility of Fast-FLAIR, FSE, and TGSE Sequences for the MRI Assessment of Brain Lesion Load in Multiple Sclerosis: A Preliminary Study. <i>Journal of Neuroimaging</i> , 1997, 7, 98-102.	1.0	20
832	Interobserver agreement for diagnostic MRI criteria in suspected multiple sclerosis. <i>Neuroradiology</i> , 1999, 41, 347-350.	1.1	20
833	The use of magnetic resonance imaging in multiple sclerosis treatment trials: power calculations for annual lesion load measurement. <i>Journal of Neurology</i> , 2000, 247, 34-40.	1.8	20
834	The precision of T1 hypointense lesion volume quantification in multiple sclerosis treatment trials: a multicenter study. <i>Multiple Sclerosis Journal</i> , 2000, 6, 237-240.	1.4	20
835	The contribution of MRI in the differential diagnosis of posterior fossa damage. <i>Journal of the Neurological Sciences</i> , 2000, 172, S43-S49.	0.3	20
836	MRI aspects of the ?inflammatory phase? of multiple sclerosis. <i>Neurological Sciences</i> , 2003, 24, s275-s278.	0.9	20
837	A diffusion tensor MRI study of basal ganglia from patients with ADEM. <i>Journal of the Neurological Sciences</i> , 2003, 206, 27-30.	0.3	20
838	The use of magnetic resonance imaging in multiple sclerosis: lessons learned from clinical trials. <i>Multiple Sclerosis Journal</i> , 2004, 10, 341-347.	1.4	20
839	Italian studies on early-onset multiple sclerosis: the present and the future. <i>Neurological Sciences</i> , 2004, 25, s346-s349.	0.9	20
840	A longitudinal conventional and magnetization transfer magnetic resonance imaging study of optic neuritis. <i>Multiple Sclerosis Journal</i> , 2007, 13, 265-268.	1.4	20
841	Incorporating Domain Knowledge Into the Fuzzy Connectedness Framework: Application to Brain Lesion Volume Estimation in Multiple Sclerosis. <i>IEEE Transactions on Medical Imaging</i> , 2007, 26, 1670-1680.	5.4	20
842	Influence of body segment position during in-phase and antiphase hand and foot movements: A kinematic and functional MRI study. <i>Human Brain Mapping</i> , 2007, 28, 218-227.	1.9	20
843	The mirrorâ€‘neuron system and handedness: A â€‘rightâ€‘world?. <i>Human Brain Mapping</i> , 2008, 29, 1243-1254.	1.9	20
844	Clinical and MRI correlates of disease progression in a case of nonfluent/agrammatic variant of primary progressive aphasia due to progranulin (GRN) Cys157LysfsX97 mutation. <i>Journal of the Neurological Sciences</i> , 2014, 342, 167-172.	0.3	20
845	Mapping white matter damage distribution in neuromyelitis optica spectrum disorders with a multimodal MRI approach. <i>Multiple Sclerosis Journal</i> , 2021, 27, 841-854.	1.4	20
846	Manual and automated tissue segmentation confirm the impact of thalamus atrophy on cognition in multiple sclerosis: A multicenter study. <i>NeuroImage: Clinical</i> , 2021, 29, 102549.	1.4	20



#	ARTICLE	IF	CITATIONS
847	Resting-state electroencephalographic biomarkers of Alzheimer's disease. <i>NeuroImage: Clinical</i> , 2021, 31, 102711.	1.4	20
848	Deep Learning on Conventional Magnetic Resonance Imaging Improves the Diagnosis of Multiple Sclerosis Mimics. <i>Investigative Radiology</i> , 2021, 56, 252-260.	3.5	20
849	Guillain-Barré syndrome and COVID-19: A 1-year observational multicenter study. <i>European Journal of Neurology</i> , 2022, 29, 3358-3367.	1.7	20
850	T1 relaxation maps allow differentiation between pathologic tissue subsets in relapsing-remitting and secondary progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2004, 10, 556-561.	1.4	19
851	Glatiramer acetate therapy for multiple sclerosis: a review. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2006, 2, 1019-1029.	1.5	19
852	Cervical cord magnetization transfer ratio and clinical changes over 18 months in patients with relapsing-remitting multiple sclerosis: a preliminary study. <i>Multiple Sclerosis Journal</i> , 2006, 12, 662-665.	1.4	19
853	Agreement between different input image types in brain atrophy measurement in multiple sclerosis using SIENAX and SIENA. <i>Journal of Magnetic Resonance Imaging</i> , 2008, 28, 559-565.	1.9	19
854	Insights from magnetic resonance imaging. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2014, 122, 115-149.	1.0	19
855	A longitudinal MRI study of cervical cord atrophy in multiple sclerosis. <i>Journal of Neurology</i> , 2015, 262, 1622-1628.	1.8	19
856	Diffusion tensor magnetic resonance imaging in very early onset pediatric multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2016, 22, 620-627.	1.4	19
857	Mesial temporal lobe and subcortical grey matter volumes differentially predict memory across stages of multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2018, 24, 675-678.	1.4	19
858	Imaging correlates of hand motor performance in multiple sclerosis: A multiparametric structural and functional MRI study. <i>Multiple Sclerosis Journal</i> , 2020, 26, 233-244.	1.4	19
859	Neural correlates of naming errors across different neurodegenerative diseases. <i>Neurology</i> , 2020, 95, e2816-e2830.	1.5	19
860	Progression of brain functional connectivity and frontal cognitive dysfunction in ALS. <i>NeuroImage: Clinical</i> , 2020, 28, 102509.	1.4	19
861	Transition to secondary progression in relapsing-onset multiple sclerosis: Definitions and risk factors. <i>Multiple Sclerosis Journal</i> , 2021, 27, 430-438.	1.4	19
862	Structural MRI Signatures in Genetic Presentations of the Frontotemporal Dementia/Motor Neuron Disease Spectrum. <i>Neurology</i> , 2021, 97, e1594-e1607.	1.5	19
863	Neutrophil-to-lymphocyte ratio: a marker of neuro-inflammation in multiple sclerosis?. <i>Journal of Neurology</i> , 2021, 268, 717-723.	1.8	19
864	European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. , 2001, 49, 290.		19

#	ARTICLE	IF	CITATIONS
865	Nonfluent/agrammatic PPA with in-vivo cortical amyloidosis and Pick's disease pathology. <i>Behavioural Neurology</i> , 2013, 26, 95-106.	1.1	19
866	Clinical trials in multiple sclerosis: methodological issues. <i>Current Opinion in Neurology</i> , 2005, 18, 245-252.	1.8	18
867	Global $\gamma$ -Acetylaspartate Declines Even in Benign Multiple Sclerosis. <i>American Journal of Neuroradiology</i> , 2011, 32, 204-209.	1.2	18
868	Functional plasticity in MS. <i>Neurology</i> , 2012, 79, 1418-1419.	1.5	18
869	Contribution of magnetic resonance imaging to the diagnosis and monitoring of multiple sclerosis. <i>Radiologia Medica</i> , 2013, 118, 251-264.	4.7	18
870	Tracking brain damage in progressive supranuclear palsy: a longitudinal MRI study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 696-701.	0.9	18
871	Diagnosis of multiple sclerosis: a multicentre study to compare revised McDonald-2010 and Filippi-2010 criteria. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 316-318.	0.9	18
872	Structural and functional brain connectomes in patients with systemic lupus erythematosus. <i>European Journal of Neurology</i> , 2020, 27, 113.	1.7	18
873	ALS Cognitive Behavioral Screen (ALS-CBS): normative values for the Italian population and clinical usability. <i>Neurological Sciences</i> , 2020, 41, 835-841.	0.9	18
874	Real world experience with teriflunomide in multiple sclerosis: the TER-Italy study. <i>Journal of Neurology</i> , 2021, 268, 2922-2932.	1.8	18
875	Recurrent acute transverse myelopathy associated with anticardiolipin antibodies. <i>American Journal of Neuroradiology</i> , 1998, 19, 781-6.	1.2	18
876	A Deep Learning Approach to Predicting Disease Progression in Multiple Sclerosis Using Magnetic Resonance Imaging. <i>Investigative Radiology</i> , 2022, 57, 423-432.	3.5	18
877	Magnetic Resonance Imaging Evaluation of Perivascular Space Abnormalities in Neuromyelitis Optica. <i>Annals of Neurology</i> , 2022, 92, 173-183.	2.8	18
878	Clinical and radiologic correlates of a novel T lymphocyte $\gamma$ -interferon-activated Ca <sup>2+</sup> influx in patients with relapsing remitting multiple sclerosis. <i>Neurology</i> , 1996, 46, 1416-1416.	1.5	17
879	A magnetization transfer study of white matter in siblings of multiple sclerosis patients. <i>Journal of the Neurological Sciences</i> , 1997, 147, 151-153.	0.3	17
880	Role of White Matter Lesions in Cognitive Impairment of Vascular Origin. <i>Alzheimer Disease and Associated Disorders</i> , 1999, 13, S49-S54.	0.6	17
881	Intense immunosuppression followed by autologous stem cell transplantation in severe multiple sclerosis. <i>Neurological Sciences</i> , 2005, 26, s200-s203.	0.9	17
882	Serial Whole-Brain N-Acetylaspartate Concentration in Healthy Young Adults. <i>American Journal of Neuroradiology</i> , 2007, 28, 1650-1651.	1.2	17

#	ARTICLE	IF	CITATIONS
883	Closing the Clinicalâ€‘imaging Gap in Multiple Sclerosis? Imaging Iron Deposition in Deep Gray Matter. <i>Journal of Neuroimaging</i> , 2009, 19, 1-2.	1.0	17
884	Novel MRI approaches to assess patients with multiple sclerosis. <i>Current Opinion in Neurology</i> , 2010, 23, 212-217.	1.8	17
885	Motor area localization using fMRI-constrained cortical current density reconstruction of movement-related cortical potentials, a comparison with fMRI and TMS mapping. <i>Brain Research</i> , 2010, 1308, 68-78.	1.1	17
886	Overcoming the Clinicalâ€‘MR Imaging Paradox of Multiple Sclerosis: MR Imaging Data Assessed with a Random Forest Approach. <i>American Journal of Neuroradiology</i> , 2011, 32, 2098-2102.	1.2	17
887	Analysis of â€‘task-positiveâ€‘ and â€‘task-negativeâ€‘ functional networks during the performance of the Symbol Digit Modalities Test in patients at presentation with clinically isolated syndrome suggestive of multiple sclerosis. <i>Experimental Brain Research</i> , 2013, 225, 399-407.	0.7	17
888	Multicenter mapping in the healthy brain. <i>Magnetic Resonance in Medicine</i> , 2014, 71, 1103-1107.	1.9	17
889	Cognitive impairment in progressive supranuclear palsy-Richardsonâ€™s syndrome is related to white matter damage. <i>Parkinsonism and Related Disorders</i> , 2016, 31, 65-71.	1.1	17
890	Effects of pharmacological and nonpharmacological treatments on brain functional magnetic resonance imaging in Alzheimerâ€™s disease and mild cognitive impairment: a critical review. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 21.	3.0	17
891	Application of advanced MRI techniques to monitor pharmacologic and rehabilitative treatment in multiple sclerosis: current status and future perspectives. <i>Expert Review of Neurotherapeutics</i> , 2019, 19, 835-866.	1.4	17
892	Hippocampal-related memory network in multiple sclerosis: A structural connectivity analysis. <i>Multiple Sclerosis Journal</i> , 2019, 25, 801-810.	1.4	17
893	<i>In vivo</i> gradients of thalamic damage in paediatric multiple sclerosis: a window into pathology. <i>Brain</i> , 2021, 144, 186-197.	3.7	17
894	Effect of cognitive reserve on structural and functional MRI measures in healthy subjects: a multiparametric assessment. <i>Journal of Neurology</i> , 2021, 268, 1780-1791.	1.8	17
895	Current application of neurofilaments in amyotrophic lateral sclerosis and future perspectives. <i>Neural Regeneration Research</i> , 2021, 16, 1985.	1.6	17
896	Firstâ€‘line therapies in lateâ€‘onset multiple sclerosis: An Italian registry study. <i>European Journal of Neurology</i> , 2021, 28, 4117-4123.	1.7	17
897	Nonfluent/Agrammatic PPA with In-Vivo Cortical Amyloidosis and Pickâ€™s Disease Pathology. <i>Behavioural Neurology</i> , 2013, 26, 95-106.	1.1	17
898	Virtual reality balance training to improve balance and mobility in Parkinsonâ€™s disease: a systematic review and meta-analysis. <i>Journal of Neurology</i> , 2022, 269, 1873-1888.	1.8	17
899	Absence of oligoclonally restricted immunoglobulins in tears from multiple sclerosis patients. <i>Journal of Neuroimmunology</i> , 1993, 44, 149-155.	1.1	16
900	Inter-rater variability in reporting enhancing lesions present on standard and triple dose gadolinium scans of patients with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 1997, 3, 226-230.	1.4	16

#	ARTICLE	IF	CITATIONS
901	The effect of repositioning on brain MRI lesion load assessment in multiple sclerosis: reliability of subjective quality criteria. <i>Journal of Neurology</i> , 1998, 245, 273-275.	1.8	16
902	Lesion load quantification on fast-FLAIR, rapid acquisition relaxation-enhanced, and gradient spin echo brain MRI scans from multiple sclerosis patients. <i>Magnetic Resonance Imaging</i> , 1999, 17, 1105-1110.	1.0	16
903	Short-term evolution of new multiple sclerosis lesions enhancing on standard and triple dose gadolinium-enhanced brain MRI scans. <i>Journal of the Neurological Sciences</i> , 1999, 164, 148-152.	0.3	16
904	Non-conventional MR techniques to monitor the evolution of multiple sclerosis. <i>Neurological Sciences</i> , 2001, 22, 195-200.	0.9	16
905	A brain magnetization transfer MRI study with a clinical follow up of about four years in patients with clinically isolated syndromes suggestive of multiple sclerosis. <i>Journal of Neurology</i> , 2007, 254, 78-83.	1.8	16
906	Multiple sclerosis. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2016, 135, 399-423.	1.0	16
907	Abnormal cerebellar functional MRI connectivity in patients with paediatric multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2016, 22, 292-301.	1.4	16
908	MRI quality control for the Italian Neuroimaging Network Initiative: moving towards big data in multiple sclerosis. <i>Journal of Neurology</i> , 2019, 266, 2848-2858.	1.8	16
909	Functional brain connectome in posterior cortical atrophy. <i>NeuroImage: Clinical</i> , 2020, 25, 102100.	1.4	16
910	Natalizumab versus fingolimod for patients with active relapsing-remitting multiple sclerosis: results from REVEAL, a prospective, randomised head-to-head study. <i>BMJ Open</i> , 2020, 10, e038861.	0.8	16
911	Occurrence and microstructural features of slowly expanding lesions on fingolimod or natalizumab treatment in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1520-1532.	1.4	16
912	Breakdown of the affectiveâ€œcognitive network in functional dystonia. <i>Human Brain Mapping</i> , 2020, 41, 3059-3076.	1.9	16
913	Network Damage Predicts Clinical Worsening in Multiple Sclerosis. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2021, 8, .	3.1	16
914	Combining DTI and MRI for the Automated Detection of Alzheimerâ€™s Disease Using a Large European Multicenter Dataset. <i>Lecture Notes in Computer Science</i> , 2012, , 18-28.	1.0	16
915	The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021. <i>Multiple Sclerosis Journal</i> , 2022, 28, 1424-1456.	1.4	16
916	Longitudinal White Matter Damage Evolution in Parkinson's Disease. <i>Movement Disorders</i> , 2022, 37, 315-324.	2.2	16
917	Effects of hyperglycaemia on visual evoked potentials in insulin-dependent diabetic patients. <i>Acta Diabetologica</i> , 1992, 29, 34-37.	1.2	15
918	Cumulative effect of a weekly low dose of interferon beta 1a on standard and triple dose contrast-enhanced MRI from multiple sclerosis patients. <i>Journal of the Neurological Sciences</i> , 1999, 171, 130-134.	0.3	15

#	ARTICLE	IF	CITATIONS
919	Sample size estimations for MRI-monitored trials of MS comparing new vs standard treatments. <i>Neurology</i> , 2001, 57, 1883-1885.	1.5	15
920	The role of non-conventional MR techniques to study multiple sclerosis patients. <i>Journal of the Neurological Sciences</i> , 2001, 186, S3-S9.	0.3	15
921	Contribution of cervical cord MRI and brain magnetization transfer imaging to the assessment of individual patients with multiple sclerosis: a preliminary study. <i>Multiple Sclerosis Journal</i> , 2002, 8, 52-58.	1.4	15
922	Imaging primary progressive multiple sclerosis: the contribution of structural, metabolic, and functional MRI techniques. <i>Multiple Sclerosis Journal</i> , 2004, 10, S36-S45.	1.4	15
923	Can rate of brain atrophy in multiple sclerosis be explained by clinical and MRI characteristics?. <i>Multiple Sclerosis Journal</i> , 2009, 15, 465-471.	1.4	15
924	MRI evolution of new MS lesions enhancing after different doses of gadolinium. <i>Acta Neurologica Scandinavica</i> , 1998, 98, 90-93.	1.0	15
925	Brain connectivity abnormalities extend beyond the sensorimotor network in peripheral neuropathy. <i>Human Brain Mapping</i> , 2014, 35, 513-526.	1.9	15
926	Functional reorganization is a maladaptive response to injury â€œ YES. <i>Multiple Sclerosis Journal</i> , 2017, 23, 191-193.	1.4	15
927	Cortico-efferent tract involvement in primary lateral sclerosis and amyotrophic lateral sclerosis: A two-centre tract of interest-based DTI analysis. <i>NeuroImage: Clinical</i> , 2018, 20, 1062-1069.	1.4	15
928	Can action observation modulate balance performance in healthy subjects?. <i>Archives of Physiotherapy</i> , 2019, 9, 1.	0.7	15
929	10Kin1day: A Bottom-Up Neuroimaging Initiative. <i>Frontiers in Neurology</i> , 2019, 10, 425.	1.1	15
930	Refractory anti-NMDAR encephalitis successfully treated with bortezomib and associated movements disorders controlled with tramadol: a case report with literature review. <i>Journal of Neurology</i> , 2020, 267, 2462-2468.	1.8	15
931	COVID-19: can we learn from encephalitis lethargica?. <i>Lancet Neurology</i> , The, 2020, 19, 570.	4.9	15
932	Cognitive impairment in benign multiple sclerosis: a multiparametric structural and functional MRI study. <i>Journal of Neurology</i> , 2020, 267, 3508-3517.	1.8	15
933	Brain activity of the emotional circuit in Parkinsonâ€™s disease patients with freezing of gait. <i>NeuroImage: Clinical</i> , 2021, 30, 102649.	1.4	15
934	Long term follow-up in advanced Parkinsonâ€™s disease treated with DBS of the subthalamic nucleus. <i>Journal of Neurology</i> , 2021, 268, 2821-2830.	1.8	15
935	COVID-19 with no antibody response in a multiple sclerosis patient treated with cladribine: Implication for vaccination program?. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 49, 102775.	0.9	15
936	Diagnostic criteria for primary progressive multiple sclerosis: A position paper. , 2000, 47, 831.		15

#	ARTICLE	IF	CITATIONS
937	Quantification of brain damage in cerebrotendinous xanthomatosis with magnetization transfer MR imaging. <i>American Journal of Neuroradiology</i> , 2003, 24, 495-500.	1.2	15
938	Amyotrophic Lateral Sclerosisâ€“Frontotemporal Dementia. <i>Neurology</i> , 2022, 98, .	1.5	15
939	Neuroimaging in Glucocerebrosidaseâ€“Associated Parkinsonism: A Systematic Review. <i>Movement Disorders</i> , 2022, 37, 1375-1393.	2.2	15
940	Effects of Long-Lasting Antiepileptic Therapy on Brainstem Auditory Evoked Potentials. <i>Neuropsychobiology</i> , 1988, 19, 104-107.	0.9	14
941	A Preliminary Study Comparing the Sensitivity of Serial Monthly Enhanced MRI After Standard and Triple Dose Gadoliniumâ€“DTPA for Monitoring Disease Activity in Primary Progressive Multiple Sclerosis. <i>Journal of Neuroimaging</i> , 1998, 8, 88-93.	1.0	14
942	Correlation between MRI and Short-Term Clinical Activity in Multiple Sclerosis: Comparison between Standard- and Triple-Dose Gd-Enhanced MRI. <i>European Neurology</i> , 1999, 41, 123-127.	0.6	14
943	Diffusion-weighted imaging in multiple sclerosis. <i>Neurological Sciences</i> , 1999, 20, S246-S249.	0.9	14
944	Assessment of posterior fossa damage in MS using MRI. <i>Journal of the Neurological Sciences</i> , 2000, 172, S50-S53.	0.3	14
945	Predictive value of MRI findings in multiple sclerosis. <i>Lancet Neurology</i> , The, 2002, 1, 9.	4.9	14
946	MRIâ€“clinical correlations in the primary progressive course of MS: new insights into the disease pathophysiology from the application of magnetization transfer, diffusion tensor, and functional MRI. <i>Journal of the Neurological Sciences</i> , 2003, 206, 157-164.	0.3	14
947	Interventions for the Prevention of Brain Atrophy in Multiple Sclerosis. <i>CNS Drugs</i> , 2003, 17, 563-575.	2.7	14
948	beta endorphin concentrations in PBMC of patients with different clinical phenotypes of multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2003, 74, 495-497.	0.9	14
949	Diffusion tensor MRI of the cervical cord in a patient with syringomyelia and multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2004, 75, 1647-1647.	0.9	14
950	Bimonthly assessment of magnetization transfer magnetic resonance imaging parameters in multiple sclerosis: a 14-month, multicentre, follow-up study. <i>Multiple Sclerosis Journal</i> , 2010, 16, 325-331.	1.4	14
951	Dementia and neuroimaging. <i>Journal of Neurology</i> , 2013, 260, 685-691.	1.8	14
952	Altered neural mechanisms of cognitive control in patients with primary progressive multiple sclerosis: An effective connectivity study. <i>Human Brain Mapping</i> , 2017, 38, 2580-2588.	1.9	14
953	The Italian Neuroimaging Network Initiative (INNI): enabling the use of advanced MRI techniques in patients with MS. <i>Neurological Sciences</i> , 2017, 38, 1029-1038.	0.9	14
954	Progression of brain white matter hyperintensities in asymptomatic patients with carotid atherosclerotic plaques and no indication for revascularization. <i>Atherosclerosis</i> , 2019, 287, 171-178.	0.4	14

#	ARTICLE	IF	CITATIONS
955	Functional brain connectivity abnormalities and cognitive deficits in neuromyelitis optica spectrum disorder. <i>Multiple Sclerosis Journal</i> , 2020, 26, 795-805.	1.4	14
956	Resting state network functional connectivity abnormalities in systemic lupus erythematosus: correlations with neuropsychiatric impairment. <i>Molecular Psychiatry</i> , 2021, 26, 3634-3645.	4.1	14
957	Clinical features and outcomes of the flail arm and flail leg and pure lower motor neuron MND variants: a multicentre Italian study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 1001-1003.	0.9	14
958	COVID-19 in cladribine-treated relapsing-remitting multiple sclerosis patients: a monocentric experience. <i>Journal of Neurology</i> , 2020, 268, 2697-2699.	1.8	14
959	What role should spinal cord MRI take in the future of multiple sclerosis surveillance?. <i>Expert Review of Neurotherapeutics</i> , 2020, 20, 783-797.	1.4	14
960	Structural MRI outcomes and predictors of disease progression in amyotrophic lateral sclerosis. <i>NeuroImage: Clinical</i> , 2020, 27, 102315.	1.4	14
961	Reduced accuracy of MRI deep grey matter segmentation in multiple sclerosis: an evaluation of four automated methods against manual reference segmentations in a multi-center cohort. <i>Journal of Neurology</i> , 2020, 267, 3541-3554.	1.8	14
962	Current state-of-art of the application of serum neurofilaments in multiple sclerosis diagnosis and monitoring. <i>Expert Review of Neurotherapeutics</i> , 2020, 20, 747-769.	1.4	14
963	Measurement of white matter fiber-bundle cross-section in multiple sclerosis using diffusion-weighted imaging. <i>Multiple Sclerosis Journal</i> , 2021, 27, 818-826.	1.4	14
964	Dynamic Functional Connectivity in the Main Clinical Phenotypes of Multiple Sclerosis. <i>Brain Connectivity</i> , 2021, 11, 678-690.	0.8	14
965	Dual-task clinical and functional MRI correlates in Parkinson's disease with postural instability and gait disorders. <i>Parkinsonism and Related Disorders</i> , 2021, 91, 88-95.	1.1	14
966	Clinical correlates of hypothalamic functional changes in migraine patients. <i>Cephalalgia</i> , 2022, 42, 279-290.	1.8	14
967	Magnetization transfer ratio changes in a symptomatic lesion of a patient at presentation with possible multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 1997, 151, 79-81.	0.3	13
968	Triple dose of gadolinium-DTPA increases the sensitivity of spinal cord MRI in detecting enhancing lesions in multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 1998, 158, 221-225.	0.3	13
969	Serial gadolinium-DTPA of spinal cord MRI in multiple sclerosis: triple vs. single dose. <i>Magnetic Resonance Imaging</i> , 2000, 18, 1183-1186.	1.0	13
970	Imaging Spinal Cord Damage in Multiple Sclerosis. <i>Journal of Neuroimaging</i> , 2005, 15, 297-304.	1.0	13
971	Antonâ€™s Syndrome following Callosal Disconnection. <i>Behavioural Neurology</i> , 2007, 18, 183-186.	1.1	13
972	Absence of diffuse cervical cord tissue damage in early, non-disabling relapsing-remitting MS: a preliminary study. <i>Multiple Sclerosis Journal</i> , 2008, 14, 853-856.	1.4	13

#	ARTICLE	IF	CITATIONS
973	Multiple Sclerosis and Chronic Cerebrospinal Venous Insufficiency: The Neuroimaging Perspective. American Journal of Neuroradiology, 2011, 32, 424-427.	1.2	13
974	DT MRI microstructural cortical lesion damage does not explain cognitive impairment in MS. Multiple Sclerosis Journal, 2017, 23, 1918-1928.	1.4	13
975	A diffusion tensor magnetic resonance imaging study of paediatric patients with severe non-traumatic brain injury. Developmental Medicine and Child Neurology, 2017, 59, 199-206.	1.1	13
976	MRI substrates of sustained attention system and cognitive impairment in pediatric MS patients. Neurology, 2017, 89, 1265-1273.	1.5	13
977	Progression of white matter damage in progressive supranuclear palsy with predominant parkinsonism. Parkinsonism and Related Disorders, 2018, 49, 95-99.	1.1	13
978	Added value of multimodal MRI to the clinical diagnosis of primary progressive aphasia variants. Cortex, 2019, 113, 58-66.	1.1	13
979	Neuraxial analgesia is not associated with an increased risk of post-partum relapses in MS. Multiple Sclerosis Journal, 2019, 25, 591-600.	1.4	13
980	Spinal Cord Atrophy in Neuromyelitis Optica Spectrum Disorders Is Spatially Related to Cord Lesions and Disability. Radiology, 2020, 297, 154-163.	3.6	13
981	Cortical axonal loss is associated with both gray matter demyelination and white matter tract pathology in progressive multiple sclerosis: Evidence from a combined MRI-histopathology study. Multiple Sclerosis Journal, 2021, 27, 380-390.	1.4	13
982	Biomarker-based stability in limbic-predominant amnesic mild cognitive impairment. European Journal of Neurology, 2021, 28, 1123-1133.	1.7	13
983	Early Predictors of 9-Year Disability in Pediatric Multiple Sclerosis. Annals of Neurology, 2021, 89, 1011-1022.	2.8	13
984	Pregnancy in multiple sclerosis women with relapses in the year before conception increases the risk of long-term disability worsening. Multiple Sclerosis Journal, 2022, 28, 472-479.	1.4	13
985	Unraveling the substrates of cognitive impairment in multiple sclerosis: A multiparametric structural and functional magnetic resonance imaging study. European Journal of Neurology, 2021, 28, 3749-3759.	1.7	13
986	CONCERTO: A randomized, placebo-controlled trial of oral laquinimod in relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal, 2022, 28, 608-619.	1.4	13
987	Imaging spinal cord damage in multiple sclerosis. , 2005, 15, 297-304.		13
988	A comparison of MR imaging with fast-FLAIR, HASTE-FLAIR, and EPI-FLAIR sequences in the assessment of patients with multiple sclerosis. American Journal of Neuroradiology, 1999, 20, 1931-8.	1.2	13
989	MR outcome parameters in multiple sclerosis: comparison of surface-based thresholding segmentation and magnetization transfer ratio histographic analysis in relation to disability (a) Tj ETQq1 1 0.7843 142gBT /Overlock 10		13
990	Magnetization transfer imaging to monitor the evolution of individual multiple sclerosis lesions. Neurology, 1999, 53, S18-22.	1.5	13



#	ARTICLE	IF	CITATIONS
991	The role of magnetic resonance imaging in the study of multiple sclerosis: diagnosis, prognosis and understanding disease pathophysiology. <i>Acta Neurologica Belgica</i> , 2011, 111, 89-98.	0.5	13
992	Exploring in vivo multiple sclerosis brain microstructural damage through T1w/T2w ratio: a multicentre study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 741-752.	0.9	13
993	Reproducibility of Brain MRI Lesion Volume Measurements in Multiple Sclerosis Using a Local Thresholding Technique: Effects of Formal Operator Training. <i>European Neurology</i> , 1999, 41, 226-230.	0.6	12
994	Multiple sclerosis: interobserver agreement in reporting active lesions on serial brain MRI using conventional spin echo, fast spin echo, fast fluid-attenuated inversion recovery and post-contrast T1-weighted images. <i>Journal of Neurology</i> , 1999, 246, 920-925.	1.8	12
995	Assessment of spinal cord damage in MS using MRI. <i>Journal of the Neurological Sciences</i> , 2000, 172, S36-S39.	0.3	12
996	Magnetic resonance imaging findings predicting subsequent disease course in patients at presentation with clinically isolated syndromes suggestive of multiple sclerosis. <i>Neurological Sciences</i> , 2001, 22, S49-S51.	0.9	12
997	Clinical and MRI assessment of brain damage in MS. <i>Neurological Sciences</i> , 2001, 22, S123-S127.	0.9	12
998	Magnetic resonance-based techniques for the study and management of multiple sclerosis. <i>British Medical Bulletin</i> , 2003, 65, 133-144.	2.7	12
999	Toward a definition of structural and functional MRI substrates of fatigue in multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2007, 263, 1-2.	0.3	12
1000	Dirty-Appearing White Matter: A Disregarded Entity in Multiple Sclerosis. <i>American Journal of Neuroradiology</i> , 2010, 31, 390-391.	1.2	12
1001	Magnetic Resonance Imaging in Alzheimer's Disease: from Diagnosis to Monitoring Treatment Effect. <i>Current Alzheimer Research</i> , 2012, 9, 1198-1209.	0.7	12
1002	The cumulative effect of genetic polymorphisms on depression and brain structural integrity. <i>Human Brain Mapping</i> , 2016, 37, 2173-2184.	1.9	12
1003	Action observation training modifies brain gray matter structure in healthy adult individuals. <i>Brain Imaging and Behavior</i> , 2017, 11, 1343-1352.	1.1	12
1004	Effectiveness and baseline factors associated to fingolimod response in a real-world study on multiple sclerosis patients. <i>Journal of Neurology</i> , 2018, 265, 896-905.	1.8	12
1005	Mirror therapy for an adult with central post-stroke pain: a case report. <i>Archives of Physiotherapy</i> , 2018, 8, 4.	0.7	12
1006	Cross-modal plasticity among sensory networks in neuromyelitis optica spectrum disorders. <i>Multiple Sclerosis Journal</i> , 2019, 25, 968-979.	1.4	12
1007	Fronto-temporal vulnerability to disconnection in paediatric moderate and severe traumatic brain injury. <i>European Journal of Neurology</i> , 2019, 26, 1183-1190.	1.7	12
1008	Brain MRI shows white matter sparing in Kennedy's disease and slow-progressing lower motor neuron disease. <i>Human Brain Mapping</i> , 2019, 40, 3102-3112.	1.9	12

#	ARTICLE	IF	CITATIONS
1009	Dysregulation of multisensory processing stands out from an early stage of migraine: a study in pediatric patients. <i>Journal of Neurology</i> , 2020, 267, 760-769.	1.8	12
1010	MRI correlates of clinical disability and hand-motor performance in multiple sclerosis phenotypes. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1205-1221.	1.4	12
1011	Are machine learning approaches the future to study patients with migraine?. <i>Neurology</i> , 2020, 94, 291-292.	1.5	12
1012	Early Management of OnabotulinumtoxinA Treatment in Chronic Migraine: Insights from a Real-Life European Multicenter Study. <i>Pain and Therapy</i> , 2021, 10, 637-650.	1.5	12
1013	Brain Metabolism and Microglia Activation in Mild Cognitive Impairment: A Combined [18F]FDG and [11C]-(R)-PK11195 PET Study. <i>Journal of Alzheimer's Disease</i> , 2021, 80, 433-445.	1.2	12
1014	Central vein sign and iron rim in multiple sclerosis: ready for clinical use?. <i>Current Opinion in Neurology</i> , 2021, 34, 505-513.	1.8	12
1015	Three subsequent single doses of gadolinium chelate for brain MR imaging in multiple sclerosis. <i>American Journal of Neuroradiology</i> , 2003, 24, 658-62.	1.2	12
1016	A longitudinal brain MRI study comparing the sensitivities of the conventional and a newer approach for detecting active lesions in multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 1998, 159, 94-101.	0.3	11
1017	Improved interobserver agreement for visual detection of active T2 lesions on serial MR scans in multiple sclerosis using image registration. <i>Journal of Neurology</i> , 2001, 248, 789-794.	1.8	11
1018	Magnetic resonance imaging techniques to define and monitor tissue damage and repair in multiple sclerosis. <i>Journal of Neurology</i> , 2007, 254, 155-162.	1.8	11
1019	Short-term combination of glatiramer acetate with IV steroid treatment preceding treatment with GA alone assessed by MRI-disease activity in patients with relapsing/remitting multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2008, 266, 44-50.	0.3	11
1020	Relationship between brain MRI lesion load and short-term disease evolution in non-disabling MS: a large-scale, multicentre study. <i>Multiple Sclerosis Journal</i> , 2011, 17, 319-326.	1.4	11
1021	The Progranulin (GRN) Cys157LysfsX97 Mutation is Associated with Nonfluent Variant of Primary Progressive Aphasia Clinical Phenotype. <i>Journal of Alzheimer's Disease</i> , 2012, 28, 759-763.	1.2	11
1022	Patterns of regional gray matter and white matter atrophy in cortical multiple sclerosis. <i>Journal of Neurology</i> , 2014, 261, 1715-1725.	1.8	11
1023	Altered Recruitment of the Attention Network Is Associated with Disability and Cognitive Impairment in Pediatric Patients with Acquired Brain Injury. <i>Neural Plasticity</i> , 2015, 2015, 1-13.	1.0	11
1024	Novel Compound Heterozygous Spatacsin Mutations in a Greek Kindred with Hereditary Spastic Paraplegia SPC11 and Dementia. <i>Neurodegenerative Diseases</i> , 2016, 16, 373-381.	0.8	11
1025	The Italian dementia with Lewy bodies study group (DLB-SINdem): toward a standardization of clinical procedures and multicenter cohort studies design. <i>Neurological Sciences</i> , 2017, 38, 83-91.	0.9	11
1026	Perfusion alterations converge with patterns of pathological spread in transactive response DNA-binding protein 43 proteinopathies. <i>Neurobiology of Aging</i> , 2018, 68, 85-92.	1.5	11

#	ARTICLE	IF	CITATIONS
1027	Functional MRI in Atypical Parkinsonisms. <i>International Review of Neurobiology</i> , 2018, 142, 149-173.	0.9	11
1028	Influence of CNS T2-focal lesions on cervical cord atrophy and disability in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1402-1409.	1.4	11
1029	Voxel-based morphometry and task functional magnetic resonance imaging in essential tremor: evidence for a disrupted brain network. <i>Scientific Reports</i> , 2020, 10, 15061.	1.6	11
1030	Clinical predictivity of thalamic sub-regional connectivity in clinically isolated syndrome: a 7-year study. <i>Molecular Psychiatry</i> , 2021, 26, 2163-2174.	4.1	11
1031	Burden of Rare Variants in ALS and Axonal Hereditary Neuropathy Genes Influence Survival in ALS: Insights from a Next Generation Sequencing Study of an Italian ALS Cohort. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3346.	1.8	11
1032	What We Gain From Machine Learning Studies in Headache Patients. <i>Frontiers in Neurology</i> , 2020, 11, 221.	1.1	11
1033	Serum naturally occurring anti-TDP-43 auto-antibodies are increased in amyotrophic lateral sclerosis. <i>Scientific Reports</i> , 2021, 11, 1978.	1.6	11
1034	In vivo detection of damage in multiple sclerosis cortex and cortical lesions using NODDI. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 628-636.	0.9	11
1035	MAGNIMS recommendations for harmonization of MRI data in MS multicenter studies. <i>NeuroImage: Clinical</i> , 2022, 34, 102972.	1.4	11
1036	Acute- and insidious-onset myelopathy of undetermined aetiology: contribution of paraclinical tests to the diagnosis of multiple sclerosis. <i>Journal of Neurology</i> , 1990, 237, 171-176.	1.8	10
1037	Does hemispheric dominance influence brain lesion distribution in multiple sclerosis?. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1995, 58, 748-749.	0.9	10
1038	Defining the response to multiple sclerosis treatment: the role of conventional magnetic resonance imaging. <i>Neurological Sciences</i> , 2005, 26, s204-s208.	0.9	10
1039	Multiple sclerosis and allied white matter diseases. <i>Neurological Sciences</i> , 2008, 29, 319-322.	0.9	10
1040	Effects of Inhibitors of the Renin-Angiotensin System on the Efficacy of Interferon beta-1b: A post hoc Analysis of the BEYOND Study. <i>European Neurology</i> , 2014, 71, 173-179.	0.6	10
1041	KIR4.1: another misleading expectation in multiple sclerosis?. <i>Lancet Neurology</i> , The, 2014, 13, 753-755.	4.9	10
1042	Basal vitamin D levels and disease activity in multiple sclerosis patients treated with fingolimod. <i>Neurological Sciences</i> , 2018, 39, 1467-1470.	0.9	10
1043	MRI of non-Alzheimer's dementia: current and emerging knowledge. <i>Current Opinion in Neurology</i> , 2018, 31, 405-414.	1.8	10
1044	Imaging the migrainous brain: the present and the future. <i>Neurological Sciences</i> , 2019, 40, 49-54.	0.9	10

#	ARTICLE	IF	CITATIONS
1045	Urinary neopterin, a new marker of the neuroinflammatory status in amyotrophic lateral sclerosis. <i>Journal of Neurology</i> , 2020, 267, 3609-3616.	1.8	10
1046	Action observation training promotes motor improvement and modulates functional network dynamic connectivity in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021, 27, 139-146.	1.4	10
1047	Physical Exercise Moderates the Effects of Disability on Depression in People with Multiple Sclerosis during the COVID-19 Outbreak. <i>Journal of Clinical Medicine</i> , 2021, 10, 1234.	1.0	10
1048	PML risk is the main factor driving the choice of discontinuing natalizumab in a large multiple sclerosis population: results from an Italian multicenter retrospective study. <i>Journal of Neurology</i> , 2022, 269, 933-944.	1.8	10
1049	Cardiorespiratory fitness and free-living physical activity are not associated with cognition in persons with progressive multiple sclerosis: Baseline analyses from the CogEx study. <i>Multiple Sclerosis Journal</i> , 2022, 28, 1091-1100.	1.4	10
1050	Effect of BDNF Val66Met polymorphism on hippocampal subfields in multiple sclerosis patients. <i>Molecular Psychiatry</i> , 2022, 27, 1010-1019.	4.1	10
1051	A new method for analyzing histograms of brain magnetization transfer ratios: comparison with existing techniques. <i>American Journal of Neuroradiology</i> , 2004, 25, 1234-41.	1.2	10
1052	Persistence of congenital mirror movements after hemiplegic stroke. <i>American Journal of Neuroradiology</i> , 2005, 26, 831-4.	1.2	10
1053	Sensitivity of enhanced MR in multiple sclerosis: effects of contrast dose and magnetization transfer contrast. <i>American Journal of Neuroradiology</i> , 1998, 19, 1863-7.	1.2	10
1054	Increased spatial resolution using a three-dimensional T1-weighted gradient-echo MR sequence results in greater hypointense lesion volumes in multiple sclerosis. <i>American Journal of Neuroradiology</i> , 1998, 19, 235-8.	1.2	10
1055	Correlations between magnetization transfer metrics and other magnetic resonance abnormalities in multiple sclerosis. <i>Neurology</i> , 1999, 53, S40-5.	1.5	10
1056	Magnetic resonance imaging of grey matter damage in people with MS. <i>International MS Journal</i> , 2007, 14, 12-21.	0.3	10
1057	A Comparison Between the Sensitivities of 3mm and 5mm Thick Serial Brain MRI for Detecting Lesion Volume Changes in Patients with Multiple Sclerosis. <i>Journal of Neuroimaging</i> , 1998, 8, 144-147.	1.0	9
1058	A comparison of the sensitivity of monthly unenhanced and enhanced MRI techniques in detecting new multiple sclerosis lesions. <i>Journal of Neurology</i> , 1999, 246, 97-106.	1.8	9
1059	No significant effect of orally administered chemokine receptor 1 antagonist on intercellular adhesion molecule-3 expression in relapsing/remitting multiple sclerosis patients. <i>Multiple Sclerosis Journal</i> , 2010, 16, 366-369.	1.4	9
1060	Dentate Nucleus T1 Hyperintensity in Multiple Sclerosis: Fig 1.. <i>American Journal of Neuroradiology</i> , 2011, 32, E120-E121.	1.2	9
1061	Variability in detection and quantification of interferon $\beta$ -1-induced neutralizing antibodies. <i>Journal of Neuroinflammation</i> , 2012, 9, 129.	3.1	9
1062	New magnetic resonance imaging biomarkers for the diagnosis of multiple sclerosis. <i>Expert Opinion on Medical Diagnostics</i> , 2012, 6, 109-120.	1.6	9

#	ARTICLE	IF	CITATIONS
1063	Efficacy and safety of interferon beta-1b sc in older RRMS patients—a posthoc analysis of the BEYOND study. <i>Journal of Neurology</i> , 2013, 260, 1838-1845.	1.8	9
1064	Preventing brain atrophy should be the gold standard of effective therapy in MS (after the first year) <i>Tj ETQq0 0 0 rgBT /Overlock 10 Tf</i>	1.4	9
1065	Estimating Brain Lesion Volume Change in Multiple Sclerosis by Subtraction of Magnetic Resonance Images. <i>Journal of Neuroimaging</i> , 2016, 26, 395-402.	1.0	9
1066	Charting Frontotemporal Dementia: From Genes to Networks. <i>Journal of Neuroimaging</i> , 2016, 26, 16-27.	1.0	9
1067	Dynamic volumetric changes of hippocampal subfields in clinically isolated syndrome patients: A 2-year MRI study. <i>Multiple Sclerosis Journal</i> , 2019, 25, 1232-1242.	1.4	9
1068	Multiple sclerosis associated with pembrolizumab in a patient with non-small cell lung cancer. <i>Journal of Neurology</i> , 2019, 266, 3163-3166.	1.8	9
1069	Effect of <i>HLA-DRB1</i> alleles and genetic variants on the development of neutralizing antibodies to interferon beta in the BEYOND and BENEFIT trials. <i>Multiple Sclerosis Journal</i> , 2019, 25, 565-573.	1.4	9
1070	Structural and functional disconnections convey the pathology progression along the Alzheimer’s continuum. <i>Molecular Psychiatry</i> , 2020, 25, 1-1.	4.1	9
1071	Effects of Fingolimod and Natalizumab on Brain T1-/T2-Weighted and Magnetization Transfer Ratios: a 2-Year Study. <i>Neurotherapeutics</i> , 2021, 18, 878-888.	2.1	9
1072	CSF extracellular vesicles and risk of disease activity after a first demyelinating event. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1606-1610.	1.4	9
1073	Injectable Versus Oral First-Line Disease-Modifying Therapies: Results from the Italian MS Register. <i>Neurotherapeutics</i> , 2021, 18, 905-919.	2.1	9
1074	Spinal Fluid Myeloid Microvesicles Predict Disease Course in Multiple Sclerosis. <i>Annals of Neurology</i> , 2021, 90, 253-265.	2.8	9
1075	Chronic active lesions: a new MRI biomarker to monitor treatment effect in multiple sclerosis?. <i>Expert Review of Neurotherapeutics</i> , 2021, 21, 837-841.	1.4	9
1076	Volume of hippocampal subfields and cognitive deficits in neuromyelitis optica spectrum disorders. <i>European Journal of Neurology</i> , 2021, 28, 4167-4177.	1.7	9
1077	Functional connectivity in Parkinson’s disease candidates for deep brain stimulation. <i>Npj Parkinson’s Disease</i> , 2022, 8, 4.	2.5	9
1078	Quantitative assessment of magnetic resonance imaging lesion load in multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1998, 64 Suppl 1, S88-93.	0.9	9
1079	Magnetisation transfer imaging in multiple sclerosis. <i>Journal of NeuroVirology</i> , 2000, 6 Suppl 2, S115-20.	1.0	9
1080	Effects of seasons on magnetic resonance imaging–measured disease activity in patients with multiple sclerosis. <i>Annals of Neurology</i> , 2001, 49, 415-6.	2.8	9

#	ARTICLE	IF	CITATIONS
1081	NEK1 Variants in a Cohort of Italian Patients With Amyotrophic Lateral Sclerosis. <i>Frontiers in Neuroscience</i> , 2022, 16, 833051.	1.4	9
1082	Interferon-gamma induced increases in intracellular calcium in T lymphocytes from patients with multiple sclerosis precede clinical exacerbations and detection of active lesions on MRI. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1997, 63, 339-345.	0.9	8
1083	Correlation between enhancing lesion number and volume on standard and triple dose gadolinium-enhanced brain MRI scans from patients with multiple sclerosis. <i>Magnetic Resonance Imaging</i> , 1999, 17, 985-988.	1.0	8
1084	The role of magnetic resonance in the assessment of multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2000, 172, S3-S12.	0.3	8
1085	Magnetization transfer and diffusion tensor MR imaging of the optic radiations and calcarine cortex from patients with Leber's hereditary optic neuropathy. <i>Journal of the Neurological Sciences</i> , 2001, 188, 33-36.	0.3	8
1086	Demyelination and cortical reorganization: functional MRI data from a case of subacute combined degeneration. <i>NeuroImage</i> , 2003, 18, 558-563.	2.1	8
1087	"Clues on Balo's concentric sclerosis evolution from serial analysis of ADC values". <i>International Journal of Neuroscience</i> , 2016, 126, 88-95.	0.8	8
1088	Clinical deterioration due to co-occurrence of multiple sclerosis and glioblastoma: report of two cases. <i>Neurological Sciences</i> , 2017, 38, 361-364.	0.9	8
1089	Northwestern Anagram Test-Italian (Nat-I) for primary progressive aphasia. <i>Cortex</i> , 2019, 119, 497-510.	1.1	8
1090	COVID-19 will change MS care forever – No. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1149-1151.	1.4	8
1091	Candesartan in migraine prevention: results from a retrospective real-world study. <i>Journal of Neurology</i> , 2020, 267, 3243-3247.	1.8	8
1092	MRI of Motor and Nonmotor Therapy-Induced Complications in Parkinson's Disease. <i>Movement Disorders</i> , 2020, 35, 724-740.	2.2	8
1093	Rethinking multiple sclerosis treatment strategies. <i>Lancet Neurology</i> , The, 2020, 19, 281-282.	4.9	8
1094	Two-year regional grey and white matter volume changes with natalizumab and fingolimod. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 493-502.	0.9	8
1095	Fingolimod as an effective therapeutic strategy for pediatric relapsing-remitting multiple sclerosis: two case reports. <i>Neurological Sciences</i> , 2021, 42, 9-13.	0.9	8
1096	Functional and structural MRI correlates of executive functions in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2022, 28, 742-756.	1.4	8
1097	Quantification of Cervical Cord Cross-Sectional Area: Which Acquisition, Vertebra Level, and Analysis Software? A Multicenter Repeatability Study on a Traveling Healthy Volunteer. <i>Frontiers in Neurology</i> , 2021, 12, 693333.	1.1	8
1098	Multiple sclerosis epidemiological trends in Italy highlight the environmental risk factors. <i>Journal of Neurology</i> , 2022, 269, 1817-1824.	1.8	8

#	ARTICLE	IF	CITATIONS
1099	Is There a Gender Difference in the Response to onabotulinumtoxinA in Chronic Migraine? Insights from a Real-Life European Multicenter Study on 2879 Patients. <i>Pain and Therapy</i> , 2021, 10, 1605-1618.	1.5	8
1100	Neuropsychological impairment in multiple sclerosis patients: the role of (juxta)cortical lesion on FLAIR. <i>Multiple Sclerosis Journal</i> , 2000, 6, 280-285.	1.4	8
1101	Gamma Knife radiosurgery as primary treatment of low-grade brainstem gliomas: A systematic review and metaanalysis of current evidence and predictive factors. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 168, 103508.	2.0	8
1102	The effect of air pollution on COVID-19 severity in a sample of patients with multiple sclerosis. <i>European Journal of Neurology</i> , 2022, 29, 535-542.	1.7	8
1103	Scan-rescan variation of measures derived from brain magnetization transfer ratio histograms obtained in healthy volunteers by use of a semi-interleaved magnetization transfer sequence. <i>American Journal of Neuroradiology</i> , 2001, 22, 681-4.	1.2	8
1104	Neurofilament light chain as a biological marker for amyotrophic lateral sclerosis: a meta-analysis study. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2022, 23, 446-457.	1.1	8
1105	Eculizumab as a fast-acting rescue therapy in a refractory myasthenic crisis: a case report. <i>Journal of Neurology</i> , 2022, 269, 6152-6154.	1.8	8
1106	Discontinuous distribution of IgG oligoclonal bands in cerebrospinal fluid from multiple sclerosis patients. <i>Journal of Neuroimmunology</i> , 1990, 30, 129-134.	1.1	7
1107	Activity revealed in MRI of multiple sclerosis without contrast agent A preliminary report. <i>Magnetic Resonance Imaging</i> , 2000, 18, 139-142.	1.0	7
1108	The role of magnetization transfer and diffusion-weighted MRI in the understanding of multiple sclerosis evolution. <i>Neurological Sciences</i> , 2000, 21, S877-S881.	0.9	7
1109	Il ruolo della RM convenzionale, della Diffusione e del Magnetization Transfer nella diagnosi di Sclerosi Laterale Amiotrofica Risultati preliminari. <i>The Neuroradiology Journal</i> , 2001, 14, 61-65.	0.1	7
1110	Can glatiramer acetate reduce brain atrophy development in multiple sclerosis?. <i>Journal of the Neurological Sciences</i> , 2005, 233, 139-143.	0.3	7
1111	Assessing "occult" cervical cord damage in patients with neuropsychiatric systemic lupus erythematosus using diffusion tensor MRI. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2007, 78, 893-895.	0.9	7
1112	Can the functional assessment of multiple sclerosis adapt to changing needs? A psychometric validation in patients with clinically isolated syndrome and early relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2011, 17, 1504-1513.	1.4	7
1113	Multiple sclerosis: new measures to monitor the disease. <i>Lancet Neurology</i> , The, 2013, 12, 12-13.	4.9	7
1114	Linking disability and spinal cord imaging outcomes in MS. <i>Nature Reviews Neurology</i> , 2013, 9, 189-190.	4.9	7
1115	Spring cleaning: time to rethink imaging research lines in MS?. <i>Journal of Neurology</i> , 2016, 263, 1893-1902.	1.8	7
1116	Cross-sectional study of smoking exposure: no differential effect on OCT metrics in a cohort of MS patients. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2019, 5, 205521731982840.	0.5	7

#	ARTICLE	IF	CITATIONS
1117	Moving beyond anti-aquaporin-4 antibodies: emerging biomarkers in the spectrum of neuromyelitis optica. <i>Expert Review of Neurotherapeutics</i> , 2020, 20, 601-618.	1.4	7
1118	Longitudinal cortical thinning progression differs across multiple sclerosis phenotypes and is clinically relevant: A multicentre study. <i>Multiple Sclerosis Journal</i> , 2021, 27, 827-840.	1.4	7
1119	Cortico-subcortical functional connectivity modifications in fatigued multiple sclerosis patients treated with fampridine and amantadine. <i>European Journal of Neurology</i> , 2021, 28, 2249-2258.	1.7	7
1120	Transcriptomic Analysis of Peripheral Monocytes upon Fingolimod Treatment in Relapsing Remitting Multiple Sclerosis Patients. <i>Molecular Neurobiology</i> , 2021, 58, 4816-4827.	1.9	7
1121	Differential association of cortical, subcortical and spinal cord damage with multiple sclerosis disability milestones: A multiparametric MRI study. <i>Multiple Sclerosis Journal</i> , 2022, 28, 406-417.	1.4	7
1122	Association of Age at Onset With Gray Matter Volume and White Matter Microstructural Abnormalities in People With Multiple Sclerosis. <i>Neurology</i> , 2021, 97, e2007-e2019.	1.5	7
1123	Effects on cognition of DMTs in multiple sclerosis: moving beyond the prevention of inflammatory activity. <i>Journal of Neurology</i> , 2022, 269, 1052-1064.	1.8	7
1124	Multiple sclerosis and Alzheimer disease through the looking glass of MR imaging. <i>American Journal of Neuroradiology</i> , 2005, 26, 2488-91.	1.2	7
1125	A multiparametric brain and cord MR imaging study of a patient with Hirayama disease. <i>American Journal of Neuroradiology</i> , 2006, 27, 2115-7.	1.2	7
1126	Long-term Cognitive Outcomes and Socioprofessional Attainment in People With Multiple Sclerosis With Childhood Onset. <i>Neurology</i> , 2022, 98, e1626-e1636.	1.5	7
1127	COVID-19 vaccine uptake among family caregivers of people with dementia: The role of attitudes toward vaccination, perceived social support and personality traits. <i>Frontiers in Psychology</i> , 0, 13, .	1.1	7
1128	Detection of multiple sclerosis lesions using EPI-FLAIR images. <i>Magnetic Resonance Imaging</i> , 2000, 18, 907-910.	1.0	6
1129	Clinical trials and clinical practice in multiple sclerosis: Conventional and emerging magnetic resonance imaging technologies. <i>Current Neurology and Neuroscience Reports</i> , 2002, 2, 267-276.	2.0	6
1130	“Importance sampling”: A strategy to overcome the clinical/MRI paradox in MS?. <i>Journal of the Neurological Sciences</i> , 2005, 237, 1-3.	0.3	6
1131	Headache and migraine. <i>Neurological Sciences</i> , 2008, 29, 336-338.	0.9	6
1132	A search for new MRI criteria for dissemination in space in subjects with a clinically isolated syndrome. <i>European Radiology</i> , 2009, 19, 2244-2248.	2.3	6
1133	The “vegetarian brain”: chatting with monkeys and pigs?. <i>Brain Structure and Function</i> , 2013, 218, 1211-1227.	1.2	6
1134	fMRI in Neurodegenerative Diseases: From Scientific Insights to Clinical Applications. <i>NeuroMethods</i> , 2016, , 699-739.	0.2	6



#	ARTICLE	IF	CITATIONS
1135	Does neuroinflammation sustain neurodegeneration in ALS?. <i>Neurology</i> , 2016, 87, 2508-2509.	1.5	6
1136	Classifying silent progression in relapsing&#x2014;remitting MS. <i>Nature Reviews Neurology</i> , 2019, 15, 315-316.	4.9	6
1137	White Matter Microstructure Breakdown in the Motor Neuron Disease Spectrum: Recent Advances Using Diffusion Magnetic Resonance Imaging. <i>Frontiers in Neurology</i> , 2019, 10, 193.	1.1	6
1138	Frequency of the TREM2 R47H Variant in Various Neurodegenerative Disorders. <i>Alzheimer Disease and Associated Disorders</i> , 2019, 33, 327-330.	0.6	6
1139	An update on magnetic resonance imaging markers in AD. <i>Therapeutic Advances in Neurological Disorders</i> , 2020, 13, 175628642094798.	1.5	6
1140	Early evidence of disease activity during fingolimod predicts medium-term inefficacy in relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1374-1383.	1.4	6
1141	Virtual reality and real-time neurofeedback functional MRI: a breakthrough in foreseeing Alzheimer&#x2019;s disease?. <i>Brain</i> , 2020, 143, 722-726.	3.7	6
1142	Neural correlates of visuospatial processing in migraine: does the pain network help?. <i>Molecular Psychiatry</i> , 2021, 26, 6599-6608.	4.1	6
1143	Beyond Neuropsychiatric Manifestations of Systemic Lupus Erythematosus: Focus on Post-traumatic Stress Disorder and Alexithymia. <i>Current Rheumatology Reports</i> , 2021, 23, 52.	2.1	6
1144	Plasma neurofilament light chain levels and cognitive testing as predictors of fast progression in Alzheimer&#x2019;s disease. <i>European Journal of Neurology</i> , 2021, 28, 2980-2988.	1.7	6
1145	Direct oral anticoagulants in patients with nonvalvular atrial fibrillation and extreme body weight. <i>European Journal of Clinical Investigation</i> , 2022, 52, e13658.	1.7	6
1146	Progression of cognitive and behavioral disturbances in motor neuron diseases assessed using standard and computer-based batteries. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2021, 22, 223-236.	1.1	6
1147	Modelling new enhancing MRI lesion counts in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2001, 7, 298-304.	1.4	6
1148	Normal-appearing white matter changes in multiple sclerosis: the contribution of magnetic resonance techniques. <i>Multiple Sclerosis Journal</i> , 1999, 5, 273-282.	1.4	6
1149	Intraobserver and interobserver variability in measuring changes in lesion volume on serial brain MR images in multiple sclerosis. <i>American Journal of Neuroradiology</i> , 1998, 19, 685-7.	1.2	6
1150	Functional MRI connectivity of the primary motor cortex in functional dystonia patients. <i>Journal of Neurology</i> , 2022, 269, 2961-2971.	1.8	6
1151	Comparing natural history of early and late onset pediatric multiple sclerosis. <i>Annals of Neurology</i> , 2022, , .	2.8	6
1152	The role of non-conventional magnetic resonance techniques in monitoring evolution of multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1998, 64 Suppl 1, S52-8.	0.9	6

#	ARTICLE	IF	CITATIONS
1153	The association between cognition and motor performance is beyond structural damage in relapsingâ€“remitting multiple sclerosis. <i>Journal of Neurology</i> , 2022, 269, 4213-4221.	1.8	6
1154	The role of cerebellar damage in explaining disability and cognition in multiple sclerosis phenotypes: a multiparametric MRI study. <i>Journal of Neurology</i> , 2022, 269, 3841-3857.	1.8	6
1155	Relation of sensorimotor and cognitive cerebellum functional connectivity with brain structural damage in patients with multiple sclerosis and no disability. <i>European Journal of Neurology</i> , 2022, 29, 2036-2046.	1.7	6
1156	Anti-SARS-CoV-2 T-stem cell memory persists in ocrelizumab-treated MS patients. <i>Multiple Sclerosis Journal</i> , 2022, 28, 1937-1943.	1.4	6
1157	Newer magnetic resonance techniques and disease activity in multiple sclerosis: new concepts and new concerns. <i>Multiple Sclerosis Journal</i> , 1998, 4, 469-470.	1.4	5
1158	Lesion load measurements in multiple sclerosis: the effect of incorporating magnetization transfer contrast in a Fast-Flair sequence. <i>Magnetic Resonance Imaging</i> , 1999, 17, 459-461.	1.0	5
1159	Safety of the long-time monthly triple dose of a Gd-based contrast agent. <i>European Radiology</i> , 2003, 13, L243-L244.	2.3	5
1160	Spinal cord atrophy and disability in multiple sclerosis over four years. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2003, 74, 1014-a-1015.	0.9	5
1161	Glatiramer acetate in multiple sclerosis. <i>Expert Review of Neurotherapeutics</i> , 2005, 5, 451-458.	1.4	5
1162	Evaluation and training of hands and feet movements performed with different strategies: A kinematic study. <i>Clinical Neurology and Neurosurgery</i> , 2011, 113, 218-223.	0.6	5
1163	<i>p</i> FDR and <i>p</i> FNR estimation for brain networks construction. <i>Statistics in Medicine</i> , 2014, 33, 158-169.	0.8	5
1164	Distributed abnormalities of brain white matter architecture in patients with dominant optic atrophy and OPA1 mutations. <i>Journal of Neurology</i> , 2015, 262, 1216-1227.	1.8	5
1165	Promoting physical activity to control multiple sclerosis from childhood. <i>Neurology</i> , 2015, 85, 1644-1645.	1.5	5
1166	A Semiautomatic Method for Multiple Sclerosis Lesion Segmentation on Dual-Echo MR Imaging: Application in a Multicenter Context. <i>American Journal of Neuroradiology</i> , 2016, 37, 2043-2049.	1.2	5
1167	Mapping face encoding using functional MRI in multiple sclerosis across disease phenotypes. <i>Brain Imaging and Behavior</i> , 2017, 11, 1238-1247.	1.1	5
1168	Thrombus hallmarks reveal atherothrombotic stroke aetiology. <i>Journal of Neurology</i> , 2019, 266, 1533-1535.	1.8	5
1169	Targeting progression in multiple sclerosis â€” an update. <i>Nature Reviews Neurology</i> , 2019, 15, 62-64.	4.9	5
1170	Specific occupational profiles as proxies of cognitive reserve induce neuroprotection in dementia with Lewy bodies. <i>Brain Imaging and Behavior</i> , 2020, 15, 1427-1437.	1.1	5

#	ARTICLE	IF	CITATIONS
1171	U-Fiber Leukoencephalopathy Due to a Novel Mutation in the TACO1 Gene. <i>Neurology: Genetics</i> , 2021, 7, e573.	0.9	5
1172	A preliminary comparison between ECAS and ALS-CBS in classifying cognitive“behavioural phenotypes in a cohort of non-demented amyotrophic lateral sclerosis patients. <i>Journal of Neurology</i> , 2022, 269, 1899-1904.	1.8	5
1173	Quantitative MRI adds to neuropsychiatric lupus diagnostics. <i>Rheumatology</i> , 2021, 60, 3278-3288.	0.9	5
1174	Lesion load reproducibility and statistical sensitivity of clinical trials in multiple sclerosis. <i>Neurology</i> , 1999, 52, 433-433.	1.5	5
1175	Is there room for MR imaging in the assessment of hereditary motor and sensory neuropathies?. <i>American Journal of Neuroradiology</i> , 2000, 21, 1779-80.	1.2	5
1176	Regional assessment of brain atrophy: a novel approach to achieve a more complete picture of tissue damage associated with central nervous system disorders?. <i>American Journal of Neuroradiology</i> , 2007, 28, 260-1.	1.2	5
1177	MRI of Transcallosal White Matter Helps to Predict Motor Impairment in Multiple Sclerosis. <i>Radiology</i> , 2022, 302, 639-649.	3.6	5
1178	Social cognition in the FTL D spectrum: evidence from MRI. <i>Journal of Neurology</i> , 2022, 269, 2245-2258.	1.8	5
1179	Intraoperative neurophysiologic monitoring in thoracoabdominal aortic aneurysm surgery can provide real-time feedback for strategic decision making. <i>Neurophysiologie Clinique</i> , 2022, 52, 232-241.	1.0	5
1180	Towards imaging criteria that best differentiate MS from NMOSD and MOGAD: large multi-ethnic population and different clinical scenarios. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 61, 103778.	0.9	5
1181	Pediatric multiple sclerosis: developments in timely diagnosis and prognostication. <i>Expert Review of Neurotherapeutics</i> , 2022, 22, 393-403.	1.4	5
1182	The relationship between processing speed and verbal and non-verbal new learning and memory in progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2022, , 135245852210881.	1.4	5
1183	Profiling morphologic MRI features of motor neuron disease caused by TARDBP mutations. <i>Frontiers in Neurology</i> , 0, 13, .	1.1	5
1184	Time-varying connectivity of the precuneus and its association with cognition and depressive symptoms in neuromyelitis optica: A pilot MRI study. <i>Multiple Sclerosis Journal</i> , 2022, 28, 2057-2069.	1.4	5
1185	EEG correlates of cognitive impairment in MS. <i>Italian Journal of Neurological Sciences</i> , 1998, 19, S413-S417.	0.1	4
1186	The effect of cross-talk on MRI lesion numbers and volumes in multiple sclerosis using conventional and turbo spin-echo. <i>Multiple Sclerosis Journal</i> , 1998, 4, 471-474.	1.4	4
1187	Detecting New Lesion Formation in Multiple Sclerosis: The Relative Contributions of Monthly Dual-Echo and T<sub>1</sub>-Weighted Scans after Triple-Dose Gadolinium. <i>European Neurology</i> , 1998, 40, 146-150.	0.6	4
1188	A longitudinal study comparing the sensitivity of CSE and RARE sequences in detecting new multiple sclerosis lesions. <i>Magnetic Resonance Imaging</i> , 1999, 17, 457-458.	1.0	4

#	ARTICLE	IF	CITATIONS
1189	Magnetization transfer imaging to monitor the evolution of multiple sclerosis. <i>Neurological Sciences</i> , 1999, 20, S232-S240.	0.9	4
1190	Neuroimaging techniques in the diagnostic work-up of patients with the antiphospholipid syndrome. <i>Current Rheumatology Reports</i> , 2001, 3, 301-306.	2.1	4
1191	Contribution of cervical cord MRI and brain magnetization transfer imaging to the assessment of individual patients with multiple sclerosis: a preliminary study. <i>Multiple Sclerosis Journal</i> , 2002, 8, 52-58.	1.4	4
1192	Diffusion tensor and magnetization transfer MR imaging of early-onset multiple sclerosis. <i>Neurological Sciences</i> , 2004, 25, s344-s345.	0.9	4
1193	Statistical Issues Related to the Use of MRI Data in Multiple Sclerosis. <i>Journal of Neuroimaging</i> , 2007, 17, 56S-59S.	1.0	4
1194	The value of chemical fat-saturation pulse added to T1-weighted spin-echo sequence in evaluating gadolinium-enhancing brain lesions in multiple sclerosis. <i>Radiologia Medica</i> , 2007, 112, 1244-1251.	4.7	4
1195	The multiple sclerosis mystery: is there a vascular component?. <i>Lancet Neurology</i> , The, 2011, 10, 597-598.	4.9	4
1196	Vitamin A: yet another player in multiple sclerosis pathogenesis?. <i>Expert Review of Clinical Immunology</i> , 2013, 9, 113-115.	1.3	4
1197	The Role of Amyloid- $\beta$ , tau, and Apolipoprotein E $\mu$ 4 in Alzheimer Disease: How Is the Team Playing?. <i>American Journal of Neuroradiology</i> , 2013, 34, 511-512.	1.2	4
1198	Let's rehabilitate cognitive rehabilitation in multiple sclerosis. <i>Neurology</i> , 2013, 81, 2060-2061.	1.5	4
1199	Predictors of disease activity in 857 patients with MS treated with interferon beta-1b. <i>Journal of Neurology</i> , 2015, 262, 2466-2471.	1.8	4
1200	Simvastatin and cognition in multiple sclerosis. <i>Lancet Neurology</i> , The, 2017, 16, 572-573.	4.9	4
1201	Cortical Lesions on 7-T MRI in Multiple Sclerosis: A Window into Pathogenetic Mechanisms?. <i>Radiology</i> , 2019, 291, 750-751.	3.6	4
1202	Extent and characteristics of carotid plaques and brain parenchymal loss in asymptomatic patients with no indication for revascularization. <i>IJC Heart and Vasculature</i> , 2020, 30, 100619.	0.6	4
1203	Neuromyelitis optica and myotonic dystrophy type 2: a rare association with diagnostic implications. <i>Journal of Neurology</i> , 2020, 267, 2744-2746.	1.8	4
1204	Corpus callosum infarction: radiological and histological findings. <i>Journal of Neurology</i> , 2020, 267, 3418-3420.	1.8	4
1205	Involvement of Genetic Factors in Multiple Sclerosis. <i>Frontiers in Cellular Neuroscience</i> , 2020, 14, 612953.	1.8	4
1206	Early functional MRI changes in a prodromal semantic variant of primary progressive aphasia: a longitudinal case report. <i>Journal of Neurology</i> , 2020, 267, 3100-3104.	1.8	4

#	ARTICLE	IF	CITATIONS
1207	Therapeutic recommendations and seasonal influenza vaccine for multiple sclerosis patients in treatment with ocrelizumab: an expert consensus. <i>Journal of Neurology</i> , 2021, 268, 1540-1543.	1.8	4
1208	Atrioventricular block after fingolimod resumption: a consequence of sphingosine-1-phosphate axis alteration due to COVID-19?. <i>Journal of Neurology</i> , 2021, 268, 3975-3979.	1.8	4
1209	Chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS) after SARS-CoV-2 pneumonia. <i>Neurological Sciences</i> , 2021, 42, 4373-4375.	0.9	4
1210	Alterations of brain structural MRI are associated with outcome of surgical treatment in trigeminal neuralgia. <i>European Journal of Neurology</i> , 2022, 29, 305-317.	1.7	4
1211	Resting-State fMRI in Multiple Sclerosis. , 2020, , 335-353.		4
1212	Magnetisation transfer ratios of contrast-enhancing and nonenhancing lesions in multiple sclerosis. <i>Neuroradiology</i> , 1996, 38, 115-119.	1.1	4
1213	A longitudinal MR study of the presymptomatic phase in a patient with clinically definite multiple sclerosis. <i>American Journal of Neuroradiology</i> , 1999, 20, 1268-72.	1.2	4
1214	Neurogenetic traits outline vulnerability to cortical disruption in Parkinson's disease. <i>NeuroImage: Clinical</i> , 2022, 33, 102941.	1.4	4
1215	MR-based technology for in vivo detection, characterization, and quantification of pathology of relapsing-remitting multiple sclerosis. <i>Journal of Rehabilitation Research and Development</i> , 2002, 39, 243-59.	1.6	4
1216	Advanced diffusion-weighted imaging models better characterize white matter neurodegeneration and clinical outcomes in multiple sclerosis. <i>Journal of Neurology</i> , 2022, 269, 4729-4741.	1.8	4
1217	Resting state functional brain networks associated with emotion processing in frontotemporal lobar degeneration. <i>Molecular Psychiatry</i> , 2022, 27, 4809-4821.	4.1	4
1218	Interferon-gamma activated calcium influx in peripheral blood lymphocytes from patients with primary and secondary progressive multiple sclerosis.. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1996, 61, 515-517.	0.9	3
1219	How does brain MRI lesion volume change on serial scans in patients with multiple sclerosis?. <i>Magnetic Resonance Imaging</i> , 1998, 16, 1181-1183.	1.0	3
1220	Brain MRI lesion volume measurement reproducibility is not dependent on the disease burden in patients with multiple sclerosis. <i>Magnetic Resonance Imaging</i> , 1998, 16, 1185-1189.	1.0	3
1221	Monitoring long-term treatments in multiple sclerosis. <i>Nature Reviews Neurology</i> , 2010, 6, 421-422.	4.9	3
1222	Journal of Neurology: ready for continued success. <i>Journal of Neurology</i> , 2013, 260, 1-2.	1.8	3
1223	Clinical Applications of the Functional Connectome. <i>NeuroMethods</i> , 2016, , 893-903.	0.2	3
1224	Crossed aphasia confirmed by fMRI in a case with nonfluent variant of primary progressive aphasia carrying a GRN mutation. <i>Journal of Neurology</i> , 2019, 266, 1274-1279.	1.8	3

#	ARTICLE	IF	CITATIONS
1225	Painful legs and moving toes syndrome: treating movement to treat pain—a case report. <i>Journal of Neurology</i> , 2020, 267, 1852-1854.	1.8	3
1226	Temporal variant of frontotemporal dementia in C9orf72 repeat expansion carriers: two case studies. <i>Brain Imaging and Behavior</i> , 2020, 14, 336-345.	1.1	3
1227	Early red nucleus atrophy in relapse-onset multiple sclerosis. <i>Human Brain Mapping</i> , 2021, 42, 154-160.	1.9	3
1228	Development and evaluation of a manual segmentation protocol for deep grey matter in multiple sclerosis: Towards accelerated semi-automated references. <i>NeuroImage: Clinical</i> , 2021, 30, 102659.	1.4	3
1229	ALS Mimics due to Affection of the Cervical Spine: From Common Compressive Myelopathy to Rare CSF Epidural Collection. <i>Case Reports in Neurology</i> , 2021, 13, 145-156.	0.3	3
1230	Genomic and functional evaluation of TNFSF14 in multiple sclerosis susceptibility. <i>Journal of Genetics and Genomics</i> , 2021, 48, 497-507.	1.7	3
1231	Could ionic regulation disorders explain the overlap between meniere’s disease and migraine?. <i>Journal of Vestibular Research: Equilibrium and Orientation</i> , 2021, 31, 297-301.	0.8	3
1232	Stress related to COVID-19 pandemic as a trigger for disease activity in multiple sclerosis: a case report. <i>Neurological Sciences</i> , 2021, 42, 3969-3971.	0.9	3
1233	Identification of differential DNA methylation associated with multiple sclerosis: A family-based study. <i>Journal of Neuroimmunology</i> , 2021, 356, 577600.	1.1	3
1234	Improved Assessment of Longitudinal Spinal Cord Atrophy in Multiple Sclerosis Using a Registration-Based Approach: Relevance for Clinical Studies. <i>Journal of Magnetic Resonance Imaging</i> , 2022, 55, 1559-1568.	1.9	3
1235	A multiparametric MRI study of structural brain damage in dementia with lewy bodies: A comparison with Alzheimer’s disease. <i>Parkinsonism and Related Disorders</i> , 2021, 91, 154-161.	1.1	3
1236	Unexpected (123I)FP-CIT SPECT findings: SWIDD, SWEDD and all DAT. <i>Journal of Neurology</i> , 2022, 269, 758-770.	1.8	3
1237	Impaired recognition of disgust in amyotrophic lateral sclerosis is related to basal ganglia involvement. <i>NeuroImage: Clinical</i> , 2021, 32, 102803.	1.4	3
1238	High-Field Strength MRI (3.0 T or More) in White Matter Diseases. , 2006, , 186-193.		3
1239	Characterizing 1-year development of cervical cord atrophy across different MS phenotypes: A voxel-wise, multicentre analysis. <i>Multiple Sclerosis Journal</i> , 2022, 28, 885-899.	1.4	3
1240	Burden of rare coding variants in an Italian cohort of familial multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2021, 362, 577760.	1.1	3
1241	Divergent time-varying connectivity of thalamic sub-regions characterizes clinical phenotypes and cognitive status in multiple sclerosis. <i>Molecular Psychiatry</i> , 2022, 27, 1765-1773.	4.1	3
1242	Natalizumab treatment and pregnancy in multiple sclerosis: A reappraisal of maternal and infant outcomes after 6 years. <i>Multiple Sclerosis Journal</i> , 2022, 28, 2137-2141.	1.4	3

#	ARTICLE	IF	CITATIONS
1243	Mapping brain structure and function in professional fencers: A model to study training effects on central nervous system plasticity. <i>Human Brain Mapping</i> , 2022, 43, 3375-3385.	1.9	3
1244	Resting state effective connectivity abnormalities of the Papez circuit and cognitive performance in multiple sclerosis. <i>Molecular Psychiatry</i> , 0, , .	4.1	3
1245	Does Ocrelizumab Limit Multiple Sclerosis Progression? Current Evidence from Clinical, MRI, and Fluid Biomarkers. <i>Neurotherapeutics</i> , 2022, 19, 1216-1228.	2.1	3
1246	Magnetic resonance in monitoring the natural history of multiple sclerosis and the effects of treatment. <i>Italian Journal of Neurological Sciences</i> , 1996, 17, 385-391.	0.1	2
1247	Brain MRI follow-up of patients with persistent isolated optic neuritis. <i>European Journal of Neurology</i> , 1996, 3, 36-39.	1.7	2
1248	Brain adaptive changes following tissue damage in PPMS: a multiparametric study using F-MRI, MTI and DTI. <i>NeuroImage</i> , 2001, 13, 789.	2.1	2
1249	The role of magnetic resonance imaging in the assessment of patients with established multiple sclerosis. <i>Neurological Sciences</i> , 2002, 23, 89-90.	0.9	2
1250	Brain Plasticity in Multiple Sclerosis. <i>European Neurology</i> , 2004, 51, 189-190.	0.6	2
1251	Toward a better understanding of cerebral plasticity in multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2006, 244, 1-2.	0.3	2
1252	What do we really see when we look at magnetic resonance images?. <i>Annals of Neurology</i> , 2007, 62, 207-209.	2.8	2
1253	Application of fMRI to the study of multiple sclerosis: an update. <i>Future Neurology</i> , 2008, 3, 141-151.	0.9	2
1254	Preface. <i>Neuroimaging Clinics of North America</i> , 2009, 19, xiii-xiv.	0.5	2
1255	The neurologist's dilemma: MS is a grey matter disease that standard clinical and MRI measures cannot assess adequately " No. <i>Multiple Sclerosis Journal</i> , 2012, 18, 557-558.	1.4	2
1256	Comment: Frontal lobes, executive dysfunction, gait, and the fallacy of pseudo-transitivity. <i>Neurology</i> , 2012, 79, 198-198.	1.5	2
1257	Multicystic demyelinating myelopathy. <i>Neurology</i> , 2014, 82, 902-903.	1.5	2
1258	Dynamic pattern of clinical and MRI findings in a tumefactive demyelinating lesion: A case report. <i>Journal of the Neurological Sciences</i> , 2016, 361, 184-186.	0.3	2
1259	The Role of DTI in Multiple Sclerosis and Other Demyelinating Conditions. , 2016, , 331-341.		2
1260	Modulation of cortical excitability to normalise brain function and improve cognition in multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 373-373.	0.9	2

#	ARTICLE	IF	CITATIONS
1261	Moyamoya disease mimicking the first attack of multiple sclerosis. <i>Journal of Neurology</i> , 2017, 264, 1005-1007.	1.8	2
1262	PET is necessary to make the next step forward in understanding MS pathophysiology – No. <i>Multiple Sclerosis Journal</i> , 2019, 25, 1088-1090.	1.4	2
1263	Large vessel occlusion stroke due to dislodged aortic valve calcification revealed by imaging and histopathology. <i>Journal of the Neurological Sciences</i> , 2020, 408, 116573.	0.3	2
1264	Allergy and dimethyl fumarate treatment in a patient with multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2020, 418, 117104.	0.3	2
1265	Stress in paediatric migraine: a trigger factor?. <i>Neurological Sciences</i> , 2020, 41, 447-449.	0.9	2
1266	Impact of multiple sclerosis risk loci in postinfectious neurological syndromes. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 44, 102326.	0.9	2
1267	Two-year macular volume assessment in multiple sclerosis patients treated with fingolimod. <i>Neurological Sciences</i> , 2021, 42, 731-733.	0.9	2
1268	Brain structural alterations in patients with GCH1 mutations associated DOPA-responsive dystonia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 332-333.	0.9	2
1269	Targeting Neuromyelitis Optica Pathogenesis: Results from Randomized Controlled Trials of Biologics. <i>Neurotherapeutics</i> , 2021, 18, 1623-1636.	2.1	2
1270	Assessment of the genetic contribution to brain magnetic resonance imaging lesion load and atrophy measures in multiple sclerosis patients. <i>European Journal of Neurology</i> , 2021, 28, 2513-2522.	1.7	2
1271	Application of deep-learning to the seronegative side of the NMO spectrum. <i>Journal of Neurology</i> , 2022, 269, 1546-1556.	1.8	2
1272	Migraine and literature: a narrative historical review. <i>Neurological Sciences</i> , 2021, 42, 565-569.	0.9	2
1273	Magnetization Transfer and Diffusion-Weighted Magnetic Resonance Imaging in Multiple Sclerosis and Other White Matter Diseases. , 2001, , 87-96.		2
1274	Antenatal diagnosis of vein of Galen aneurysmal malformation: MR study of fetal brain and postnatal follow-up. <i>Neuroradiology</i> , 1995, 38, 87-90.	1.1	2
1275	The precision of T1 hypointense lesion volume quantification in multiple sclerosis treatment trials: a multicenter study. <i>Multiple Sclerosis Journal</i> , 2000, 6, 237-240.	1.4	2
1276	Intra-observer, inter-observer and inter-scanner variations in brain MRI volume measurements in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2001, 7, 27-31.	1.4	2
1277	Functional magnetic resonance imaging and multiple sclerosis. <i>Future Neurology</i> , 2006, 1, 67-76.	0.9	2
1278	Magnetization Transfer Imaging. , 2003, , 11-32.		2



#	ARTICLE	IF	CITATIONS
1279	Necrotic-hemorrhagic myelitis: A rare malignant variant of parainfectious acute disseminated encephalomyelitis in childhood. <i>Journal of the Neurological Sciences</i> , 2018, 384, 58-60.	0.3	2
1280	Measuring social cognition in frontotemporal lobar degeneration: a clinical approach. <i>Journal of Neurology</i> , 2021, , 1.	1.8	2
1281	Real world comparison of teriflunomide and dimethyl fumarate in naïve relapsing multiple sclerosis patients: Evidence from the Italian MS register. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 58, 103489.	0.9	2
1282	HSV encephalitis associated with off-label rituximab treatment of multiple sclerosis. <i>Neurological Sciences</i> , 2022, 43, 2095-2097.	0.9	2
1283	Prognosis of a second clinical event from baseline MRI in patients with a CIS: a multicenter study using a machine learning approach. <i>Neuroradiology</i> , 2022, 64, 1383-1390.	1.1	2
1284	The use of modern magnetic resonance techniques to monitor disease evolution in multiple sclerosis. <i>Advances in Neurology</i> , 2006, 98, 167-83.	0.8	2
1285	Current and future applications of artificial intelligence in multiple sclerosis. , 2022, , 107-144.		2
1286	Impact of immunotherapies on COVID-19 outcomes in multiple sclerosis patients. <i>Expert Review of Clinical Immunology</i> , 2022, 18, 495-512.	1.3	2
1287	Subacute sensory neuropathy associated with Merkel cell carcinoma with unknown primary: a case report with literature review. <i>Journal of Neurology</i> , 2022, , 1.	1.8	2
1288	A multi-step genomic approach prioritized TBKBP1 gene as relevant for multiple sclerosis susceptibility. <i>Journal of Neurology</i> , 2022, 269, 4510-4522.	1.8	2
1289	Association between inflammatory central nervous system lesions and Cerebellar Ataxia, Neuropathy and Vestibular Areflexia Syndrome (CANVAS): a case series. <i>Journal of Neurology</i> , 2022, , .	1.8	2
1290	Token test and multiple sclerosis. <i>Italian Journal of Neurological Sciences</i> , 1993, 14, 333-336.	0.1	1
1291	Natural interferon-β in chronic progressive multiple sclerosis: results after 2 years of treatment and 2 years of follow up. <i>European Journal of Neurology</i> , 1995, 2, 139-141.	1.7	1
1292	The influence of slice orientation on brain MRI lesion load measurement in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 1997, 3, 382-384.	1.4	1
1293	Contribution of magnetic resonance imaging techniques in understanding cognitive impairment in multiple sclerosis. <i>Italian Journal of Neurological Sciences</i> , 1998, 19, S399-S402.	0.1	1
1294	Serial Contrast-Enhanced MR in Patients with Multiple Sclerosis and Varying Levels of Disability. <i>Journal of Neuro-Ophthalmology</i> , 1999, 19, 115.	0.4	1
1295	Introduction to the supplement. <i>Journal of the Neurological Sciences</i> , 2001, 186, S1.	0.3	1
1296	Preface. <i>Neuroimaging Clinics of North America</i> , 2008, 18, xv-xvi.	0.5	1

#	ARTICLE	IF	CITATIONS
1297	Measures of magnetization transfer. , 0, , 112-127.		1
1298	Reply: MRI measurements of brain stem structures in patients with Richardson's syndrome, progressive supranuclear palsyâ€“parkinsonism, and Parkinson's disease. <i>Movement Disorders</i> , 2011, 26, 1575-1576.	2.2	1
1299	Advances with MRI in Parkinson disease. <i>Neurology</i> , 2012, 79, 2222-2223.	1.5	1
1300	Brain structural and functional abnormalities in Fahrâ€™s disease : a report of two cases. <i>Journal of Neurology</i> , 2013, 260, 1927-1930.	1.8	1
1301	Functional and structural disruption of the precuneus contributes to cognitive impairment in pediatric multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2013, 333, e386.	0.3	1
1302	The Thalamus: A Small but Precious Window on Â-Related Neurodegeneration?. <i>American Journal of Neuroradiology</i> , 2014, 35, 904-905.	1.2	1
1303	Weakness and fatigue. , 0, , 347-358.		1
1304	P3-185: THE EUROPEAN DTI STUDY IN DEMENTIA: A NOVEL FRAMEWORK TO TEST THE DIAGNOSTIC USE OF DTI IN ALZHEIMER'S DISEASE. , 2014, 10, P697-P697.		1
1305	P1-255: PREDICTION OF PRODROMAL AD IN MCI SUBJECTS USING MULTICENTER DTI AND MRI DATA AND MULTIPLE KERNELS SVM: AN EDSO STUDY. , 2014, 10, P400-P401.		1
1306	A Semi-automatic Method for Segmentation of Multiple Sclerosis Lesions on Dual-Echo Magnetic Resonance Images. <i>Lecture Notes in Computer Science</i> , 2016, , 80-90.	1.0	1
1307	fMRI of Pain. <i>NeuroMethods</i> , 2016, , 495-521.	0.2	1
1308	fMRI of the Sensorimotor System. <i>NeuroMethods</i> , 2016, , 523-543.	0.2	1
1309	Optic neuritis in multiple sclerosis. <i>Neurology</i> , 2016, 87, 338-339.	1.5	1
1310	Natalizumab vs fingolimod in patients with active relapsing-remitting multiple sclerosis (RRMS): comparative MRI assessments of disease activity from reveal, a randomized, head-to-head phase 4 study. <i>Journal of the Neurological Sciences</i> , 2017, 381, 246.	0.3	1
1311	High-dose steroid therapy for CNS inflammatory diseases increases INR in patients taking oral vitamin K antagonist. <i>Journal of Neurology</i> , 2019, 266, 3160-3161.	1.8	1
1312	Concurrence of NMOsD and ALS in a patient with hexanucleotide repeat expansions of C9orf72. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2019, 20, 449-452.	1.1	1
1313	Deep learning: a turning point in acute neurology. <i>The Lancet Digital Health</i> , 2020, 2, e273-e274.	5.9	1
1314	Successful treatment of HIV-associated tumefactive demyelinating lesions with corticosteroids and cyclophosphamide: a case report. <i>Journal of Neurology</i> , 2020, 267, 3773-3775.	1.8	1

#	ARTICLE	IF	CITATIONS
1315	Risk attitude and personality in people with multiple sclerosis facing the choice of different disease-modifying therapy scenarios. <i>Journal of the Neurological Sciences</i> , 2020, 417, 117064.	0.3	1
1316	Other primary headaches. Cough headache, nummular headache and primary exercise headache: a secondary point of view. <i>Neurological Sciences</i> , 2020, 41, 377-379.	0.9	1
1317	Fishing an anemone in the brain: embolized cardiac fibroelastoma revealed after stroke thrombectomy. <i>European Heart Journal</i> , 2021, 42, 4094-4095.	1.0	1
1318	Striatal Atrophy and Hypometabolism in Drug-Resistant Non-Ketotic Hyperglycemic Chorea-Ballism. <i>Movement Disorders Clinical Practice</i> , 2021, 8, 486-488.	0.8	1
1319	Dynamic Functional Connectivity For The Classification Of Multiple Sclerosis Phenotype: A Hidden Markov Model Approach. , 2021, , .		1
1320	Correlations between Magnetic Resonance Spectroscopy and Other Magnetic Resonance Parameters in Multiple Sclerosis. , 2001, , 79-86.		1
1321	Functional MRI of the Spinal Cord. <i>Neuroinformatics</i> , 2009, , 811-835.	0.2	1
1322	Neurodegenerative Diseases and Changes in Artistic Expression. , 2020, , 27-39.		1
1323	MAPT Q336H mutation: Intrafamilial phenotypic heterogeneity in a new Italian family. <i>European Journal of Neurology</i> , 2022, , .	1.7	1
1324	Transcriptional effects of fingolimod treatment on peripheral T cells in relapsing remitting multiple sclerosis patients. <i>Pharmacogenomics</i> , 2022, 23, 161-171.	0.6	1
1325	Primary Lateral Sclerosis Presenting With Focal Onset Spreading Through Contiguous Neuroanatomic Regions. <i>Neurology</i> , 2022, , 10.1212/WNL.0000000000200011.	1.5	1
1326	Accuracy of the clinical diagnosis of dementia with Lewy bodies (DLB) among the Italian Dementia Centers: a study by the Italian DLB study group (DLB-SINdem). <i>Neurological Sciences</i> , 2022, 43, 4221-4229.	0.9	1
1327	MR T2-relaxation time as an indirect measure of brain water content and disease activity in NMOSD. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, , jnnp-2022-328956.	0.9	1
1328	Interferon beta treatment in multiple sclerosis: the European clinical trials. <i>Multiple Sclerosis Journal</i> , 1996, 1, 317-320.	1.4	0
1329	Correspondence. <i>Magnetic Resonance Imaging</i> , 1999, 17, 1236-1237.	1.0	0
1330	Introduction. <i>Neurological Sciences</i> , 1999, 20, S227-S228.	0.9	0
1331	Introduction to the supplement. <i>Journal of the Neurological Sciences</i> , 2000, 172, S1-S2.	0.3	0
1332	RM funzionale nella sclerosi multipla secondariamente progressiva. <i>The Neuroradiology Journal</i> , 2003, 16, 250-250.	0.1	0

#	ARTICLE	IF	CITATIONS
1333	Studio con RM della volumetria, diffusione e trasferimento della magnetizzazione encefalica in pazienti con malattia di Huntington. The Neuroradiology Journal, 2003, 16, 43-43.	0.1	0
1334	Diffusion imaging in demyelination and inflammation. , 2004, , 444-459.		0
1335	Diffusion and perfusion MRI in inflammation and demyelination. , 0, , 488-500.		0
1336	Do interferon beta-1b and glatiramer acetate grow brain? â€œ Authors' reply. Lancet Neurology, The, 2009, 8, 1086-1087.	4.9	0
1337	IN09-MO-01 New imaging techniques in multiple sclerosis. Journal of the Neurological Sciences, 2009, 285, S10.	0.3	0
1338	<i>Reply:</i>. American Journal of Neuroradiology, 2010, 31, E46-E46.	1.2	0
1339	Assessing lesion morphology in MS: Why does this matter?. Journal of the Neurological Sciences, 2010, 290, 194-195.	0.3	0
1340	S.17.04 Magnetic resonance imaging correlates of cognitive and neuropsychiatric disturbances in multiple sclerosis. European Neuropsychopharmacology, 2011, 21, S213.	0.3	0
1341	Thank you Jan van Gijn. Journal of Neurology, 2013, 260, 1451-1451.	1.8	0
1342	Network analysis of intrinsic functional connectivity in the semantic variant of primary progressive aphasia. Journal of the Neurological Sciences, 2013, 333, e334.	0.3	0
1343	Intrinsic damage to the cerebellar peduncles is associated to multiple sclerosis clinical disability. Journal of the Neurological Sciences, 2013, 333, e387.	0.3	0
1344	Brain structural changes in primary focal dystonia. Journal of the Neurological Sciences, 2013, 333, e89-e90.	0.3	0
1345	Neuroanatomical patterns of central nervous system involvement in myotonic dystrophy type 1 and clinical correlates. Journal of the Neurological Sciences, 2013, 333, e457.	0.3	0
1346	Atrophy. , 2014, , 207-217.		0
1347	Intellectual dysfunction. , 0, , 34-64.		0
1348	Acute, multifocal neurological symptoms. , 0, , 209-227.		0
1349	Neuromuscular weakness. , 0, , 317-331.		0
1350	Radiologically isolated syndrome. Journal of the Neurological Sciences, 2015, 357, e462-e463.	0.3	0

#	ARTICLE	IF	CITATIONS
1351	Imaging of network disruption in dementia. <i>Journal of the Neurological Sciences</i> , 2015, 357, e467.	0.3	0
1352	Demyelinating Diseases. , 2015, , 895-905.		0
1353	fMRI of Memory. <i>Neuromethods</i> , 2016, , 419-450.	0.2	0
1354	Application of fMRI to Multiple Sclerosis and Other White Matter Disorders. <i>Neuromethods</i> , 2016, , 609-637.	0.2	0
1355	fMRI in Psychiatric Disorders. <i>Neuromethods</i> , 2016, , 657-697.	0.2	0
1356	Functional MRI of the Spinal Cord. <i>Neuromethods</i> , 2016, , 871-892.	0.2	0
1357	Surrogate Markers in Multiple Sclerosis. , 2016, , 163-187.		0
1358	The neurology community mourns the passing of Dr. John F. Kurtzke. <i>Journal of Neurology</i> , 2016, 263, 421-421.	1.8	0
1359	DTI in Dementing Conditions. , 2016, , 343-358.		0
1360	Characteristics of carotid atherosclerosis and brain white matter hyperintensities in asymptomatic patients with intermediate stenosis. <i>Atherosclerosis</i> , 2017, 263, e57.	0.4	0
1361	FRI0624â€¦Structural MRI-based connectomics in SLE: a pilot study. , 2017, , .		0
1362	Cognitive Processes Underlying Vegetarianism as Assessed by Brain Imaging. , 2017, , 71-91.		0
1363	086â€¦The rapid efficacy of natalizumab vs fingolimod in patients with active relapsing-remitting multiple sclerosis (RRMS): results from reveal, a randomised, head-to-head study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, A35.1-A35.	0.9	0
1364	Repeat expansions contribute to TDP-43 pathologic heterogeneity in ALS. <i>Neurology</i> , 2019, 93, 823-824.	1.5	0
1365	Author response: Gray matter volume modifications in migraine: A cross-sectional and longitudinal study. <i>Neurology</i> , 2019, 92, 587.2-588.	1.5	0
1366	Teaching Neurolmages: Osteolytic intraosseous meningioma causing transcalvarial herniation. <i>Neurology</i> , 2020, 95, e1110-e1111.	1.5	0
1367	Editorial: Functional and Structural Brain Alterations in Headache: A Trait or a State?. <i>Frontiers in Neurology</i> , 2020, 11, 859.	1.1	0
1368	Dampened Immune Response After EarlyÂRecurrence of Ischemic Stroke. <i>Journal of the American College of Cardiology</i> , 2020, 76, 1385-1387.	1.2	0

#	ARTICLE	IF	CITATIONS
1369	Biomarker-based definition of limbic-predominant long-lasting amnesic mild cognitive impairment. <i>Alzheimer's and Dementia</i> , 2020, 16, e037879.	0.4	0
1370	Predictive MS risk factors and axonal disintegration. <i>Neurology</i> , 2020, 94, 771-772.	1.5	0
1371	Frontotemporal Lobar Degeneration. , 2021, , 61-89.		0
1372	Vascular Cognitive Impairment. , 2021, , 31-59.		0
1373	Parkinsonian Dementias. , 2021, , 91-117.		0
1374	The Benign Course of PLS. <i>Neurology</i> , 2021, 96, 783-784.	1.5	0
1375	Asymmetric rapidly progressive idiopathic normal-pressure hydrocephalus: description of a case. <i>Journal of Neurology</i> , 2022, 269, 486-489.	1.8	0
1376	Editorial for "Utility of Advanced <sc>DWI</sc> in the Detection of Spinal Cord Microstructural Alterations and Assessment of Neurologic Function in Cervical Spondylotic Myelopathy Patients" <i>Journal of Magnetic Resonance Imaging</i> , 2022, 55, 941-942.	1.9	0
1377	Encoding Brain Networks Through Geodesic Clustering of Functional Connectivity for Multiple Sclerosis Classification. , 2021, , .		0
1378	PCA-LBD in Gaucher disease type 1: a case description. <i>Neurological Sciences</i> , 2022, 43, 715-718.	0.9	0
1379	A quality network model for the daily care of multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2000, 6, 231-236.	1.4	0
1380	Enhanced magnetic resonance imaging in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2000, 6, 320-326.	1.4	0
1381	Functional Magnetic Resonance Imaging. , 2002, , 113-124.		0
1382	Diffusion-Weighted MRI. , 2003, , 33-45.		0
1383	Functional MRI. , 2003, , 83-97.		0
1384	The Grey Matter Component of MS Pathology: Magnetization Transfer and Diffusion-Weighted Imaging. , 2004, , 121-127.		0
1385	Functional MRI in Multiple Sclerosis. , 2004, , 145-155.		0
1386	Diffusion-Weighted Imaging of the Normal-Appearing White Matter in Multiple Sclerosis. , 2004, , 79-89.		0

#	ARTICLE	IF	CITATIONS
1387	Imaging for Tissue Characterization in Multiple Sclerosis and Other White Matter Diseases. , 2004, , 83-95.		0
1388	MRI-Clinical Correlations in Multiple Sclerosis: Implications for Our Understanding of Neuronal Changes. , 2005, , 215-225.		0
1389	Application of fMRI to Multiple Sclerosis and Other White Matter Disorders. Neuromethods, 2009, , 573-596.	0.2	0
1390	fMRI of the Sensorimotor System. Neuromethods, 2009, , 493-511.	0.2	0
1391	A Voxel-Based Assessment of Cervical Cord Atrophy in MS Patients (P03.061). Neurology, 2012, 78, P03.061-P03.061.	1.5	0
1392	Imaging of Migraine and Vestibular Migraine. , 2014, , 193-209.		0
1393	The effect of cross-talk on MRI lesion numbers and volumes in multiple sclerosis using conventional and turbo spin-echo. Multiple Sclerosis Journal, 1998, 4, 471-474.	1.4	0
1394	Newer magnetic resonance techniques and disease activity in multiple sclerosis: new concepts and new concerns. Multiple Sclerosis Journal, 1998, 4, 469-470.	1.4	0
1395	The contribution of magnetic resonance imaging to the understanding of multiple sclerosis pathogenesis. , 1999, , 59-66.		0
1396	New Strategies to Increase Magnetic Resonance Imaging Sensitivity in Detecting Individual Multiple Sclerosis Lesions and Short-term Disease Activity: Perspectives for Future Clinical Trials. , 1999, , 74-84.		0
1397	Magnetic Resonance and Blood-Brain Barrier Dysfunction in Multiple Sclerosis. , 1999, , 195-209.		0
1398	High-Field-Strength MRI (3.0 T or More) in White Matter Diseases. , 2017, , 223-237.		0
1399	Neuromyelitis Optica Spectrum Disorders. , 2020, , 67-94.		0
1400	Pediatric Multiple Sclerosis. , 2020, , 37-66.		0
1401	Validation of MRI Surrogates. , 2007, , 107-112.		0
1402	Diffusion-Weighted Imaging. , 2007, , 65-74.		0
1403	Functional MRI. , 2007, , 85-104.		0
1404	Multiple Sclerosis: Other MR Techniques. , 2005, , 225-240.		0

#	ARTICLE	IF	CITATIONS
1405	White Matter Pathology in Systemic Immune-Mediated Diseases. , 2005, , 343-352.		0
1406	AÎ²-PET pathology accumulation index. Neurology, 2020, 95, 943-944.	1.5	0
1407	Spinal Cord Atrophy Is a Preclinical Marker of Progressive <scp>MS</scp>. Annals of Neurology, 2022, 91, 734-735.	2.8	0
1408	Editorial for "Amide Proton Transfer <scp>MRI</scp> Could Be Used to Evaluate the Pathophysiological Status of White Matter Hyperintensities". Journal of Magnetic Resonance Imaging, 2022, 56, 310-311.	1.9	0
1409	Magnetic resonance imaging to assess gray matter damage in multiple sclerosis. , 0, , 86-92.		0
1410	Application of functional magnetic resonance imaging in multiple sclerosis. , 0, , 93-102.		0
1411	Functional magnetic resonance imaging monitoring of therapeutic interventions in multiple sclerosis. , 0, , 120-126.		0
1412	Natural Speech Analysis: A Window Into Alzheimer Disease Phenotypes. Neurology, 2022, , 10.1212/WNL.0000000000200843.	1.5	0
1413	Early use of fingolimod is associated with better clinical outcomes in relapsing&acirc"remitting multiple sclerosis patients. Journal of Neurology, 0, , .	1.8	0